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Pertussis toxin is a bacterial protein toxin consisting of five subunits, SI, S2,
S3, S4 and S5, in a ratio of 1:1:1:2:1. The whole toxin has a molecular mass of 104
950, calculated from the nucleotide sequence of the toxin subunits.
Receptor-recognition of pertussis toxin is mediated by the B-oligomer, which
consists of lxS2, lxS3, 2xS4and lxS5and delivers the enzymatically active SI
subunit to target cells, where SI catalyses the transfer of ADP-ribose from NAD+ to
Gj, a protein involved in regulation of adenylate cyclase activity. ADP-ribosylation of
G} prevents inhibition of adenylate cyclase activity and leads to a build-up of
intracellular cAMP.
Overlapping decameric peptides derived from the entire amino acid sequence of
the SI, S3 and S4 subunits of pertussis toxin were synthesised on polyethylene pins,
to study the antigenicity of the SI, S3 and S4 pin decapeptides and fetuin binding to
the S3 pin decapeptides. No major continuous antigenic sites were identified using the
S1 and S3 pin decapeptides. One pin decapeptide derived from the amino acid
sequence of the S4 subunit (residues 86-95, sequence QLTFEGKPAL) did react
strongly with one rabbit anti-(pertussis toxin) antisera and the reaction was inhibited
by pre-incubation of the anti-toxin sera with whole pertussis toxin. However, binding
of the rabbit anti-toxin sera to whole toxin was not inhibited by antipeptide sera raised
against a free peptide S4b that contained amino acids 86-95, possibly because anti-S4b
did not bind strongly to whole toxin. No other polyclonal antisera or monoclonal
antibodies bound to the pin decapeptide that contained residues 86-95, so this peptide
does not form a major continuous antigenic site.
Fetuin bound to an S3-derived pin decapeptide (amino acids 46-55, sequence
RQITPGWSIY). (E)S3c, a free peptide containing residues 44-58 also bound a-1-
acid glycoprotein, mixed bovine brain gangliosides and fetuin. The ability of peptide
(E)S3c to bind glycoprotein and glycolipid suggest that amino acids within the peptide
are involved in toxin binding to target cells, so rabbit antisera raised against peptide
(E)S3c were included in a pertussis toxin-mediated Chinese Hamser Ovary cell
clumping assay. Rabbit anti-(E)S3c did not inhibit pertussis toxin-mediated clumping
of Chinese Hamster Ovary cells, so (E)S3c is not likely to induce protective antibodies
and be a candidate for replacement of detoxified pertussis toxin as a pertussis vaccine
component.
Binding of NAD+ to the SI subunit of whole pertussis toxin, isolated SI
subunit and recombinant SI analogues was investigated using intrinsic tryptophan
fluorescence quenching with NAD+. Dissociation constants (Kd values) were
obtained at several temperatures for the whole toxin and isolated SI subunit. Kj
xv
values were similar for the whole toxin and isolated SI subunit, suggesting that the B-
oligomer is not essential to provide a suitable conformation for binding of NAD+ to
the SI subunit.
Dissociation constants for binding of NAD+ to a truncated SI analogue, rSld, lacking
the C-terminal 47 amino acids and dissociation constants for binding of NAD+ to rS Id
containing a substitution of a glutamate residue at position 129 for aspartate were not
dramatically different. This suggests that the C-terminal 47 amino acids and glutamate
129 are not essential for binding of NAD+ to the S1 subunit.
The spatial arrangement of the toxin subunits was studied using reversible and
non-reversible cross-linking reagents, one- and two-dimensional SDS PAGE and
Western blotting. Results suggest that S4 and S3, S4 and S5 lie close together in the
whole toxin, with SI 'on top' of the B-oligomer subunits. No cross-linked species
that contained S2 were obtained, possibly because S2 was shielded from the cross-




1.1 Pertussis : A brief overview
Pertussis (whooping cough) is an endemic disease with periodic epidemics
affecting infants and young children. The disease was first recognised in Europe in
the 16th century, and until the first recommendations for pertussis vaccination in 1957,
whooping cough was a major cause of childhood mortality (Fine and Clarkson, 1987).
A killed whole cell vaccine is in routine use in most countries (Robinson et al., 1985).
Uptake of the vaccine increased throughout the nineteen fifties and sixties, leading to a
corresponding decline in the occurrence and severity of whooping cough
(Miller et al., 1982; Robinson et al., 1985; Moxon and Rappuoli, 1990).
Reports of adverse reactions and variation in efficacy of this vaccine lead to
decreased vaccine uptake in the mid 1970's (Ad hoc group for study of pertussis
vaccines, 1988; Cherry et al., 1988), and the argument over whether the vaccine is
responsible for seizures and brain damage continues (Cherry, 1990; Griffin et al.,
1990), so the search for a better characterised, safer vaccine for pertussis has been
given considerable momentum (Robinson et al., 1985; Moxon and Rappuoli, 1990;
Hewlett, 1992).
1.1.1 The cause of pertussis
Pertussis is caused by the gram negative bacterium Bordetella pertussis, which
was first isolated by Bordet and Gengou (1906) and specifically colonises human
ciliated respiratory epithelium (Mallory and Horner, 1912; Tuomanen and Weiss,
1985). The bacteria are transmitted by aerosol from infected individuals and the
disease is common in crowded conditions (Muller et al., 1986).
Many virulence factors are secreted by B. pertussis. Pertussis toxin may be
the major one (Pittman, 1984; Monack et al., 1989; Loosemore et al., 1991; Miller et
al., 1991), and the importance of other virulence factors in vaccine development is still
being studied.
1.1.2 The disease
The only natural host for Bordetella pertussis is man. The bacteria specifically
attach to and colonise host ciliated respiratory epithelium. An incubation period of




Ciliostasis and respiratory cell damage result in the paroxysmal (or spasmodic)
coughing phase, which lasts approximately four weeks. As the patient attempts to
clear the lungs of obstructing bacteria and mucus the characteristic 'whoop' of the
disease, resulting from rapid inhalation after severe bouts of coughing may be heard in
a small number of cases (Hewlett, 1992). Cyanosis, tongue protrusion, hernia,
vomiting and seizures may be also be observed (Cherry et al., 1988). Coughing
gradually abates and a convalescent stage is reached, lasting about three weeks.
1.1.3 Prevention and Treatment
Antibiotics can be used to combat Bordetella pertussis infection, but by the
time the disease is diagnosed, cell damage has been done and toxins have been
released. Erythromycin is the most used antibiotic, but is only effective if given before
the paroxysmal phase begins (Bass, 1985).
The killed whole cell vaccine (1.1) is administered with diphtheria and tetanus
toxoids adsorbed onto aluminium salts (Robinson et al., 1985). The UK has an
established programme of three preschool immunisations at two, three and four
months, with a booster at four years (Booy et al., 1992). Vaccination of infants in the
UK has recently risen to the highest level recorded (White et al., 1991), but decreased
public acceptance in the nineteen seventies and eighties, decreased efficacy and
possible inherent toxicity of the whole cell vaccine, coupled with evidence that the
whole cell vaccine may not give lifetime protection against infection (Linneman and
Nasenby, 1977; Addiss et al., 1991; Halperin and Marrie, 1991), have created the
requirement for a better characterised, acellular vaccine.
Japan has an acellular vaccine which has been widely used since 1981
(Sato et al., 1984) and was included in Swedish trials in the late nineteen eighties (ad
hoc group for study of pertussis vaccines, 1988). It was given to children over two
years old in the Japanese trials, and differences in efficacy were seen between the
Swedish and Japanese trials. Consequently, the Japanese vaccine was not advised for
routine vaccination of infants in the Western world.
Research into vaccine components continues; at least thirteen potential,
acellular vaccines are at various stages of development at the moment (this number
recently entered phase II clinical trials in the USA), containing a range of B. pertussis
antigens (Podda et al., 1992; Miller et al., 1991; Pizza et al., 1989; Ad hoc group for
study of pertussis vaccines, 1988).
The next advances in acellular vaccine development will involve identification
of subunits and peptides from B. pertussis antigens which contain epitopes, and are
immunogenic and protective against the disease, without the toxicity associated with
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the whole cell vaccine.
1.2 Virulence factors of Bordetella pertussis
There are several virulence factors produced by B. pertussis, including the
agglutinogens, pertactin, adenylate cyclase toxin, endotoxin, tracheal cytotoxin, heat-
labile toxin and pertussis toxin. They will be discussed in this section with the
exception of pertussis toxin, which is covered in section 1.3.
1.2.1 Agglutinogens
1.2.1.1 A brief summary
Agglutinogens (Aggs) are generally described as serotype-specific proteins
(Mr 10 000 to 23 000), which generate antibodies, which agglutinate bacteria.
Agg 1 is thought to be a non-fimbrial protein common to all strains of B. pertussis ,
but its nature has not been determined; Fim 2 and Fim 3 (Robinson et al., 1989),
otherwise known as Agg 2 and 3 are fimbrial proteins, found in various combinations
on different strains of B. pertussis, and are major serotyping antigens of B. pertussis.
Aggs 4, 5, 6 and 7 are minor antigens : Agg 6 is thought to be identical to Fim 3 (Agg
3) and Agg 7 is common to all Bordetella species (Robinson et al., 1989).
1.2.1.2 B. pertussis fimbriae
The major types of fimbriae of B. pertussis are fim 2 and fim 3 (Mr 22 500 and
22 000 respectively, as determined by SDS PAGE). Their amino acid sequences
show a high degree of homology and they are antigenically distinct (Mooi et al.,
1990). B. pertussis has three sequenced fimbrial subunit genes :fim2,fim3 and
fimX (Livey et al., 1987; Pedroni et al., 1988; Mooi et al., 1990) and a fourth
(fimY) has been suggested. FimX and Y may be silent genes (Mooi et al., 1992), or
expressed at low levels (Riboli et al., 1991).
Fim 2 and 3 monomers are assembled into fimbriae of about 100 nm length
(Steven et al., 1986), possibly involved in adhesion to the respiratory tract of mice
and possibly humans (Robinson et al., 1990). Fim 2 and 3 also protect against
infection by B. pertussis, leading to their consideration for inclusion in an acellular
vaccine (Miller et al., 1991).
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1.2.2 Filamentous Haemagglutinin
B. pertussis secretes two haemagglutinins, filamentous haemagglutinin (FHA)
and pertussis toxin (see section 1.3). FHA is a non-fimbrial protein
(apparent Mr 220 000) and has been sequenced (Relman et al., 1989; Delisse-Gayothe
et al., 1990). It is required for adhesion of B. pertussis to ciliated epithelium, as well
as to integrins on macrophages (Relman et al., 1990; Shahin et al., 1992;) and
contains the amino acid triplet RGD (ArgGlyAsp) which acts as a cell binding site for
some eukaiyotic proteins (Ruoslahti and Pierschbacher, 1986). FHA also contains a
lectin-like binding site; FHA binding to epithelial cells can be inhibited by galactose
(Tuomanen et al., 1988). FHA also binds sulphated saccharides (e.g. heparin)
(Menozzi et al., 1991), which may be the mechanism of binding of B. pertussis to
sulphated glycolipids, present in large amounts in the human trachea and lung
(Brennan et al., 1991).
FHA's importance in adhesion has meant that it has been included in potential
acellular vaccines (Ad hoc group for study of pertussis vaccines, 1988; Podda et al.,
1992).
1.2.3 Pertactin
Pertactin (P69) is a non - fimbrial agglutinogen (Mr 69 000) which has been sequenced
(Brennan et al., 1988; Charles et al., 1989). Its role in pathogenesis is unclear, but it
has been associated with the adenylate cyclase toxin (1.2.4 ) and contains the RGD
sequence involved in adhesion to some eukaryotic proteins (Leininger et al., 1991). It
has also been linked to active uptake of B. pertussis, by interaction with eukaryotic cell
receptors (Leininger et al., 1992). There is a strong antibody response to pertactin
(Anwar, 1991) and it protects against pertussis aerosol challenge (Shahin et al., 1990)
adding to the reasoning that it should be included in acellular pertussis vaccines (Podda
et al., 1992).
1.2.4 Adenylate cyclase toxin
B. pertussis secretes an adenylate cyclase toxin (ACT, cya A; Hewlett and
Wolf, 1976) whose production is governed by the cya operon (containing five genes :
cyaA, B, C, D and E) which codes for a protein of Mr about 200 000 (Glaser et al.,
1988). ACT is toxic to neutrophils, causes lysis of red blood cells and is partly
responsible for the incidence of secondary bacterial infection due to impaired host
immune responses.
ACT is activated by calmodulin binding (Wolf et al., 1980), enters eukaryotic
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cells, possibly by receptor-mediated endocytosis (Donovan and Storm, 1990) and
transiently increases levels of intracellular cAMP (Confer and Eaton, 1982; Hanski and
Farfel, 1985). This differs from toxins acting by ADP-ribosylation, which cause a
more protracted increase in cAMP levels.
The N-terminal, catalytic region which binds calmodulin has recently been
better defined (Ladant et al., 1992); two insertions between amino acids 247 and 248,
and 335 and 336, affect calmodulin activation of ACT. The C-terminal region of the
protein is thought to be involved in invasion and haemolysis (Rogel et al., 1991;
Gross et al., 1992).
In clinical trials acellular vaccines which were mostly based on pertussis toxin
and FHA decreased the severity of the disease, but gave incomplete protection.
(Storsaeter, 1990). The importance of ACT in virulence (Goodwin and Weiss, 1990;
Khlef et al., 1992) means it is a possible candidate for inclusion in an acellular
vaccine.
1.2.5 Endotoxin (lipopolysaccharide)
Endotoxins are lipooligo- or -polysaccharides (LPS) found in the outer
membrane of gram negative bacteria (e.g. Bordetella pertussis, Escherichia coli and
Salmonella typhimurium). They are variations of one molecule (fig. 1.1) which
consists of lipid A linked by 3-deoxy-D-manno-2-octolusonic acid (kdo) to a core
oligosaccharide, which is connected to a longer, more variable O-specific chain
(consisting of repeating units of three to eight sugars). The O-chain is the most
variable region and triggers a specific immune response (i.e. antibody production).
The lipid A domain is mainly responsible for the non-specific immune response by
macrophages, complement molecules and granulocytes.
B. pertussis produces two endotoxins, LPS-I which contains non -
phosphorylated kdo, and LPS-II which contains phosphorylated kdo (LeDur et al.,
1980; Peppier, 1984). Endotoxins stimulate macrophages to produce mediators
(proteins such as cytokines : tumour necrosis factor and interleukins 1, 6, and 8;
lipids, some of which cause fever and are transformed into oxygen free radicals,
which aid microbial killing). So if moderate amounts of endotoxin are released,
macrophage stimulation leads to eradication of disease by a controlled localised
immune response. If a more severe infection is encountered, larger amounts of
endotoxin are released (Morrison and Ryan, 1987) which can result in hypotension,
high fever and shock (leading to cell malfunction and cell death).
There are several possible mechanisms of endotoxin action. The endotoxin
may bind a carrier, then possibly to CD14 receptors on macrophages, which then
stimulate mediator release. Another view is that endotoxin directly binds receptors on
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Fig. 1.1 Schematic diagram of Bordetella endotoxin
Six saturated fatty acid chains are linked to two glucosamine residues (GlcN) in lipid A
The core oligosaccharide region of the lipooligosaccharide contains 3-deoxy-D-
manno-2-octolusonic acid (kdo), glucose (Glc), heptose (hept), glucosamine (GlcN)
and glucuronic acid (GlcA). The O-chain consists of repeating oligosaccharide units
including heptose, N-acyl hexosamine (NAcHex), mono/di-N-acylaminohexuronic
acid (NAchexA) and glucosamine.
lipidA
the macrophage surface without using a carrier, again stimulating mediator release
(Raetz et al., 1991).
Endotoxin is therefore thought to be responsible for the milder side effects of
the whole cell vaccine (fever; inflammation around the injection site) and is not
generally considered for inclusion in an acellular vaccine.
1.2.6 Tracheal cytotoxin
Tracheal cytotoxin (TCT) causes lung ciliostasis and cilial cell damage
(Goldman et al., 1982). TCT is produced by all strains of Bordetella and is a small
glycopeptide, N-acetyl glucosaminyl-1,6-anhydro-N-acetylmuramyl-alanyl-
glutamyldiaminopimelyl-alanine (Mr921 Da), derived from cell wall peptidoglycans
(Cookson et al., 1989) and it inhibits DNA synthesis in vitro, so slowing replacement
of static, damaged cilia (Goldman et al., 1982).
The mechanism of action of TCT is not fully understood; it has no observed
enzyme activity, so it may act via receptors on host cells.
1.2.7 Heat labile toxin
B. pertussis expresses a heat-labile toxin (inactivated by heating to 56°C;
Munoz, 1971) also called dermonecrotic toxin because it causes lesions when injected
into the skin. Its activity was first discovered by Bordet and Gengou (1909) and is a
single polypeptide (Mr 140 000) (Zhang and Sekura, 1991) produced by all strains of
Bordetella..
HLT may be involved in vasoconstriction (Endoh et al., 1986),which could
result in inflammation of highly vascularised tissues (e.g. lung, spleen), possibly
enhanced by endotoxin, in the initial stages of pertussis infection.
HLT has low antigenicity; it interferes with the adjuvant effect of pertussis
toxin, and relatively little is known about its biochemical action. It is not usually
considered for use in acellular vaccines.
1.3 Pertussis Toxin
1.3.1 General Introduction
Many of the effects of B. pertussis infection stem from the action of one
antigen called pertussis toxin (PT) (Pittman, 1979, 1984), which was known in the
past under names such as lymphocytosis promoting factor (LPF), histamine
sensitising factor (HSF) and islet activating protein (IAP).
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Pertussis toxin is believed to be involved in bacterial adhesion to glycoproteins
of cilia of the respiratory tract (3.3.8 ); it acts as an adjuvant, activates adenylate
cyclase, causes lymphocytosis, histamine sensitisation, T-cell mitogenicity,
haemagglutination, and increased insulin production leading to hypoglycaemia.
Several of the effects of pertussis are produced by the toxin alone (Ui, 1988), so
pertussis toxin is regarded as one of the major virulence factors of B. pertussis (Weiss
and Hewlett, 1986; also see section 1.1.2).
The toxin is also involved in bacterial uptake by macrophages. It binds to
carbohydrates on their surface, activating an integrin called CR3 which can then bind
filamentous haemagglutinin, resulting in the bacteria being taken up into the
macrophage (Hoepelman and Tuomanen, 1992; van't Wout et al., 1992).
1.3.2 Structure
The estimated molecular mass of pertussis toxin differs slightly depending on
whether it was measured by experimental methods, or was calculated from the
nucleotide sequence of the toxin subunits. Tamura et al., (1982) estimated the
molecular mass at 117 000, using equilibrium ultracentrifugation. They also found
that when the purified toxin was boiled with 1 %(w/v) SDS, it dissociated into five
subunits which were resolved by SDS-PAGE (Laemmli, 1970), in gradient gels of
10%(w/v) (top) to 30%(w/v) (bottom) acrylamide and the subunits were named SI,
S2, S3, S4 and S5 according to decreasing molecular weight (SI 28 000, S2 23 000,
S3 22 000, S4 11 700 and S5 9 300). These molecular masses add up to a total for
the whole toxin of 105 700. The difference between this value and the 117 000 value
could possibly be explained by the partial specific volume required for analytical
ultracentrifugation calculations being calculated from amino acid composition, instead
of being determined experimentally. Comparison of coomassie blue staining of the
subunits by scanning densitometry of SDS-PAGE gels suggested that S1-S5 exist in a
molar ratio of 1:1:1:2:1 in the holotoxin.
Sekura et al. (1983) purified pertussis toxin by affinity and gel filtration
chromatography. They analysed their toxin preparation by SDS-PAGE in 15%(w/v)
acrylamide gels and resolved only four subunits; the S4 and S5 subunits identified by
Tamura et al.{ 1982) ran as one band in the Sekura et al.( 1983) system, so Sekura et al.
(1983) proposed that the stoichiometry of the toxin, based on scanning densitometry
of SDS-PAGE gels was the toxin was a hexamer, SI, S2, S3 and S4 being in a
1:1:1:3 ratio. Molecular masses of each subunit also differed from those obtained by
Tamura et al. (1982), SI being 26 100, S2 25 300, S3 22 000, S4/S5 was a single
band of 13 200, giving a total mass for the whole toxin of 113 000.
Other groups have estimated slightly different molecular masses for the whole
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toxin and separated subunits by SDS-PAGE (Morse and Morse, 1976; Irons and
MacLennan, 1979; Peppier et al., 1985; Perera et al., 1985), but the estimates are hard
to compare as they were made using different protein standards, and/or different gel
systems. All the experimentally-determined molecular masses are similar to those
calculated by Locht and Keith (1986) and Nicosia et al., (1986) (see section 1.3.3)
with one exception. Cowell et al. (1982) estimated the molecular mass of the whole
toxin to be 170 000 under non-dissociating conditions using PAGE at acid pH, but
this is a notoriously difficult technique to interpret, so this value can be discounted.
The subunit stoichiometrics obtained by Tamura et al., (1982) and Sekura
et al., (1983) probably differ due to the acrylamide concentration used in SDS-PAGE;
the gradient system used by Tamura et al., (1982) having the better resolving power.
Both groups based their stoichiometry results on the assumption that all the subunits
have the same affinity for the Coomassie stain. This is not a wise assumption; since
dye binding in dissociating agents is a poor method of determining the concentrations
of different proteins; in particular, S5 is known to stain poorly on SDS-PAGE
(Nicosia et al., 1986).
At present the spatial position of the subunits in the toxin can only be inferred,
from toxin dissociation and association studies in urea (Tamura et al., 1982) and exact
subunit positioning awaits crystallisation of the protein (further investigation of
subunit organisation using chemical cross-linking reagents is discussed in chapter 4).
Tamura et al. (1982) dissociated the toxin into two dimers, 1 and 2, and two
monomers, S1 and S5, after treatment with 5 M urea (pH 6.0) at 4°C for four days
and separation by CM-sepharose cation exchange chromatography. Further treatment
with 8 M urea (pH 8.4) at 4°C for 16 hours and separation by DEAE-sepharose anion
exchange chromatography resolved dimer 1 into S2 and S4, while dimer 2 was
resolved into S3 and S4 (Tamura et al., 1982). This two-step purification was
required for quantitative analysis because S5 was denatured by exposure to 8 M urea.
Toxin assembly in the periplasm may occur in three steps: S2 and S3 each
combine with an S4 subunit; these dimers are then connected by one S5, making the
B-oligomer. The SI subunit binds only when the B-oligomer is formed
(Tamura et al., 1982; fig. 1.2).
If S3 is missing or defective the subunits accumulate in the periplasm (Nicosia and
Rappuoli, 1987), so S3 is needed for B-oligomer assembly. SI is also needed for
efficient release of the whole toxin into the extracellular medium, as strains with
mutations within SI still assemble the B-oligomer, which is released into the medium
in low amounts in the absence of mammalian cells (pertussis toxin is also thought to be
a bacterial adhesin) and SI is not incorporated into the toxin (Pizza et al., 1990).
Pertussis toxin is an A-B type toxin, like several other bacterial toxins, such as
cholera toxin, E.coli heat labile toxin, diphtheria toxin and Pseudomonas aeruginosa
exotoxin A (Gill, 1976; Pappenheimer, 1977; Tamura et al., 1982; Pastan and
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Fig. 1.2. Schematic model of pertussis toxin dissociation in urea










































Fitzgerald, 1989). The A protomer is the SI subunit of pertussis toxin, acting as an
ADP-ribosyltransferase (section 1.3.6) and the B-oligomer is S2 to S5, which binds
eukaryotic cells (section 1.3.5.and chapter 3). Pertussis toxin is also the only known
AB type bacterial toxin that is involved in attachment of bacteria to mammalian cells
(Tuomanen and Hendley, 1983)
Labelling of the holotoxin subunits has given another insight into subunit
organisation (Montecucco et al., 1986). To determine which subunits interact with
membrane lipids, labelling of pertussis toxin with two phospholipid micelles was
observed and the results agreed with the accepted model of pertussis toxin (Figures
1.2 and 1.3). It is thought that SI is quite weakly attached to the B-oligomer (Tamura
et al., 1982), but precisely how the subunits of the B-oligomer are arranged, where
they bind SI, and where the S3-S4 and S2-S4 dimers are held together is not known.
1.3.3 Cloning and sequencing of pertussis toxin
The DNA sequence of the pertussis toxin operon has been obtained (Locht and
Keith, 1986; Nicosia et al., 1986). The genes are organised in the order SI, S2, S4,
S5, S3 (Fig 1.4) with the open reading frame for S4 overlapping the S2 and S5 genes.
There is a promoter upstream of SI and a site for a trans activating regulatory protein
(produced by the bvg regulon, see 1.3.4), which switches expression of the toxin
subunits on and off at the level of transcription (Nicosia and Rappuoli, 1987).
Each subunit has an N-terminal signal sequence of variable length. The
subunits are secreted into the periplasm separately and their signal sequences are
cleaved, to give the mature subunits with calculated molecular masses of:
51 26 024 (234amino acids (aa)) S4 12 058(110 aa)
52 21 924 (199 aa) S5 11 013 (100 aa)
53 21 873 (199 aa)
(Locht and Keith, 1986). S4 has a long signal sequence of 42 residues (Nicosia
et al., 1986) and a high positive charge at its N-terminal and this may mean that
secretion of S4 is very efficient (Nicosia et al., 1986). That there are two copies of S4
in the holotoxin produced from a single copy gene may be due to different promoter
strengths controlling transcription. SI has no lysine residues in its deduced amino
acid sequence and contains two regions of homology with the A protomers of
Escherichia coli heat labile toxin (HLT) and cholera toxin :
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Fig. 1.3. Model of pertussis toxin interaction with
phospholipid micelles
(Montecucco et al., 1986)
Phospholipid 1 was labelled at the head group and interacted with parts of the toxin
which did not penetrate deep into the micelle.
Phospholipid 2 was labelled at the fatty acid methyl terminus and interacted with parts
of the toxin which did penetrate deep into the micelle.
 
Fig. 1.4. Organisation of the pertussis toxin operon
(Locht & Keith 1986; Nicosia et al 1986)
The arrow shows the direction of translation; shaded boxes
show the presence of signal peptides and the bars within the SI
subunit represent regions 1 and 2 (1.3.3) which are homologous
to the A protomers of E. coli heat labile toxin and cholera toxin.
Directionoftranslatio
Region 1
Pertussis toxin S1 subunit (8) YRYDSRPP (15)
Cholera toxin A subunit (6) YRADSRPP (13)
E. coli HLT A subunit (6) YRADSRPP (13)
Region 2
Pertussis toxin S1 subunit (51) VSTSSSRR (58)
Cholera toxin A subunit (60) VSTS ISLR (67)
E. coli HLT A subunit (60) VSTSLSLR (67)
(Numbers in parentheses denote amino acid sequence number).
Mutations within region 1 affect the enzymic activity of the SI subunit of
pertussis toxin and the other two toxins (Cieplak et al., 1988; Burnette et al., 1991;
Lobet et al., 1991).
1.3.4 Regulation of expression of virulence factors
The expression of bacterial proteins is often regulated by environmental
conditions. Many bacteria have a temperature-regulated method of expressing proteins
needed for colonisation of a host (Miller et al., 1989) and chemical agents can also
control transcription of the 'virulence genes' giving rise to these proteins. Bordetella
pertussis virulence genes are induced by both temperature and chemicals (Arico et al.,
1989; Roy et al., 1989; Scarlato et al., 1990, 1991).
Expression of the virulence factors of B.pertussis is under the control of the
bvg locus, or regulon (Bordetella virulence gene ), which contains several operons and
unlinked genes, two of these coding for regulatory proteins BvgA and BvgS
(originally called BvgABC ), which have calculated molecular masses of 23 000 and
135 000. These are members of a family of signal transduction proteins, judged by
sequence homology (Gross et al., 1989; Scarlato et al., 1990).
A model suggested by Arico et al. (1989) and Stibitz and Yang (1990, 1991) is
that BvgS is a monomeric trans-membrane protein; its N-terminal end senses external
signals which trigger dimerisation of BvgS and transmits the signals to a cytoplasmic
domain, which phosphorylates BvgA, enabling it to dimerise, bind DNA and activate
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transcription.
All except one of the promoters controlling the bvg locus (called Pj, P3,P4; the
exception being P2) and the promoters of the Bordetella virulence genes are regulated
by environmental factors. A temperature shift from 25 to 37°C immediately induces
Pi and P4 of the bvg locus, Pfha which produces fdamentous haemagglutinin
(FHA)and the fimbrial gene promoters (Willems et al., 1990; Scarlato et al., 1991).
Other promoters are induced after a time lag of about two hours (eg. P3 of the bvg
locus; Prox and Pad which control pertussis toxin and adenylate cyclase toxin
transcription), which may be due to large amounts of BvgA and S being required for
activation of these promoters (Scarlato et al., 1991). In summary, genes involved in
bacterial adhesion (eg. FHA, fimbriae) are switched on before those involved in
systemic effects of the disease.
1.3.5. Interaction of pertussis toxin with cell membranes and
entry into the cell
1.3.5.1 Binding to cell membrane receptors
Pertussis toxin interacts with cells via its B-oligomer, which can be said to
have three functions; to bind receptors containing glycoproteins and glycolipids on the
host cell surface, bind whole bacteria to cells (Tuomanen and Weiss, 1985) and to
deliver SI to its target cell. Purified B-oligomer causes erythrocytes to agglutinate,
blocks entry of whole toxin to adipocytes and is also responsible for the mitogenic
action of the toxin on T-cells.
Binding of the B-oligomer to eukaryotic cell membrane receptors has been well
documented (Tuomanen et al., 1988; Clark and Armstrong, 1990; Relman et al., 1990;
Saukkonen et al., 1992). The B-oligomer binds a 165kDa glycoprotein on Chinese
Hamster Ovary (CHO) cells (Brennan et al., 1988), a 70kDa and a 43kDa membrane
protein on T-lymphocytes (Clark and Armstrong, 1990; Rogers et al., 1990) and a
115kDa protein in goose erythrocyte extracts (Witvliet et al., 1989).
Certain carbohydrate residues are important in toxin binding to eukaryotic
cells, but little is known about the mechanism of binding and entry of the toxin to the
cell. Sialyllactosamine (NeuAc-^ Galp4) needs to be present for binding; a CHO
cell line lacking terminal sialyllactosamine residues on N-linked oligosaccharides did
not react to toxin treatment. When a normal CHO cell line is treated with toxin,
morphological changes occur and the cells cluster (Hewlett et al., 1983; Gillenius et
al., 1985; Witvliet et al., 1989).
B-oligomer also binds to serum glycoproteins, eg. fetuin and haptoglobin
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(Irons and MacLennan, 1979; Sekura et al., 1983; Capiau et al., 1986) and mucosal
proteins such as a-1 acid glycoprotein (Armstrong et al., 1988). Fetuin contains both
N- and O-linked oligosaccharides. Removal of the O-linked chains has no effect on
fetuin's ability to bind toxin (Sekura et al., 1985), so binding must involve N-linked
oligosaccharides. Further investigation of this observed binding was carried out by
Armstrong et al., (1988), who suggested that sialic acid (neuraminic acid), galactose
and N-acetyl glucosamine are important in toxin binding, as are these residues'
orientation within the carbohydrate chains. Monosaccharides were sequentially
removed from the non-reducing termini of the carbohydrate chains of fetuin and then
replaced one sugar at a time. Removal of sialic (neuraminic acid ) creating asialofetuin,
reduced toxin binding to fetuin considerably. Sialic acid replacement in the a 2,6
orientation, found only in N-linked oligosaccharides restored fetuin's pertussis toxin
binding; replacement in the a 2,3 orientation found in both N- and O-linked
oligosaccharides had little effect. Removal of galactose, linked (31,4 in the N-linked
chains was also found to decrease binding of the toxin, as was removal of GlcNAc,
only found in N-linked oligosaccharides.
B-oligomer receptor binding is mainly mediated by the S2 and S3 subunits
(Capiau, et al., 1986; Van't Wout et al., 1991; 1992). S2 and S3 are each linked to
one S4 subunit, these dimers are linked by an S5 subunit. Antipeptide antibodies to
52 or S3 peptides inhibited toxin-mediated erythrocyte agglutination (Schmidt et al.,
1989; 1991).
Recent data suggest that regions of S2 bind galactose-containing
glycoconjugates and recognise respiratory cilia and T-cells, but do not bind galactose-
containing glycoconjugates on macrophages, nor sialylated glycoproteins; regions of
53 recognise and bind sialylated glycoconjugates, for example on macrophages and
monocytes (Rogers et al., 1990; Saukkonen et al., 1992; Van't Wout et al., 1992); but
do not bind respiratory cilia.
A study of peptides of pertussis toxin subunits involved in carbohydrate
recognition, and attachment to eukaryotic cells, is discussed in more detail in chapter
3.
1.3.5.2 Pertussis toxin entry into the cell
Pertussis toxin SI subunit needs to pass through the cell membrane to reach its
substrates located on the inner face of the plasma membrane, and catalyse transfer of
ADP-ribose from NAD+ to intracellular proteins (1.3.6, 1.3.7).
The whole toxin's B-oligomer binds its cellular receptor, may penetrate the
plasma membrane and bind ATP which is thought to weaken interactions between SI
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is thought to weaken interactions between SI and the B-oligomer and releases S1
(Burns and Manclark, 1986; Hausman et al., 1990). How much of the B-oligomer
needs to penetrate the plasma membrane to facilitate SI entry is unknown.
The mechanism for SI entry is unknown, but is thought to involve one of two
mechanisms, which are endocytosis, like diphtheria toxin and possibly cholera toxin
(Saelinger, 1990; Janicot et al., 1991) or direct entry through the plasma membrane
(cholera toxin is believed to enter some cells by this mechanism; see section 1.5.1 and
Ribi et al., 1988)
Diphtheria toxin requires an acidic environment to enter eukaryotic cells, an
environment which is found in endosomes. Pertussis toxin appears not require an
acidic environment for entry to cells (Hausman and Burns, 1992) as pertussis toxin
intoxication of CHO cells was not reduced by abolition of membrane pH gradients by
NH4CI.
Parts of the toxin interact with detergents (Moss et al., 1986) and
phospholipids (Montecucco et al., 1986; Hausman and Burns, 1992). The latter
workers suggest that as the isolated SI subunit binds phospholipid-containing vesicles
in the presence of reducing agents, which are required for enzymic activity (Kaslow
and Lesikar, 1987), then SI entry to cells may involve whole toxin binding to a cell
receptor via its B-oligomer, ATP binding to the B-oligomer facilitating the release of
SI, and direct interaction of SI with the membrane.
The degree of the B-oligomer's involvement in facilitating SI entry and
mechanism are still to be fully clarified. It is not known if the B-oligomer penetrates
the plasma membrane, if so how far, and which subunits are involved in the
penetration.
1.3.6 Effects of pertussis toxin on adenylate cyclase
Pertussis toxin prevents inhibition of eukaryotic membrane adenylate cyclase
by ADP-ribosylation of a 41kDa membrane protein (Katada and Ui, 1982). The toxin
does this by enzymically cleaving NAD and binding the ADP-ribose released to its
eukaryotic protein substrate, which is Gi in the adenylate cyclase system, at a cysteine
residue four residues from the C-terminus (Hurley et al., 1984; West et al., 1985).
The protein substrates ADP-ribosylated by pertussis toxin are a family of
guanine nucleotide binding proteins (G proteins) involved in regulation of adenylate
cyclase activity. The major G protein modified is Gi (inhibitory GTP binding protein,
subunit Mr41kDa) which normally mediates the effects of inhibitory hormones on
adenylate cyclase (Smith and Limbird, 1982; Murayama and Ui, 1983; Gilman, 1987).
The mechanism for ADP-ribosylation of Gi and other pertussis toxin sensitive G
proteins is shown in fig. 1.5.
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Two or more G proteins are involved in adenylate cyclase regulation; Gi and
Gs (stimulatory GTP binding protein), Gs being the protein which normally mediates
the effects of stimulatory hormones on adenylate cyclase and the substrate for cholera
toxin. ADP-ribosylation of Gs leads directly to cAMP production; ADP-ribosylation of
Gi removes inhibition of cAMP production induced by stimulatory hormone-receptor
signals.
Gs and Gi are heterotrimeric proteins (Mr about 90kDa) which have highly
conserved amino acid sequences, and are associated with the inner face of the plasma
membrane. They contain one a ( ai Mr41kDa; Katada and Ui, 1982; Burns et al.,
1987; as Mr 42kDa), one p (Mr about 35kDa) and one y subunit (Mr about 5kDa).
In their 'resting' state (Milligan, 1988), G proteins have GDP bound to their a
subunit. When a ligand binds to its receptor, the ligand-receptor complex binds the G
protein, enabling it to exchange GDP for GTP (Brandt and Ross, 1986) and dissociate
to active a.GTP and a Py dimer (Hanski and Gilman, 1982; Bokoch et al., 1983).
The presence of Py increases dissociation of the G protein (Higashijima et al., 1987).
In the presence of Mg-+ions, a.GTP can then bind its effector and either stimulate or
inhibit its activity.
Normally, Gi a.GTP binds its effector, adenylate cyclase, and inhibits
production of cAMP, which acts as a second messenger and activates protein kinase
leading to phosphorylation of a range of proteins, altering their function. The a
subunit acts as a GTPase, and the GTP bound to Gia.GTP is hydrolysed to GDP.
The a subunit dissociates from its effector, reassociates with Py and returns to its
resting state (fig. 1.6).
The C-termini of Ga subunits which are sensitive to pertussis are highly
conserved (Price et al., 1990) and are thought to interact with the receptor-ligand
complex, promoting dissociation and activation of the G protein. The direct ADP-
ribosylation of these G proteins by pertussis toxin occurs at a cysteine four residues
from the C-terminal, blocking their interaction with the receptor-ligand complex and
blocking binding of GTP to the a subunit. If the G protein is Gi, when it is ADP-
ribosylated by pertussis toxin at its C-terminal, it can no longer interact with the
inhibitory receptor-ligand complex, or bind GTP, and so can no longer inhibit
adenylate cyclase, leading to unregulated production of cAMP (Gs has a tyrosine at
this position and so is not a substrate for pertussis toxin; Fong et al., 1988). One form
of a i.GTP also activates potassium channels in heart and is involved in regulation of
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Fig. 1.6. Activation/deactivation cycle of a G protein.
GTP binding results in dissociation of the G protein
a subunit from the Py dimer (activation). GTP
hydrolysis results in reassociation of the G protein
subunits (deactivation).
Activation is dependent on GTP and magnesium ions.
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Gsa.GTP binds adenylate cyclase and stimulates production of cAMP via
stimulatory hormones. Gsa is ADP-ribosylated at an arginine residue and locked in
its active state, with GTP bound (i.e.. the GTPase activity is inhibited), leading to
continuous stimulation of adenylate cyclase and unregulated production of cAMP.
The structure-function relationships of the various types of (3 and y subunits are still to
be fully defined. The two subunits exist as a dimer, and may anchor the G protein to
the plasma membrane (Toro et al., 1987; Birnbaumer, 1987, 1990; Boquet and Gill,
1991). p subunits are highly homologous even in G proteins with different functions
(Tamir et al., 1991), and recent data suggest that p subunits may regulate steps in the
GTP hydrolytic cycle, as Py has been found to interact directly with some of the
specific effector systems linked to the GTP hydrolysis cycle (Okabe et al., 1990;
Stryer, 1991).
y subunits are very divergent among species (Tamir et al., 1991), possibly
helping the Py dimer to recognise and deactivate the a subunit from which they
dissociated on activation of the G protein.
1.3.7 Other pertussis toxin-sensitive proteins
Several other G proteins are ADP-ribosylated at a cysteine four residues from
their C-terminals by pertussis toxin, and these are also involved in signal transduction.
Gt (transducin) is a retinal rod protein which regulates cyclic GMP-
phosphodiesterase (cGMP-PDE; Tsuda et al., 1986). The a subunit (now called atl)
has an Mr of 39 000, p has an Mr of 36 000 and y has an Mr of about 7 000. The
initial 'ligand-receptor' interaction is the activation of rhodopsin by light (Gilman,
1987; Stryer, 1991). Normally, when light activates rhodopsin, it interacts with GDP-
bound Gat which exchanges GDP for GTP and dissociates from Py as described in
section 1.3.6. at.GTP then stimulates cGMP-PDE, which leads to reduction of
cGMP levels in the cytoplasm, closes cGMP-regulated ion channels and causes
hyperpolarisation of rod outer segment plasma membranes (Stryer, 1991).
ADP-ribosylation of Gt caused by pertussis toxin in the dark locks it in its
inactive form with GDP bound, so visual signals are blocked. Cortina et al. (1991)
have shown that residues between 180 and 219 of the SI subunit of pertussis toxin are
needed for efficient ADP-ribosylation of Gt.
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Another form of at subunit (called at 2) has been discovered in retinal cones
and it is similar to that in rods.
An interesting development is the discovery of a protein in retinal rods, which
has an Mr of 12 000 and appears to stimulate GTP binding to rod Gt a. The protein,
called 6, occurs in 3-10% of the amount of y. (36 stimulates GTP binding to a more
than (3y, so may be involved in GTP binding to Gt and activation of cGMP-PDE
(Umbarger et al., 1992). This work needs clarification, as 6 could have originated
from retinal cones contaminating the rod preparation.
Another pertussis-sensitive G protein is Go; two forms of Go have been
discovered called aol and ao2, which are both sensitive to pertussis toxin
(Spicher et al., 1992). They are widely distributed throughout the central nervous
system (Hsu et al., 1990) and as many as four Go-like proteins may exist, which
have been resolved by ion exchange chromatography (Ianobe et al., 1990). The two
forms have molecular masses of 39 000 and may be involved in potassium channel
regulation, inactivate calcium channels and activate phospholipase C (Schultz et al.,
1990; Brown et al., 1991). The biochemical function of these G proteins remains to
be fully determined. Several G proteins involved in activation of membrane
phospholipases have still to be fully studied. They are called Gp; the class being
subdivided into those which activate phospholipase C or A2 (PLC or PLA2).
Responses to vasopressin and angiotensin II are due to PLC stimulation by a
pertussis-sensitive G protein. Receptor-mediated arachidonic acid release (eg. from
macrophages) is due to PLA2 stimulation.
ADP-ribosylation of G proteins by pertussis toxin can have a number of
effects, for example, a-adrenergic receptors involved in regulation of insulin secretion
can be uncoupled from adenylate cyclase by ADP-ribosylation of Gi, resulting in over-
secretion of insulin leading to hypoglycaemia; this effect was noted by Katada and Ui
(1979) as the islet-activating activity of pertussis toxin. Inhibition of histamine
secretion could also be due to ADP-ribosylation of Gi, leading to over-secretion of
insulin, increased vascular permeability, resulting in histamine sensitisation. Arciniega
et al., (1991) recombined a mutant form of SI having no enzymic activity with toxin
B-oligomer, resulting in a mutant holotoxin which had decreased histamine sensitising
activity compared to native whole toxin. This suggests the activity belongs to the SI
subunit.
The effect of pertussis toxin on Chinese Hamster Ovary (CHO) cells may be
due to ADP-ribosylation (Burns et al., 1987; Nencioni et al., 1991); CHO cells cluster
and their shape alters after toxin treatment (see section 3.3.8.2.6.6). Nencioni et al.,
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(1991) suggested that the effect is caused by the SI subunit as isolated B-oligomer did
not cause morphological changes in CHO cells. Askelof et al. (1990) suggest that
Chinese Hamster ovary (CHO) cell clustering is due to a whole toxin-binding event
involving part of the SI subunit, as rabbit antiserum to an SI subunit synthetic peptide
conjugated to diphtheria toxin cross-reactive mutant protein (CRM) inhibited ADP-
ribosylating activity of the toxin in CHO cells, but had no effect on CHO cell
clustering. Antiserum to a different peptide conjugate whose sequence was derived
from the SI subunit had the converse effect.
Whether CHO cell clustering is a direct effect of ADP-ribosylation and exactly
how toxin binding to the CHO cells is involved is yet to be fully defined.
It must be remembered that not all effects of pertussis toxin are due to ADP-
ribosylation; toxin B-oligomer binding alone produces some of them (see section
1.3.5). A summary diagram of some of the pathways affected by pertussis toxin are
shown in fig. 1.7.a and b.
1.4 Towards partially/wholly synthetic pertussis vaccines
1.4.1 Immune response to a foreign molecule
The immune response consists of several nonspecific components, including
mononuclear phagocytes, polymorphonuclear leukocytes and the complement system.
The specific recognition molecules of the immune system are the B- and T-
lymphocytes. Usually both humoral (B lymphocytes, antibody) and T cell systems
interact in response to an antigen.
Antibodies are secreted from B cells and bind antigen molecules or cells, via
epitopes on the antigen. This binding is recognised by a responsive B cell and
internalisation of the antigen-antibody complex is triggered. The native antigen is
cleaved in the cytoplasm into peptides ten to twenty amino acids in length, that are
presented on the B cell surface by type II major histocompatability complexes (MHC).
T helper cells carrying a glycoprotein CD4 on their surface recognise the antigen-MHC
II complex and B cell functions are altered, e.g. proliferation and isotype switching
occur.
Another class of MHC molecule called type I are found on the plasma
membrane of all cells with nuclei. Peptides of eight to ten residues are presented by
MHC I and recognised by a subset of cytotoxic T cells important in lysis of virally
infected cells, for example. These cytotoxic T cells recognise the MHC I-antigen
complex via CD8 glycoprotein on their surface and lyse the infected cell.
There are several types of T cell, classified according to their various cell
surface markers and functions. Primitive T cells develop T cell specific surface
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Fig. 1.7a, b Other proteins sensitive to pertussis toxin
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antigens in the thymus and when they mature they leave the thymus expressing CD4 or
CD8 glycoproteins, for example.
B cells are specifically activated by antigen binding to an Ig isotype on the cell surface
and nonspecific activation can be achieved by B cell mitogens.
Protein antigens can activate antibody response in two ways:
T-dependent antigen activation
When an MHC 11-antigen complex is presented by a B cell to a T helper cell, it
is activated and releases lymphokines. The antigen and lymphokines switch the B cell
on to antibody secretion. The primary antibody response to antigen involves IgM
secretion and this is switched by T helper cells to IgG, IgA and sometimes IgE in the
secondary response. This type of activation can lead to a large pool of T and B
memory cells.
T-independent antigen activation
Some antigens (e.g. polysaccharides) trigger B cell functions directly,
needing no T cell help, but they induce little memory and produce mainly IgM
responses.
There are two subclasses of T-independent antigen: Type I (e.g. LPS) that
result in a large direct response but with little memory and Type II, a subclass
including some linear antigens containing repeat sequences, that are not easily handled
by the body and induce largely a direct IgM response.
In summary of the T cell dependent immune response, antigen binds Ig expressed on
the surface of B cells and is internalised and degraded (priming). The peptides created
are presented at the cell surface complexed with MHC II molecules and trigger T
helper cells to secrete lymphokines, that switch B cells to antibody making B memory
cells. This antigen priming makes for a faster secondary immune response to antigen.
1.4.2 Recognition of antigenic sites
Antigenicity is the ability of a molecule to be recognised by B cell (antibodies)
and T cell receptor molecules. Structures recognised and bound by B or T cells are
known as antigenic determinants, or epitopes. B cell molecules (antibodies) are
thought to recognise mainly conformational epitopes formed by discontinuous
sequences on the native protein surface (Blundell et al., 1987). Several 'linear'
(continuous) sequences that would be surface-exposed on the native antigen are
believed to form domains of these discontinuous epitopes and be recognised by
antibody (Kazemi and Finkelstein, 1991). The minimum number of amino acids in
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required to induce a B cell response has been put at six (Geysen et al., 1988) when
presented correctly to the B cells.
T cells recognise peptide fragments about 10 amino acids long (Horsfall et al., 1991)
presented by a major histocompatability complex (MHC). These T cell epitopes may
originate from regions not exposed on the surface of the native antigen, so they have
also been termed cryptotopes (Laver et al., 1990).
1.4.3 Identification of antigenic epitopes
Several methods are available to aid in identification of protein epitopes. X-ray
crystallography has identified discontinuous epitopes of lysozyme and influenza virus
neuraminidase, for instance (Davies et al., 1990; Tulip et al., 1990), each consisting of
15 -22 residues in contact with the antibody over an area of 65-90nm on the protein.
This is a method that relies on crystallisation of the protein, and as relatively few
crystal structures are known at the present time, other methods have to be employed.
Site-directed mutagenesis can be utilised to detoxify a protein without
destroying antigenic sites, as used when a single mutation in the SI subunit of
pertussis toxin (R9 to K) was introduced to create a detoxified toxin in Bordetella
(Burnette et al., 1988; Pizza et al., 1989). Although whole recombinant toxin was
assembled, it was at low levels and with the possibility of contamination with other
Bordetella toxins (Weiss and Hewlett, 1986). Even so the recombinant toxoid was
included in human vaccine trials in 1990 (Podda et al., 1990).
Epitope libraries using phage lambda, with each virion expressing one peptide
sequence on its surface, could be screened for antibody binding. A random library of
peptides is created in this way and epitopes, or 'mimotopes' (sequences mimicking
native protein epitopes) can be identified (Scott and Smith, 1990; Devlin et al., 1990).
Computer prediction of antigenic regions, from primary amino acid sequence
has been attempted by predicting (1 turn potential and surface exposure
(Krchnak et al., 1987). Molecular modelling of antibody-antigen interactions have
been tried to identify antigenic sites (Blundell et al., 1987).
Both free and immobilised peptides are used to identify antigenic sites (and
receptor binding sites, for instance). Both were used in the study of antigenicity of
pertussis toxin subunits, which is discussed in more detail in chapter 3.
1.4.4 Peptide synthesis
Development of automated long chain tBoc peptide synthesis by Merrifield
(1963) opened the way for the study of structure and function of discrete regions of
proteins. The tBoc (tertiary butyloxycarbonyl) group can be used to protect the amino
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function of amino acids used in solid phase protein synthesis. Peptide synthesis has
been refined and changed since then, for several reasons, some of which are listed
below. Solid phase supports were developed that were more polar than the ones used
originally, to increase peptide solvation. The tBoc group used in the Merrifield
method was removed from the N-terminal amino acid by acidolysis using TFA before
each amino acid coupling step. Acidolysis derivatises some peptides and side
reactions side reactions can occur, for example t-butyl cations created in N-terminal
deprotection can react with nucleophilic amino acid side chains (e.g. of histidine,
tryptophan and tyrosine). As a result a protecting group for the amino function was
sought that could be removed under mild alkaline conditions. The search resulted in
the development of the fmoc group (9-fluorenylmethoxycarbonyl; Chang and
Meienhofer, 1978; Atherton et al., 1978) which is removed by treatment with a mild
base. Other changes of the side chain protecting groups used, and the methods used
for their removal, as well as improvement of conditions for peptide solvation have also
occurred (for a review of fmoc solid phase peptide synthesis see Fields and Noble,
1990).
Solid phase peptide synthesis on derivatised 'pins' was developed by Geysen
et al., (1984; 1987). Peptides, usually six to ten amino acids long are covalently
linked one at a time, to derivatised polypropylene pins arranged in blocks of 96 and
screened for antibody binding using a modified ELISA system, with the aim of
identifying antigenic sites (in this case linear peptides which may or may not be part of
conformational epitopes on a protein). The technique has been used to map B cell
epitopes of many proteins, for example from viruses, e.g. foot and mouth disease
(Geysen et al., 1984; Meloen and Barteling, 1986) and from bacteria, e.g. E.coli
colonization factor antigen I (Cassels et al., 1992). Cholera toxin B cell epitopes have
been studied using this technique (Kazemi and Finkelstein, 1991) as have B cell
epitopes of eucaryote proteins, for example bovine growth hormone (Beattie et al.,
1992) and dihydrofolate reductase (Tan et al., 1990).
1.4.5 Peptide antigenicity
Synthetic peptides must be able to induce production of antipeptide antibodies
that can bind specifically to the native antigen and some synthetic peptides can cross-
react with antibodies to the native protein, suggesting that the peptides exist in the
same (or a similar) conformation as in the native protein. Therefore, they may induce
antibodies that neutralise the biological activity of the native protein when included in a
vaccine.
A number of factors determine which sequences are antigenic, assuming that
antibodies bind residues on the protein surface:
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Regions of hydrophilicity may be antigenic, and charged residues are likely to be at the
protein surface (Hopp and Woods, 1981).
Local mobility of proteins and mobility of peptides seems important in determining
antigenicity (Tainer et al., 1984; Westhof et al., 1984). The tendency to form 13 turns
is also used (Hopp and Woods, 1981).
A linear peptide which binds antibody is termed a continuous epitope (Atassi and
Smith, 1978) and most continuous epitopes occur in surface regions of a protein
(Barlow et al., 1986), have a convex shape, a high local mobility (Getzoff et al.,
1987) and are either chain termini or 8 turns (i.e. on the protein surface). A
continuous epitope may be part of a more complex, discontinuous epitope (Getzoff
et al., 1987; Rini et al., 1992).
A problem of short peptides is that they may not be recognised by antibody as
they may not have a recognisable structure and they may not be immunogenic.
Peptides are assumed to exist in a number of random conformations and a small
number of these correspond to the conformation in the native protein (Furie et al.,
1975; Dyson et al., 1988a, b). About 90% of continuous epitopes are six amino acids
or less; this is thought to be the minimum number to induce a B cell response (Geysen
etal, 1988).
1.4.6 Requirements for a pertussis vaccine containing synthetic
peptides
An ideal vaccine should be safe, immunogenic and produce a large pool of B
and T memory cells to protect against a disease for an indefinite period. This should
be backed by vaccine stability and the ability to produce it economically on a large
scale. This has lead to attempts to develop more characterised vaccines containing
immunogenic peptides with multiple T and B cell epitopes, to ensure that most host
immune systems recognise some of the epitopes and produce a protective response.
An antigen may contain one immunodominant B-epitope, which simplifies the choice
of peptides for inclusion in a vaccine (e.g. the hypervariable loop of the gpl20 protein
of HIV). If there is no immunodominance, e.g. in the case of influenza virus
haemagglutinin (Wang et al., 1986) the range of peptides which may be suitable for
inclusion in a vaccine expands.
1.4.7 Presentation of peptide
Peptides shorter than 20 amino acids may not be immunogenic, so they are
linked to larger carriers, such as bovine serum albumin (BSA) or keyhole limpet
haemocyanin (KLH), which are recognised by B cells. KLH is highly immunogenic,
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so antigenic competition can occur, inducing a response to the carrier rather than the
peptide. A carrier can alter the peptide's conformation and recognition may differ
depending on whether the peptide is linked via its N- or C-terminal, so more than one
carrier and method of conjugation is usually considered (Dryrberg et al., 1986; Chong
etal, 1991; 1992).
If several administrations of a vaccine containing carrier-conjugated peptides
are required, sensitization to the carrier can be induced. This may be reduced by use
of an adjuvant, other than those used in rabbits and mice (e.g. Complete Freunds
adjuvant) which causes inflammation and granuloma and so can not be used in
humans. Another carrier system being investigated is the linking of a peptide to a
detoxified toxin known to be immunogenic, such as tetanus toxoid, cholera and
diphtheria toxoids and meningococcal outer membrane proteins (Ballou et al., 1987;
Ballou, 1991). A repeating unit of Plasmodiumfalciparum circumsporozoite protein
has been linked to Pseudomonas aeruginosa exotoxin A and tested for immunogenicity
in humans (Fries et al., 1992).
1.4.8 Antigenicity of pertussis toxin
Pertussis toxin is a major protective antigen against pertussis, as shown by
clinical trials of several vaccines (Ad hoc group for the study of pertussis vaccines,
1988; Miller et al., 1989; Olin et al., 1989) but is also a major virulence factor in
pertussis, as discussed in section 1.3, complicating vaccine development.
Some vaccines currently in use employ chemically detoxified pertussis toxin.
This detoxification method may alter antigenic regions of the protein and so affect
immunogenicity of the toxoid. Also, rigorous purification procedures may not remove
contamination by other Bordetella pertussis toxins (Weiss and Hewlett, 1986).
Haptoglobin- or fetuin-affinity chromatography are most widely used for pertussis
toxin purification and eluants used with these methods include high concentrations of
magnesium chloride, which may alter the toxin structure (Chong and Klein, 1989), or
thiocyanate, which is expensive to dispose of and highly toxic. These elution
conditions also have the potential of leaching of the fetuin or haptoglobin into toxin
preparations. Haptoglobin is purified from human plasma and transmission of blood-
carried disease is possible, as well as sensitization to human and bovine (the source of
fetuin) blood constituents can be induced.
So antigenic epitopes of pertussis toxin are being located (mapped) in the hope
that some are immunogenic and can be used in the induction of protective immune
responses to either detoxified whole toxin, subunits, or synthetic peptides in acellular
vaccines. Multiple B and T cell epitopes of pertussis toxin subunits are being
discovered, and B cell epitopes were the subject of studies by the author. B cell
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antigenicity of particular subunits is discussed in chapter 3.
1.5 Other Toxins
There are a number of toxins with similarities to pertussis toxin, including their
A-B type structures, the way they bind cells and their mechanism of action. Cholera
toxin, diphtheria toxin, E. coli heat labile toxin and Pseudomonas aeruginosa exotoxin
A are among the other examples of ADP-riboyslating toxins. These toxins, as well as
tetanus and botulinum neuro- and cytotoxins will be briefly discussed in this section.
1.5.1 Cholera toxin and Escherichia coli heat labile toxin
Cholera is caused by the non-invasive organism Vibrio cholerae which infects
the gastrointestinal tract. The resulting severe loss of fluid, diarrhoea and dehydration
can kill, although fluid replacement is an effective treatment.
Some strains of E. coli secrete a toxin called heat labile toxin (HLT), which
has about 80% amino acid identity with cholera toxin. HLT has been crystallised
(Sixma el ah, 1991; 1992) and its crystal structure deduced from X ray diffraction is
assumed to be almost identical to the crystal structure of cholera toxin. The crystal
structure of cholera toxin is being investigated and structural similarities to HLT have
been identified (Westbrook, personal communication). Both are A-B type toxins,
having one A subunit of Mr about 27 000, and five B subunits of Mr about 11 000,
coded for by the genes ctxA and ctxB (Mekalanos et al., 1983) in Vibrio cholerae .
Both A and B are synthesised with signal peptides which are cleaved on
secretion into the periplasm where the mature toxins are assembled. The A subunit of
cholera toxin (CTX A) is modified further by proteolysis to give an N-terminal Al
fragment (Mr about 22 000) and C-terminal A2 fragment (Mr about 5 000) (Mekalanos
et al., 1979; van Heyningen, 1982) linked by a disulphide bond; cleavage of this bond
is thought to be necessaiy for activation of the ADP-ribosyltransferase (Gill, 1976).
Like cholera toxin A subunit, HLT A is proteolytically nicked after binding its
cell receptor, to give Al and A2fragments. A] is then internalised possibly by
endocystosis (Janicot et al., 1991).
The B subunits of both HLT and cholera toxin A bind GMj on the cell surface
(van Heyningen, 1977; Moss and Vaughan, 1988) and crystallisation of HLT with
lactose (Sixma et al., 1992) has revealed the toxin binding site for GMi and shown
that Al apparently faces away from the cell binding site, which is assumed to be the
case in cholera toxin. The C-terminal of A2 may interact with GMi ; Al appears
flexible, a feature which may be important in membrane translocation.
31
The mechanism of entry of the A subunit to the cell is not understood. It could
enter some cells by directly penetrating the membrane (van Heyningen, 1982;
Ribi et al., 1988), although endocytosis may be involved in entry to other cells
(Janicot et al., 1991).
Cholera toxin and HLT catalyse ADP-ribosylation of an arginine residue of
Gsa (Moss and Vaughan, 1977), locking it in its GTP-bound, active form, leading to
unregulated production of cAMP and disruption of the normal ion flow across the
intestinal epithelium (fig. 1.7). Both cholera toxin A (CTX A) subunit and HLT have
regions of almost identical sequence with pertussis toxin SI subunit (see section 1.3.3;
Locht and Keith, 1986; Nicosia et al., 1986). The N-terminal of SI is known to be
part of a major protective epitope (Bartoloni et al., 1988) and mutation of the arginine
mentioned has been used to produce detoxified pertussis toxin (also mutated at a
glutamate at position 129) in Bordetella for use in an acellular vaccine. The levels of
toxin synthesised were not very high (Pizza et al.,1989), but the toxoid was included
in human trials (Podda et al., 1992).
1.5.2 Diphtheria toxin
Diphtheria toxin (DT) is an A-B type toxin secreted by pathogenic strains of
Corynebacterium diphtheriae. It is synthesised as one polypeptide chain which is
proteolytically cleaved, either before or after cell binding, to give the active form
consisting of an ADP-ribosylating A fragment (Mr about 21 kDa) and a B fragment
(Mr about 37kDa), and its crystal structure was analysed by X ray diffraction and
published by Choe et al., 1992. The fragments are linked by a disulphide bond,
which is probably reduced inside the target cell to activate the A fragment (Greenfield
et al., 1983). The B subunit binds the cell surface, probably to glycoprotein targets,
and enters the cell by endocytosis (Saelinger, 1990).
When inside an endosome, the acidic pH causes a conformational change in the
A fragment which is thought to enable it to cross the endosome membrane and find its
target in the cytoplasm (Dumont and Richards, 1988; Olnes and Sandvig, 1985). DTA
catalyses ADP-ribosylation of elongation factor 2 (EF-2). This blocks the elongation
of polypeptides on ribosomes. This inhibition of protein synthesis causes cell death
(Honjo et al. , 1968). The modified residue is diphthamide, which is a derivative of




This toxin (ETA) also catalyses ADP-ribosylation of the diphthamide residue
of EF-2, inhibits protein synthesis and causes cell death. ETA is synthesised as a
single polypeptide proenzyme which appears to undergo covalent changes to activate it
in vivo (Vasil et al., 1977; Leppla et al., 1978). The proenzyme has an N-terminal
signal sequence which is cleaved on secretion (the calculated Mr of the proenzyme
after signal sequence removed is 66 583). ETA and DT have no nucleotide sequence
similarity, but their active sites contain corresponding amino acids (Carroll and Collier,
1988). ETA has been crystallised and its structure determined by X ray diffraction
(Allured et al., 1986) and is proposed to contain three domains. Domain I is the N-
terminal half of the molecule and binds the cell receptor (binding domain). Domain II
splits domain I in two, and seems to be involved in translocation of the toxin across
the target cell membrane (Chaudhary et al., 1988) but the precise mechanism of entry
is unknown. Domain III is contained in the C-terminal part of ETA (Gray et al., 1984;
Hwang et al., 1987) and is the enzymatic part of the toxin, so this is another example
of an A-B type toxin.
1.5.4 Clostridial cytotoxins
Various clostridial toxins have ADP-ribosylating activity, their substrate being
monomelic actin. They include Botulinum C2 toxin, Clostridiumperfringens iota
toxin, Clostridium sporiforme toxin and a toxin produced by Clostridium difficile.
These toxins block polymerisation of monomeric actin (Aktories et al., 1986).
Some strains of Clostridium botulinum types C and D produce a toxin C3,
which modifies small GTP binding proteins (molecular mass 21-24kDa) (Braun et al.,
1989).
Botulinum C2 toxin is well studied, and has two components, one responsible
for binding (I) and one which has enzymic activity (II). C2 is not a usual A-B toxin,
as components I and II act as separate proteins in intoxication (Ohishi et al., 1980;
Simpson, 1982).
1.5.5 Clostridium botulinum neurotoxins
At least nine toxins are produced by Clostridium botulinum, including the
cytotoxins C2 and C3 discussed above, and the neurotoxins A,B,C1,D,E,F and G.
The neurotoxins are absorbed from gastrointestinal tract, reach susceptible neurons,
bind presynaptic terminals and block exocytosis of acetylcholine resulting in
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respiratory paralysis, inability to swallow and speech difficulties.
The neurotoxins have a similar overall structure with a light and a heavy chain
linked by a disulphide bond.
1.5.6 Tetanus toxin
Clostridium tetani secretes a neurotoxin called tetanus toxin, which causes
spastic paralysis due to block of neurotransmitters (especially gamma-amino butyric
acid, GABA) from inhibitory neurons (Simpson, 1989), which leads to uninhibited
neuronal firing.
The toxin is synthesised as a single chain precursor, cleaved by proteases to
form a heavy chain, H(Mr 100 000) and a light chain, L(Mr 50 000). The H chain is
involved in cell binding and the L chain is responsible for inactivation of a component
in neuroexocytosis (Niemann, 1991). The two chains are linked by a disulphide
bond.
Recently Schiavo et al., (1992a) demonstrated that tetanus toxin L contains a
zinc binding motif characteristic of metalloproteinases, and has a proteolytic effect on
an integral membrane protein called VAMP(vesicle-associated membrane protein)
found in synaptic vesicles (Schiavo et al., 1992b).
1.6 Aims of the Project
The aims of the project were to investigate the spatial arrangement of pertussis
toxin subunits within the whole toxin, using chemical cross-linking reagents.
Reversible and non-reversible cross-linking, one- and two-dimensional SDS-PAGE,
Western blotting techniques were to be used. A range of cross-linked species would
generated and the cross-linked species separated from non-cross-linked material using
SDS PAGE. Inter-subunit cross-links could then be broken and the component
subunits of a particular species separated, again using SDS PAGE and the component
subunits identified by their size. Cross-linked species with bridges that were difficult
to break, could be separated on one-dimensional SDS PAGE and their composition
wholly or partly identified using Western blotting using subunit specific antibodies.
Antigenicity (antibody binding) and glycoprotein-binding peptides derived
from the whole amino acid sequence of pertussis toxin subunits SI, S3 and S4 were to
be investigated, using the epitope mapping technique of Geysen et al. (1984) and free
peptides. Glycoprotein-binding was used as an identifier of peptides that could be
involved in receptor-recognition in the native toxin.
The Geysen et al., (1984) technique involves manual synthesis of peptides
which are covalently attached via their C-terminus, to derivatised polypropylene pins.
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Anti-(pertussis toxin) antibody and glycoprotein-binding to the pin peptides was
assayed using an ELISA technique. Only peptides whose entire sequence or part of
that sequence was exposed on the surface of the whole toxin should be antigenic or
bind glycoprotein, unless a peptide mimicked a binding site on a protein subunit for an
antibody or glycoprotein. Antigenic and/or glycoprotein-binding peptides were to be
studied for their ability to induce antibodies that recognised 'native' pertussis toxin and
neutralised some of the toxin's biological activities.
Finally, the binding of NAD+ to whole pertussis toxin SI subunit is the initial
event in both the ADP-ribosyltransferase and NAD+-glycohydrolase activities of
pertussis toxin, so that binding event was to be studied using intrinsic tryptophan
fluorescence quenching. Whether NAD+-binding to the SI subunit was altered by S1
being associated with the B-oligomer of the toxin was to be assessed, using SI
subunit isolated from a preparation of whole pertussis toxin. Binding of NAD+ to
recombinant SI subunit analogues was also to be looked at, to try to identify whether a
specific region or residue of the SI subunit was involved in binding of NAD+ and





Dithiobis-(succinimidylpropionate) (DSP), Disuccinimidyl tartarate (DST) and
succinimidyl 4-(p-maleimidophenyl) butyrate (SMPB) were purchased from Pierce
and Warriner Ltd., Chester, Cheshire, UK.
Solid phase peptide synthesis kits including polypropylene pins and polypropylene
microtitre plates, activated amino acid esters and 1-hydroxybenzotriazole (HOBT)
were from Cambridge Research Biochemicals, Northwich, Cheshire, U.K.
Phenol, piperidine, acetic anhydride, hydroxylapatite, silver nitrate, citric acid and
triethanolamine hydrochloride were from BDH Chemicals, Hampshire, U.K.
Ethanedithiol, diisopropylethylamine, 3,3',5,5' - tetramethylbenzidine (TMB) and
Triton X - 100 were purchased from Aldrich Chemical Co., Dorset, U.K.
Mixed bovine brain gangliosides (approx. 21% GMi, 40% GDla, 16% GDlb, 19%
GTlb, in 150 mM NaCl, 10 mM NaHP04, pH 7.2) were from Calbiochem,
Nottingham, U.K.
Nicotinamide adenine dinucleotide (NAD+) (grade 1, 100%) was from Boehringer
Mannheim, East Sussex, UK.
Eagles Minimal Essential Medium (MEM) was obtained from Gibco Laboratories,
Surrey, U.K.
Dithiothreitol was obtained from Bio-Rad, Hertfordshire, UK.
Fetuin, asialofetuin, alpha-l-acid glycoprotein, haptoglobin, Fast blue RR salt,
Napthol AS-MX alkaline phosphate solution, anti-human and anti-bovine IgG's, horse
radish peroxidase- and alkaline phosphatase-conjugated antibodies, glutaraldehyde
(grade 1, 25% aqueous solution), Ellman's reagent (5,5'-dithiobis-(2-nitrobenzoic
acid, DTNB) and glycerol were from Sigma Chemical Company, Poole, Dorset, UK.
Cyanogen bromide-activated sepharose 4B, DEAE-sepharose CL4B, Mono-Q anion
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exchange FPLC columns and PD10-G25M gel filtration columns (pre-packed,
1x10 cm) were purchased from Pharmacia LKB, Buckinghamshire, U.K.
TMS-250 reverse phase FPLC column was from Anachem, Bedfordshire, U.K.
All other reagents were of the highest grade possible.
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2.2 Methods
2.2.1 Pertussis toxin purification
Pertussis toxin was purified following the method below (Imaizumi et al.,
1983, Irons and MacLennan 1979):
1. 0.5 ml freeze-dried Bordetella pertussis (Wellcome strain 28) in culture
medium (see below) was resuspended in water and grown at 35°C for 48 hours, on
charcoal agar (oxoid CM 119) supplemented with 10%(v/v) defibrinated horse blood
(Difco Lab., Surrey, U.K.).
2 . Bacteria grown on this medium were used to inoculate three seed culture flasks
containing 100 ml culture medium. These were incubated at 35°C for 24 hours on an
orbital shaker.
To prepare 10 litres of culture medium, the following constituents were added to 7
litres of water:
Sodium glutamate 106.0 g
Tris (pH 7-9) 61.0 g
NaCl 25.0 g






Ascorbic acid 4.0 g
CaCl2 0.4 g
O-methyl -(3-cyclodextrin 10.0 g
Three stock solutions were prepared separately:
i) 0.5 g FeS04.7H20 in 200 ml water
ii) 0.2 g nicotinic acid in 200 ml water
iii) 2.5 g L-cysteine in 200 ml 2.5 M HC1
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40 ml of each stock was added to the medium and the pH adjusted to 7.6 with
concentrated HC1 and the volume made up to 10 litres with water.
3 . 30 x 2.5 1 Thompson flasks containing 250-300 ml culture medium were
inoculated with 9 ml of seed culture and incubated on a lateral shaker, on their sides at
35°C for 48 hours.
4 . Bacterial cultures were centrifuged at 6000# for one hour at 6°C; remaining
bacteria were removed by passing the supernatant through a capsule filter (Sartorius,
Surrey, UK., 0.22 //m).
5 . Spherical hydroxyl apatite (BDH Ltd., U.K.) was resuspended in 500 ml
0.1 M NaOH, allowed to settle and the procedure repeated. The hydroxyl apatite
matrix was the washed several times with water until the pH of the decanted liquid was
8.0. The matrix was then resuspended in 10 mM potassium phosphate buffer, pH 8.0
and packed into a column (5 cm I.D. x 17 cm L) and equilibrated with the phosphate
buffer. The filtered supernatant was passed through the column at 500 ml/hour, 4°C,
to remove filamentous haemagglutinin (FHA), leaving pertussis toxin in the
supernatant.
6 . Column eluate was precipitated by addition of ammonium sulphate crystals, to
74% saturation and left over 18-48 hours, at 4°C.
7 . Precipitated protein was centrifuged at 6000# for 20 minutes at 4°C. The
pellet was retained washed three times with 100 ml 50 mM potassium phosphate,
0.5 M NaCl pH 7.5 and centrifuged at 12000# for 30 minutes, at 6°C.
Supernatant was discarded, the pellet resuspended in 100-150 ml of the above buffer
and dialysed against the above buffer for 48 hours at 4°C.
8 . During the dialysis step, 15 g CNBr-activated sepharose 4B powder
(Pharmacia) was suspended in 100 ml 1 mM HC1 and filtered through a sintered glass
funnel using about 150 ml 1 mM HCl/g powder. 200 mg of fetuin was dissolved in
coupling buffer and added to the swelled matrix and the mixture was rotated end-over-
end for 3.5 hours at room temperature. Excess, uncoupled fetuin was washed away
by washing the matrix with coupling buffer and the filtrate tested for protein content
using a Bradford assay with bovine serum albumin as standard. Successful coupling
was indicated by a low protein content of the filtrate (<50 //g/ml). The remaining
active groups were blocked using blocking buffer for two hours at room temperature.
The coupled fetuin-sepharose 4B was then washed with three cycles of high and low
pH, each cycle consisting of one wash with acetate buffer, pH 3.8 followed by one
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wash with Tris buffer, pH 8.0. Fetuin-sepharose 4B was then packed into a column
(2 cm I.D. x 10 cm L) and equilibrated with 10 column volumes of 50 mM potassium
phosphate, 0.5 M NaCl pH 7.5.
Dialysis residue was applied at 1 ml/min to the fetuin-sepharose 4B affinity
column and recirculated through the column three times.
9. After washing the column with 5-10 column volumes of 50 mM potassium
phosphate, 0.5 M NaCl pH 7.5, pertussis toxin specifically bound to the column was
eluted with 50 mM Tris-Cl, 130 mM NaCl, 2.7 M MgC^ pH 6.5 at 0.5 ml/min.
50 x 3 ml fractions were collected, their protein content estimated from their A28O and
fractions estimated to contain most protein were run on 17.5%(w/v) SDS-PAGE to
confirm their composition.
1 0. Fractions containing pertussis toxin (identified by the five resolved bands seen
after silver or coomassie staining of the gels, see figure 4.2) were dialysed for 36
hours at 4°C against 50 mM Tris-Cl, 1M NaCl pH 7.5 to remove traces of MgCK
11. The pertussis toxin was then dialysed against 10 mM phosphate, 0.5 M NaCl
pH 7.5 overnight.
1 2. Toxin was precipitated to 1.5-3 mg/ml with ammonium sulphate (74%
saturation) and stored in this form at 4°C, until used.
2.2.2. Pin peptide synthesis
Peptide synthesis was carried out using a kit (Cambridge Research
Biochemicals, Cheshire, UK), according to the method of Geysen et al (1987).
Polypropylene pins derivatised with an fmoc N-(9-fluoroenylmethoxycarbonyl)
protected linker were provided in blocks of 96 to fit polypropylene microtitre plates.
The linker allowed covalent bonding of the C-terminal of each peptide to to the pins.
Consecutive cycles of washing, deprotection and amino acid coupling resulted in
peptides of the required length, which were then N-terminal and side chain deprotected
and acetylated, ready for use in subsequent binding assays.
2.2.2.1 Washing and N-terminal deprotection
The derivatised pins were washed before deprotection at room temperature
with four cycles of:
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DMF 100 ml 2 min
Methanol 100 ml 2 min
DMF 100 ml 2 min
Pins were N-terminal deprotected for 20 minutes at room temperature in 100 ml of
20%(v/v) piperidine in DMF. (Note that DMF was supplied standing over molecular
sieve to remove amines).
Pins were then washed:
DMF 100 ml 5 min
Methanol 100 ml 2 min (repeated four times)
Air dry >10 min
DMF 100 ml 5 min (immediately before amino acid coupling).
2.2.2.2 Amino acid coupling
Pentafluorophenyl (Pfp) activated esters of L-amino acids were used in solid
phase synthesis. 3-hydroxy-2,3-dihydro-4-oxo-benzotriazine (ODhbt) replaced Pfp
for serine and threonine.
All coupling reactions were performed in 30 mM 1-hydroxybenzotriazole
(HOBT) in DMF.
All amino acid N-terminals were fmoc protected. Side chains were protected
where necessary by t-butyl derivatives, with the exception of arginine, which was
protected by 4-methoxy-2,3,6-trimethylbenzene sulphonyl (Mtr).
100 pi\ aliquots of 30 mM amino acid ester and 30 mM HOBT in DMF were
dispensed into the appropriate wells of a polypropylene microtitre plate. Deprotected
pins were correctly oriented and immersed as blocks of 96 into the wells. Coupling
was allowed to proceed for 18 hours at room temperature, with gentle shaking.
Washing and N-terminal deprotection was repeated, ready for the next coupling
reaction.
The cycle of washing, deprotection and coupling continued until peptides of the
required length were reached.
2.2.2.3 Acetylation
The N-terminal amino acid (and side chain amino group of lysines) of each
complete peptide was deprotected as in 2.2.2.1 and the N-terminus acetylated to
remove the positive charge by immersing the pins in microtitre plate wells containing
100 pd 10%(v/v) acetic anhydride, 2%(v/v) diisopropylethylamine in DMF
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for 90 minutes at room temperature, while shaking gently.





2 min (repeated four times)
>10 min
2.2.2.4 Side chain deprotection
Pin blocks were reacted with 100 ml 95%(v/v) TFA, 2.5%(w/v) phenol and
2.5%(v/v) ethanedithiol in sealed polypropylene boxes for four hours, followed by a










2 min (repeated twice)
e in DCM





Pin peptides were then dried over silica in a desiccator at room temperature for
18 hours and stored in boxes containing silica gel at 4°C until use.
2.2.2.5 Disruption of peptides
Newly synthesised pin peptides were disrupted by sonication before their first
enzyme linked immunoassay (EL1SA) screen, to remove residual solvents, and after
each subsequent assay, to remove bound antibody complexes from the pins. This
involved sonication of the pins in pin peptide disruption buffer (100 mM NaH2PO_|.,
pH 7.2, containing 0.1%(v/v) 2-ME and l%(w/v)SDS), at 60°C for 30 minutes,
followed by two washes in 100ml water for two minutes, at 60°C. The pins were then
immersed in a bath of boiling methanol for two minutes, removed and dried in air for
not less than 10 minutes, before either storage or the next screening.
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2.2.3 Pin peptide screening by enzyme linked immunoassay
(ELISA)
2.2.3.1 Antibody binding to pin decapeptides
Nonspecific binding to peptides was reduced by immersion of the pins in
microtitre plate wells containing 200 j,i\ blocking buffer (10% (v/v) newborn calf
serum (NCS), 0.4%(v/v) Tween 20 in PBS, pH 7.2) for 90 minutes. Pin peptides
were then incubated with 175 fAIwell of an appropriate dilution of antibody, in
blocking buffer overnight.
Pins were then washed four times for 2 minutes per wash in 0.1 %(v/v) Tween
20 in PBS, pH7.2 and immersed in 175 /<l/well 1:500 dilution of anti-lgG, species
specific (whole molecule) horse radish peroxidase conjugate, in 0.1%(v/v) Tween 20
in PBS, for 90 minutes. The pins were then washed as above.
Colour was developed for 30 minutes by incubation with 150 //I/well substrate
at room temperature:
0.05%(w/v) 2,2'-azino-bis(3-ethylbenzthiazoline)-6-sulphonic acid, 80 mM citric
acid, 100 mM Na2HP04, 0.01%(v/v) H202, pH 4.0.
The reaction was stopped by removal of pins from the substrate and colour
development was measured at 405 nm on a Titertek Multiskan™. Pins were then
disrupted (2.2.2.5). Residual binding to the pins after sonication was tested by the
same ELISA: pins were incubated without test antibody (or glycoprotein) and the rest
of the assay carried out as described above.
2.2.3.2 Binding of glycoprotein and glycolipid to pin decapeptides
Nonspecific binding to the pin peptides was reduced as described in the
previous section. This was followed by incubation with the glycoprotein in blocking
buffer (175 /.d/well) for seven hours at room temperature. Three 5-minute washes in
0. l%(v/v) Tween 20 in PBS, pH 7.2 followed. The pin decapeptides were then
incubated overnight in 1:250 dilution of affinity-purified rabbit anti-fetuin serum
(Provided by Dr. L.A.E. Ashworth, PHLS CAMR Porton Down, U.K.) in blocking
buffer, four 2-minute washes in 0.1%(v/v) Tween 20 in PBS and a 90 minute
incubation with goat anti-(rabbit IgG) serum conjugated to horse radish peroxidase and
washed four times as above.
Colour was developed as described in the previous section and was measured
on a Titertek multiscan™ at 405 nm. Pins were then sonicated in disruption buffer,
ready for the next assay.
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2.2.4. Monoclonal antibody (MAB) purification
2.2.4.1 FPLC anion exchange chromatography
Monoclonal antibodies, as ascites fluid were a gift from Dr. L.A.E. Ashworth,
PHLS Centre for Applied Microbiology and Research, Porton Down, Salisbury,
Wiltshire and their preparation is described in Gorringe et al. (1985). The ascites
fluid, containing monoclonal antibody (1 or 2 ml) were diluted to 10 ml using buffer A
(5 mM Tris-Cl pH 8.0), filtered to remove insoluble matter and applied via a 10 ml
superloop to a Mono-Q anion exchange column (Pharmacia, 1 cm I.D.x 5 cm L)
equilibrated with buffer A.
The column was eluted with buffer B (5 mM Tris-Cl, 200 mM NaCl, pH 8.0) at a
flow rate of 1 ml/min. Protein concentrations were estimated by A280 and fractions
judged to contain protein were analysed for pertussis toxin binding activity, by ELISA
(section 2.2.8.1)
2.2.4.2 Anion exchange chromatography
Ammonium sulphate was added to ascites fluid containing monoclonal
antibody (1-3 ml) to a concentration of 50-60% saturation and agitated gently for 15
minutes. The precipitated protein was centrifuged at 10 000# for 30 minutes. The
pellet was washed once with ammonium sulphate solution and the pellet resuspended
in buffer A (10 mM Tris-Cl pH 8.0) and dialysed for 18 hours at 4°C. The dialysate
was loaded onto a DEAE Sepharose CL-6B column (2 cm I.D x 20 cm L) equilibrated
with buffer A and eluted with a gradient of 0% B to 100% B (10 mM Tris-Cl, 500 mM
NaCl, pH 8.0) at a flow rate of 1 ml/min. Protein containing fractions (estimated by
A280) were assayed for pertussis binding by ELISA (section 2.2.8.1).
2.2.4.3 Protein A-sepharose affinity chromatography
For a column of dimensions 1 cm I.D. x 5 cm L of protein A-sepharose CL4B
(Pharmacia LKB), 3 ml ascites fluid containing monoclonal antibody was dialysed
against 140 mM sodium phosphate buffer, pH 8.0 overnight (buffer A). The dialysate
was then applied to the column, which was equilibrated with buffer A and the fluid
recirculated through the column for at least three hours at a flow rate of 5 ml/hour.
The column was then washed with three column volumes of buffer A at 5 ml/hour,
followed by three column volumes of 100 mM citrate/citric acid, pH 6.0, then three
column volumes of 100 mM citrate/citric acid, pH 3.0 and 1 ml fractions collected
throughout. Fractions containing protein estimated from A28O were pooled and
44
immediately dialysed against buffer A. Anti-(pertussis toxin)-IgG-containing fractions
were identified by solid-phase ELISA using pertussis toxin as coating antigen
(2.2.8.1).
2.2.5 Synthesis and purification of free peptides
2.2.5.1 Overview
Antigenic pin peptides were synthesised with a C-terminal amide from
4-(2',4'-dimethoxyphenyl-N-(9-fluorenylmethoxycarbonyl)-aminomethyl|phenoxy
resin (Novabiocem, U.K.), using the Applied Biosystems Fastmoc synthesis system,
by Dr. C. Shone (PHLS Centre for Applied Microbiology and Research, Porton
Down, UK) using an Applied Biosystems A431A amino acid synthesiser. Isolation of
the free peptide from the resin and deprotection were carried out by the author.
Peptide (CGE)S3c, which was to be conjugated to keyhole limpet
haemocyanin (KLH) had a glycine residue used as a spacer and a cysteine (C) residue
at its N-terminal. Peptide S4b had the same two residues at its C-terminal. Both
peptides were coupled to KLH using a chemical cross-linker, m-maleimidobenzoyl-N-
hydroxysuccinimide ester (MBS), which reacts with cysteine residues between pH 7
and 7.5. Peptide S4b was also coupled to bovine serum albumin (BSA) using
glutaraldehyde as the cross-linking reagent. Peptide (E)S3c was to be conjugated to
BSA by carbodiimide and had a glutamate added at its N-terminal (see table 3.2 for
amino acid sequences of the free peptides), but conjugation of (E)S3c to BSA using
glutaraldehyde generated an anti-(pertussis toxin) response judged to be adequate for
the studies to be carried out.
2.2.5.2 Deprotection and removal of peptide from resin
For peptides (E)S3c and (CGE)S3:
0.75 g phenol
0.25 ml 1,2 ethanedithiol
0.25 ml deionised water
10 ml TFA
in a round bottomed flask. The mixture was stirred on ice for two hours. Deprotected
peptide was then isolated from the resin (2.2.5.3)
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For peptide S4b(GC)
0.25 ml 1,2 ethanedithiol
0.25 ml deionised water
9.5 ml TFA
in a round bottomed flask. The mixture was stirred on ice for two hours and
deprotected peptide was isolated from the resin (2.2.5.3).
2.2.5.3 Isolation and concentration of crude free peptide
from resin
The mixture of deprotected free peptide and resin was vacuum filtered through
a size 3 glass filter into a 250 ml round bottomed flask and the filter rinsed with
10-15 ml DCM. The yellow peptide solution was concentrated on a rotary evaporator
to about 3 ml. The temperature of the water bath was kept between 30 and 37°C to
retain the peptide in an undamaged form.
2.2.5.4 Precipitation of free peptide
About 50 ml cold diethyl ether (Et20) was added to precipitate the peptide
(leaving a cloudy yellow suspension). The precipitate was filtered through a size 3
filter and washed with 10-15 ml Et20.
2.2.5.5 Drying and reprecipitation of free peptide
The precipitate from 2.2.5.4 was dried in a desiccator for two hours under
vacuum, then redissolved in 10 ml 90%(v/v)TFA in water and 2.2.5.4 repeated.
Purified peptide precipitate was again dried in a desiccator and assayed for purity by
reverse phase HPLC and mass spectrometry (2.2.5.6 and 2.2.5.7). Remaining
peptide was stored as solid at -20°C, until use.
2.2.5.6 Reverse phase chromatography of free peptide
3-5 mg of peptide was dissolved in 50 jA 0.1%(v/v) TFA in water (buffer A).
The resulting solution was filtered through a 0.2 pim filter and loaded onto a C8 reverse
phase HPLC column (Beckman, 1 cm I.D. x 20 cm L) equilibrated with buffer A.
A 40 minute gradient from 100% A to 0.1% TFA, 60%(v/v) acetonitrile in water was
run at a flow rate of 1 ml/min, peptide being detected by A220
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2.2.5.7 Mass spectrometry of free peptide
Mass spectrometry was carried out using a Kratos MS80 RFA mass
spectrometer fitted with an Iontech FAB 11 NF saddle field gun, using xenon as
bombarding gas (thanks to Dr. R. Wait, PHLS Centre for Applied Microbiology and
Research, Porton Down, UK) and calibrated with caesium ion clusters.
Peptides were dissolved in 30%(v/v) acetic acid and 1 pil containing about 5 pig
of peptide was applied to the same volume of matrix on a stainless-steel probe tip.
Spectra were recorded with a 5 KeV accelerating voltage and a scan rate of 30 s per
decade.
Between 10 and 20 scans were obtained and averaged using the raw data facilities of
the DS90 data system.
Matrix : DTT : DTE (5:1, w/w) (if peptide Mr > 1500)
Glycerol (if peptide Mr< 1500)
2.2.5.8 Solubilisation of free peptide
All peptides were dissolved to the required concentration in water, after
preliminary observations of solubility in water plus or minus a drop of glacial acetic
acid, or ammonium carbonate.
2.2.6 Peptide conjugation
2.2.6.1 Activation of keyhole limpet haemocyanin (KLH)
The method of Green et al. (1982) was used, with modifications.
4 mg/ml KLH was dissolved in 50 mM sodium phosphate buffer, pH 7.4 and stored
at -20°C until use. 50 pd of 14 mg/ml m-maleimidobenzoyl-N-hydroxysuccinimide
ester (MBS) in DMF was added to 250 pi\ KLH solution and mixed at room
temperature for 30 min.
2.2.6.2 Separation of activated KLH from unreacted KLH and
MBS
The sample from 2.2.6.1 was loaded onto a PD10-G25 M column
(1 cm l.D. x 10 cm L) equilibrated with 50 mM sodium phosphate buffer, pH 6.0.
10 x I ml fractions were eluted using the pH 6.0 buffer, protein content estimated by
A280 and the first protein peak used in section 2.2.6.4.
47
2.2.6.3 Determination of peptide free thiol
This was done to estimate free thiol groups in the activated KLH that were
available for coupling to KLH. The method used was that of Ellman (1959) with
slight modifications. 100 //I of 4 mg/ml 5,5'-dithiobis-(2-nitrobenzoic acid) (DTNB,
Ellmans reagent) in 100 mM sodium phosphate buffer, pH 7.4, containing 0.5 mg/ml
EDTA was added to 5 //I of 5 mg/ml peptide in water. This was made up to 1 ml with
the pH 7.4 buffer. After a standing time of five minutes absorbance of the sample at
412 nm was read. Moles of free thiol were estimated from a calibration curve of 0-
100 nmoles L-methyl cysteine against absorbance at 412 nm
2.2.6.4 Coupling of peptide to activated Keyhole Limpet
Haemocyanin (KLH)
The pH of the activated KLH (2.2.6.2) was raised to about 7 with 1M NaOH.
A 40-100 molar excess of peptide (calculated from the free thiol content of each
peptide in the previous section) was added and the sample mixed, for three hours at
room temperature. The peptide-KLH conjugate was dialysed against PBS pH 7.2 at
4°C. Aliquots were tested for protein using an automated Lowry assay
(Lowry et al., 1951), with bovine serum albumin as standard, performed at the PHLS
CAMR, Porton Down, U.K. The remainder was stored in small aliquots, at -20°C.
2.2.6.5 Peptide conjugation to bovine serum albumin (BSA)
About 2 mg peptide was added as solid to 250 pi (1 mg) of 4 mg/ml BSA
(96-98% pure fraction V, Sigma Chem. Co., Dorset, UK) in PBS pH 7.2, on ice.
10 pi glutaraldehyde was added in 2.5 pi aliquots and the sample shaken vigorously.
The sample was left on ice for 60 minutes and the reaction inhibited by addition of
0.1 mg sodium borohydride. Sample volume was made up to 1 ml with PBS pH7.2
and dialysed against PBS overnight. Protein estimation was carried out using an
automated Lowry assay (2.2.6.4).
2.2.7 Peptide conjugate immunisation
2.2.7.1 Mouse polyclonal serum preparation
Mice were immunised by Dr. A. Robinson, (PHLS CAMR, Porton Down,
UK) with 10 pg antigen adsorbed onto alhydrogel adjuvant and boosted with the same
dose after three weeks. Sera were obtained six weeks after the initial dose.
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2.2.7.2 Rabbit polyclonal serum preparation
New Zealand White rabbits were immunised at multiple intramuscular sites by
Dr. L. A.E. Ashworth, (PHLS CAMR, Porton Down, UK) with 150 pig peptide
(E)S3c-BSA-conjugate in 0.75 ml Freund's incomplete adjuvant and boosted with the
same dose after three weeks and six weeks. Serum was obtained eight weeks after the
initial dose.
150 pig peptide S4b-KLH-conjugate was administered in 0.75 ml incomplete
Freund's adjuvant and the dose repeated after three weeks. Serum was harvested six
weeks from the first dose.
2.2.8. Microtitre plate enzyme-linked immunoassay (ELISA)
techniques
2.2.8.1 Antibody binding to antigen-coated plates
1. 2 pig /ml pertussis toxin, peptide or peptide-conjugate in 50 mM carbonate
buffer, or free peptide in water, were coated onto microtitre plates
(Nunc Immunoplates 1) overnight at room temperature (toxin and conjugates), or at
37°C (free peptide).
Peptide coated plates were then fixed with 50%(v/v) methanol in water for 15 minutes.
All plates were washed three times with 300 pi\lwell PBS pH 7.2 containing 0.1%(v/v)
Tween 20.
Nonspecific binding was blocked with 100 /<l/well blocking buffer (PBS, pH 7.2
containing 10%(v/v) newborn calf serum (NCS) and 0.1%(v/v) Tween 20) for 90
minutes at room temperature. Each step was followed by washing (above).
2 . Test antibodies were serially diluted in blocking buffer on a separate plate.
100 pi\lwell were transferred to the blocked, antigen-coated plate and incubated for 90
minutes. Plates were then washed.
3 . 100 /d/well of 1: 625 dilution, species specific, anti-IgG (whole molecule)
antibody, conjugated to horse radish peroxidase in blocking buffer was added, the
plates incubated for a further 90 minutes and washed
4 . Developer : 1 mg of 3,3',5,5'-tetramethylbenzidine (TMB), dissolved in
100 pi\ DMSO was added to 10 ml 50 mM acetate buffer pH 6.0, giving a final
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concentration of 0.01 mg/ml TMB. H2O2 was added to 0.012%(v/v) and each well
was incubated with 100 /d of the developer for 20 minutes at room temperature.
Development was stopped by addition of 35 //1/well H2SO4. The resulting absorbance
was read at 450 nm on a Titertek Multiskan.
2.2.8.2 Recognition of pertussis toxin captured by fetuin or
gangliosides by antipeptide antibody
Experimental procedure was adapted from 2.2.8.1:
1 . 2 //g/ml of glycoprotein or mixed gangliosides were coated onto microtitre
plate wells as described in section 2.2.8.1.
2. (i) 50/<g/ml pertussis toxin in blocking buffer was added to the blocked antigen-
coated plate and incubated for 90 minutes and the plate washed.
Antipeptide antibody was serially diluted in a microtitre plate in blocking buffer and
100 /d/well was transferred to the plate containing captured pertussis toxin, incubated
for 90 minutes and the plate washed.
(ii) 100 /d/well diluted antipeptide antisera was added, incubated for 90 minutes,
the plate washed and developed as described in section 2.2.8.1.
2.2.8.3. Binding of pertussis toxin or peptide to glycoprotein- or
glycolipid-coated plates
2 //g/ml glycoprotein or mixed bovine brain gangliosides were coated onto
microtitre plates and blocked as in 2.2.. Blocked plates were washed as before and
incubated for 90 minutes with 100 )A /well toxin or peptide serially diluted in blocking
buffer. The plates were washed and incubated for a further 90 minutes with anti-toxin
antibody or anti-peptide antisera diluted in blocking buffer and washed again.
Procedure then followed steps 3 and 4 of section 2.2.8.1.
2.2.8.4 Inhibition of binding to antigen
Procedure followed that of 2.2.8.1, with this addition:
2.(i) Test antiserum (giving an A45oof 1.2-1.5 on binding to antigen-coated plates)
was pre-incubated with serially diluted inhibitor in blocking buffer for 90 minutes in a
separate plate, while the coated plate was being blocked. 100 /d/well was transferred
to the coated plate and incubated for a further 90 minutes.
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2.2.9 SDS Polyacrylamide gel electrophoresis (SDS PAGE)
2.2.9.1 Molecular weight markers used for SDS PAGE
SDS PAGE was performed using the method of Laemmli (1970). Samples
were prepared for electrophoresis in l%(w/v) SDS, by boiling for three minutes.
Glycerol was added to a final concentration of 5%(v/v) and bromophenol blue was
added as a marker of protein migration. The prepared samples were then loaded onto
SDS polyacrylamide gels and run to completion.
Gels were calibrated using one of two molecular weight marker kits:
1. Dalton mark VII-L (Sigma Chemical Co., Dorset, UK) which contained
bovine serum albumin (Mr 66000), hen egg ovalbumin (Mr 45000), rabbit muscle
glyceraldehyde-3-phosphate dehydrogenase (subunit, Mr 36000), carbonic anhydrase
from bovine erythrocytes (Mr 29000), bovine pancreas trypsinogen (Mr 24000),
soybean trypsin inhibitor (Mr 20100) and bovine milk ocdactalbumin (Mr 14200).
2 . Bio-Rad (Hertfordshire, U.K.) low range SDS-PAGE markers, containing
phosphorylase b (Mr 97000), bovine serum albumin, hen egg ovalbumin, bovine
carbonic anhydrase, soybean trypsin inhibitor and hen egg white lysozyme (Mr
14400).
2.2.9.2 Coomassie staining
Gels were fixed in 20%(v/v) methanol, 10%(v/v) acetic acid in water for 1
hour. They were then transferred to a staining solution containing 0.25%(w/v)
coomassie blue R-250, 45%(v/v) methanol, 9%(v/v) acetic acid in water at 60°C for
15 minutes. Protein bands were visualised by destaining the background with
10%(v/v) methanol, 7%(v/v) acetic acid in water.
2.2.9.3 Electroelution
Areas of gel containing the protein of interest were excised, cut into small
pieces and placed in the larger cup of a concentrating apparatus (ISCO), resting in
25 mM Tris-Cl, 0.5 M glycine, pH 8.3, containing l%(w/v) SDS. A constant current
of 40 mA was applied for four hours. 50 //I concentrated, eluted protein solution was
collected in the smaller cup.
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2.2.9.4 Silver staining
The method followed was that of Wray (1981). Gels were soaked for one
hour at 60°C in 50%(v/v) methanol in water, then for five minutes in water. 0.8 g
silver nitrate was dissolved in 4 ml water in glass and added dropwise to 22.4 ml
0.36%(w/v) NaOH containing 2.2%(v/v) ammonia solution. This was made up to
100 ml with water and the gel soaked in it for 15 minutes at room temperature. Three
five minute washes with water followed. The stain was developed by soaking the gel
in 0.5%(w/v) citric acid, 0.02%(v/v) formaldehyde in water. Development was
stopped by placing the gel in 5%(v/v) methanol, 10%(v/v) acetic acid in water.
2.2.9.5 Western blotting
Proteins separated by SDS-PAGE were transferred by Western blotting
(Towbin et al 1979) onto nitrocellulose paper.
TM
Blotting was performed in an LKB tank blotter at 1 A for two hours at room
temperature using 20%(v/v) methanol, 0.02%(w/v) SDS, 20 mM Na2HPC>4as protein
transfer buffer. The nitrocellulose was then cut into strips and nonspecific antibody
binding was blocked for 90 minutes with l%(w/v) BSA, 0.3% Tween 20 in PBS pH
7.2. The strips were then incubated in an appropriate dilution of test antibody in
blocking buffer, for 90 minutes, then washed three times for 10 minutes with
0.1%(v/v) Tween 20 in PBS pH 7.2. This was followed by a 90 minute incubation
with an appropriate dilution of anti-IgG (whole molecule), species specific antibody,
conjugated to alkaline phosphatase, followed by three 10 minute washes with water.
Blots were developed for 10 minutes using 2.5 ml developer: 12 mg fast blue RR salt
dissolved in 50 ml water containing 0.01%(v/v) naphthol AS-MX alkaline phosphate
solution (Sigma Chem. Co., U.K.). Development was stopped by rinsing the
nitrocellulose with water.
2.2.10 Cross-linking of pertussis toxin subunits
2.2.10.1 Cross-linking of pertussis toxin and separation by SDS
PAGE
A 2-3 mg/ml ammonium sulphate suspension of pertussis toxin in 10 mM
sodium phosphate, 0.5 M NaCl pH 7.5 was centrifuged at 10 000 g for 20 minutes.
The pellet was resuspended in cross-linking buffer (50 mM triethanolamine
hydrochloride, 150 mM NaCl pH 8.3 containing l%(v/v) Triton X-100, 2%(v/v)
glycerol) to a final concentration of 0.35, 0.7, or 1.4 mg/ml and dialysed against
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cross-linking buffer at 4°C overnight.
Cross-linking reagents were dissolved to 100 mM in DMSO and stored at
-20°C until use.
Toxin was incubated with 0.1-10 mM cross-linker for 1-60 minutes at 30°C.
The reaction was stopped by addition of 4 M Tris-Cl pH 7.8. Cross-linked protein
was prepared for loading onto a 10-20%(w/v) gradient or 17.5%(w/v) SDS
polyacrylamide gel.
2.2.10.2 Two-dimensional SDS-PAGE
Cross-linked pertussis toxin samples were run on SDS PAGE as described in
section 2.2.9 . A strip was cut from this first dimension gel and coomassie or silver
stained to determine the cross-linking pattern.
Another strip from the same gel was soaked in cross-link cleavage buffer:
1. Dithiobis-(succinimidyl propionate) (DSP): 100 mM Tris-Cl pH 8.9
containing 3%(v/v) 2-mercaptoethanol and l%(w/v) SDS for 45 minutes at 60°C. The
strip was washed twice for 5 minutes in equilibration buffer (50 mM Tris-Cl, 1 mM
EDTA pH 6.7 containing l%(w/v) SDS). It was then fixed to the stacking gel of a
17.5%(w/v) SDS polyacrylamide gel with l%(w/v) agarose and run at 30 mA to
completion.
2 . Disuccinimidyl tartarate (DST): 30 mM sodium periodate in 100 mM Tris-Cl
pH 6.0, containing l%(w/v)SDS, for one to four hours, at 60°C. The strip was then
washed in equilibration buffer, fixed to the stacking gel of a 17.5%(w/v) SDS
polyacrylamide separating gel and run as above.
Cleaved cross-links were detected by coomassie or silver staining, or Western blotting
using subunit specific antibodies.
Several conditions were tried for cross-link cleavage, leading to the methods described
above:
i. A strip was cut from the first dimension gel and soaked in 100 mM Tris-Cl
pH 8.9, l%(w/v) SDS, 15 mM DTT (cleavage buffer) at room temperature for 60
minutes. The strip was then soaked in 50 mM Tris-Cl, l%(w/v) SDS, (pH 6.7). The
strip was then fixed to the stacking gel of the second dimension gel using 1 % agarose.
ii. Next the concentration of DTT was increased to 30 and then 45 mM, the other
conditions being the same as in the previous section.
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iii. The method described in part i, above was used but l%(v/v) 2-ME was
substituted for DTT.
i v. The method described in part iii was used and the cleavage-reaction
temperature was increased to 40, 50 and then to 60°C, for 20, 30, 40, 45 and 50
minutes. 45 minutes was judged to produce the highest yield of cleaved cross4inked
species.
v . Finally the concentration of 2-ME used in part iii was increased to 2%(v/v) and
then 3%(v/v). 3%(v/v) 2-ME was most successful.
2.2.10.3 HPLC-separation of cross-linked pertussis toxin subunits
Pertussis toxin was prepared in cross-linking buffer, as described in section
2.2.10.1 and buffer B (0.1%(v/v) TFA in acetonitrile) added to a final concentration of
15%(v/v) acetonitrile. The sample was centrifuged to remove debris and applied to a
TMS-250 reverse phase column (0.46 cm I.D. x 7.5 cm L, Anachem, Bedfordshire,
U.K.), equilibrated with 15% B and 85% buffer A (0.1% TFA in water).
The column was eluted with a gradient of 15-55% B over 120 minutes at a flow rate
of 0.4 ml/min. Fractions containing protein estimated by A220 were evaporated to
dryness in a Gyrovap vacuum centrifugal evaporator (Howe instruments, UK),
resuspended in cross-linking buffer and run on SDS-PAGE (2.2.9).
2.2.11 Fluorescence measurements
Fluorescence measurements were performed in a Perkin Elmer 3000
spectrofluorimeter with a 1 cm pathlength and a thermostatically controlled cuvette
holder. Samples were protected from incident light when readings were not being
taken. Fluorescence was measured at 333 nm (excitation 285 nm), slit widths both
being 10 nm.
All fluorescence data were corrected for dilution and inner filter effects
(Honore and Pedersen 1989). Protein concentration was calculated using the
Lambert-Beer law from A280using the molecular mass of the whole toxin or SI
subunit, deduced from the DNA-sequence of the subunits (Locht and Keith, 1986). A
molar extinction coefficient (e) was calculated for pertussis toxin, isolated SI subunit
and the S1 subunit analogues, from the subunit amino acids that absorb light at 280
nm (tryptophan, tyrosine and cystines- assuming that all cysteines are disulphide-
bonded) (Gill and von Hippel, 1989).
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2.2.11.1 NAD+ binding to pertussis toxin and isolated SI subunit
Isolated SI subunit was a kind gift of Dr. C. Capiau (Smith Kline Beecham,
Rixensart, Belgium). 2 ml of 50/ig/ml pertussis toxin or isolated SI subunit protein
sample equilibrated in 5 mM potassium phosphate, 100 mM NaCl, pH 7.2) was
titrated with 2-6 ]A aliquots of 1-20 mM NAD at 14, 20, 23, 30 and 40°C, to a final
concentration of between 160 and 200 //M, depending on the experiment.
2.2.11.2 NAD+-binding to pertussis toxin and SI subunit analogues
SI subunit analogues rSld and rSldE129D were a kind gift from Dr. C. Locht
(Institut Pasteur, Lille, France). 2 ml of 50 piglm\ subunit was equilibrated in 5 mM
potassium phosphate, 100 mM NaCl, pH 7.2 and titrations were carried out as
described in section 2.2.11.1, at 37°C.
2.2.12 Chinese Hamster Ovary (CHO) cell clumping
The method of Gillenius et al. (1985) was adapted to study pertussis toxin-
mediated clumping of CHO cells. A CHO cell line (CB169, European Collection of
Animal cell culture, PHLS Porton Down, U.K.) was maintained in Eagle's Minimal
Essential Medium (MEM) supplemented with 10 %(v/v) foetal calf serum (Gibco
Laboratories, Surrey, U.K.), 0.11 %(w/v) sodium bicarbonate, 15 mM Hepes buffer
and 0.06% L-glutamine, 25 U/ml gentamycin (growth medium).
1. 25 pi\ growth medium was added to each well of a microtitre plate, then 25 //I
of serum sample was added to row H of the test wells.
2 . 25/d of the diluted sample was removed from row H and serially diluted one in
two from row H to row A, leaving 25 /d of diluted sample in each well.
3 . 25 ]A of 20 ng/ml pertussis toxin (final concentration was the lowest found to
clump the cells, to detect weak inhibition of clumping) was added to all the wells
containing diluted sample and incubated for one hour.
4 . The growth medium from a confluent monolayer of CHO cells was discarded
and the cells washed with sterile PBS, pH 7.2, which was then discarded.
5 . A single cell suspension was obtained by washing the cells with 2 ml of
0.1 %(w/v) trypsin and 0.02 %(w/v) EDTA in PBS, pH 7.2 and observed under a
microscope until they were detached from the culture flask and were not attached to
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any other cells.
6 . The wall of the culture flask was then washed with 5 ml growth medium to
remove any remaining single cells and the cell suspension was then centrifuged at
1000o and the supernatant discarded.
7 . The cell pellet was resuspended in 10 ml growth medium and a viable cell
count carried out in a Neubauer Haemocytometer. The cell suspension was then
adjusted to 5 x 10^ cells/ml and 200 pi\ added to each well of a microtitre plate.
8 . The microtitre plate was sealed, placed in a humidified container with a sheet of
damp paper touching the base of the microtitre plate, to prevent uneven distribution of
the cells due to static electricity and incubated for 48 hours at 37°C in a CO2 incubator.
9 . The wells of the plate were scored as completely clumped (score 2), partially
clumped (score 1) or not clumped (score 0). For direct comparison with the test rows,
each plate contained a row with a serial toxin dilution used as a positive control
(score 2) and a row containing neither toxin nor serum, used as a negative control
(score 0). A row containing diluted serum sample with no toxin added was also
included, to assess the effect of the sample on the CHO cells.
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Chapter 3
Epitope mapping and glycoprotein binding to pertussis toxin subunits
3.1 Introduction
3.1.1 Binding to peptides attached to polyethylene pins
The aims of this section of work were to identify antigenic peptides
(i.e. antibody-binding) and glycoprotein-binding peptides derived from the whole
amino acid sequence of pertussis toxin. Those antigenic and glycoprotein-binding
peptides were to be studied for their ability to induce antibodies that recognised
'native' pertussis toxin and neutralised some of the toxin's biological activities. In
order to study the binding of antibody to subunits S1, S3 and S4 of pertussis toxin,
and the glycoprotein binding properties of the S3 subunit, the solid phase epitope
mapping procedure of Geysen et al. (1984) was used. This was employed as a
primary screening technique and used a pin peptide synthesis kit supplied by
Cambridge Research Biochemicals (U.K.). Polypropylene pins derivatised with an
fmoc N-(9-fluoroenylmethoxycarbonyl) protected linker were provided in blocks of 96
to fit polypropylene microtitre plates. The linker allowed covalent bonding of the C-
terminal of each peptide to to the pins. Consecutive cycles of washing, deprotection
and amino acid coupling resulted in decapeptides, which were then N-terminal and
side chain deprotected and acetylated, ready for use in subsequent binding assays.
This technique has been used to map 'linear' B-cell epitopes of many proteins
(see section 1.4.4), for example respiratory syncytial virus fusion protein (Scopes
et al., 1990), Clostridium perfringens Alpha toxin (Logan et al., 1991) and herpes-
simplex-virus type 1 thymidine kinase (Zimmerman et al., 1991).
Binding of murine monoclonal antibodies (either as ascites fluid and as affinity
purified antibody), rabbit polyclonal and human polyclonal antibodies to pin peptides
derived from the amino acid sequences of the SI, S3 and S4 subunits of pertussis
toxin was studied. Glycoprotein and glycolipid binding of the S3 subunit, and to a
lesser extent, of the SI and S4 subunits, were also studied.
3.1.2 Binding to peptides in solution
Some of the peptides that produced interesting (see later in this section) results
in the pin peptide form were chosen for synthesis as free peptides. There were several
reasons for this secondary technique being employed. Firstly, the pin peptides were
covalently linked to the pins at their C-termini. This linkage could have produced a
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conformation not present in the native protein. Secondly, a spurious result could be
produced by binding to the pin itself, which could account for the high background
sometimes seen in the ELISA assay used to detect binding to the pin peptides.
Thirdly, pin peptides cannot be used for immunisation, whereas free peptides can be
prepared as peptide-carrier-conjugates and used to raise antipeptide antisera. Previous
pin peptide mapping results have indicated that some antipeptide antibodies cross-react
with peptide sequences that are found in the amino acid sequence of the carrier and not
the peptide immunogen (Trifilieff et al., 1991). Non-specific reaction of antipeptide
antibodies with sequences unrelated to the peptide immunogen has also been reported
(Savoca et al., 1991) and may be due to peptide flexibility (Jemmerson et al., 1985).
For these reasons it was necessary to confirm interesting pin peptide results by
carrying out studies using free peptides.
Several criteria had to be fulfilled before results were judged interesting:
1. The free peptide should inhibit binding of antibody or glycoprotein of interest to the
pin-bound peptide, showing that free and bound peptide bind the same sites on the
antibody or glycoconjugate.
2. Whole pertussis toxin should inhibit binding of antibody or other glycoconjugate of
interest to the pin-bound peptide, showing that the peptide and native protein bind the
same site, or adjacent sites on the antibody or glycoconjugate. That is, if an antibody
bound both peptide and whole pertussis toxin, it would suggest that all or part of the
peptide sequence is exposed on the surface of the native protein.
3. When linked to an immunogenic carrier, the free peptide should elicit antibodies
that cross-react with the native protein, for example in a solid phase ELISA using
pertussis toxin as the coating antigen as described in section 2.2.8. This cross-
reaction should be inhibited by the free peptide in solution, which would again suggest
that the peptide sequence is in a conformation which is at least similar to the native
protein. Conversely, reaction of an antipeptide antibody with the peptide immunogen
captured onto an ELISA plate should be inhibited by native protein in solution.
Is an antipeptide antibody truly capable of recognising the native protein from
which its sequence was derived? To answer this question, it is necessary to ensure
that assays used to determine cross-reactivity between peptides and proteins present
antigen to antibody in a conformation as near to 'native' as possible.
Cross-reaction of antibodies between proteins and peptides may be due, at least
in part to the presence of denatured protein in the immunogen, or in the antigen used to
test the reaction of the antipeptide antibodies. This would mean that antibodies raised
against a protein may contain populations of antibodies raised against the denatured
portion of the protein. These anti-(denatured protein) antibodies could then recognise
denatured antigen present in an assay supposed to test whether the antibody recognised
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native protein!
ELISA assays in which the antigen is adsorbed to a plastic surface can be
responsible for partial denaturing of the antigen used to test the anti-native protein
reactivity of antipeptide antibodies (Darstet al., 1988). Capture of the native antigen,
for example by a monoclonal antibody, could present the antigen in a more native form
for assay of cross-reaction of the captured antigen with an antipeptide antibody. This
presumption was made for antipeptide antibody binding to pertussis toxin. As well as
assessment binding to pertussis toxin directly captured onto a microtitre plate, binding
of antipeptide antibody to the toxin captured by another antibody or other
glycoconjugate was assessed and is described later in this chapter.
3.2 Methods
3.2.1 Pin decapeptides
The method of pin decapeptide synthesis is described in section 2.2.2, but briefly,
short peptides of ten amino acids were synthesised spanning the entire amino acid
sequence of subunits SI, S3 and S4. The peptides each had a sequence overlap with
the next peptide synthesised, as seen in the example below:
Peptide 1 VAPGIVIPPK Pin
Peptide 2 VIPPKALFTQ Pin
Subunits SI, S3 and S4 were synthesised as ten amino acid peptides with a five amino
acid overlap, in duplicate. The S3 decapeptide that contained the C-terminal residues
of the subunit (peptide 39) overlapped with the previous peptide by six residues. SI
was also synthesised in duplicate as ten amino acid peptides with an eight amino acid
overlap and decapeptide that incorporated the C-terminal end of the subunit amino acid
sequence (peptide 115) overlapped the previous peptide by nine residues. The
sequences of the pin decapeptides are given in appendix 1.
Activated amino acid esters were coupled one at a time to the developing
peptide, which was covalently coupled to the polyethylene pin at its C-terminus by a
linker consisting of acrylic acid and hexamethylene diamine coupled to ^-alanine
(fig. 3.1). The amino group of the (3-alanine was protected by a base-labile group,
called 9-fluorenylmethoxycarbonyl (fmoc), that was removed before the coupling
reaction with the first amino acid ester.
Synthesis involved successive cycles of washing, N-terminal deprotection and
amino acid coupling. Incorrect coupling and side reactions were avoided by using
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Fig. 3.1. Pin decapeptide linker
The linker covalently attached the C-terminal of synthetic peptides to a










amino acid esters that had acid-labile side-chain protecting groups.
On completion of the synthesis, the peptides were N-terminally deprotected
and acetylated to remove their positive charge. Side-chain protecting groups were then
removed and the pin peptides washed and sonicated in disruption buffer (see section
2.2.2), to remove remaining scavengers and cleaved protecting groups that could
derivatise the peptides. Antibody and glycoconjugate binding to the pin peptides was
estimated from the results of a modified ELISA (see section 2.2.3).
The pin decapeptide reactions were repeated at least once. A reaction which
gave a repeatable pattern and reasonable agreement between duplicate peptides was
considered positive.
A decapeptide was considered strongly reactive and worthy of further study when the
absorbance at 405 nni was twice the mean value of the background non-specific
binding and the actual absorbance was greater than 0.7. Weakly reactive peptides
were considered to be those that produced an absorbance at 405 nm between 20% and
100% above the mean value of the background. The background binding was
calculated by averaging the absorbances of the lowest 80% of the duplicate peptides.
It was assumed that pmol quantities of peptide were required for antibody
detection (Geysen et al., 1984). If synthesis was inefficient, e.g. with an overall yield
of 1%, 1 mmol of activated amino acid ester should generate more than the pmol
amounts necessary for a detectable reaction.
3.2.2 Free peptides
Peptides chosen for further work from the results of the pin peptide studies
were synthesised with a C-terminal amide as described in section 2.2.5.
Three pin peptides (each ten amino acids) were chosen as the core sequences
for free peptides. Two free peptides derived from the sequence of S3 were
synthesised, from the pin peptide sequence 46-55. The first free peptide, (E)S3c,
contained amino acids 44-58 of the S3 sequence, with an N-terminal glutamic acid, to
facilitate coupling to BSA using carbodiimide (this was not carried out because (E)S3c
coupled to BSA using glutaraldehyde raised antisera that cross-reacted with pertussis
toxin). The second free peptide, (CGE)S3c, contained the same amino acids, with the
addition of an N-terminal glycine and cysteine, to facilitate coupling to keyhole limpet
haemocyanin (KLH). One free peptide was synthesised from the sequence of S4, and
the pin peptide that it was based on contained amino acids 86-95, with a C-terminal
glycine and cysteine, to facilitate KLH-conjugation. Their sequences are shown in
table 3.2 and the methods of conjugation of the peptides to the carriers are described in
section 2.2.6.
Each synthesised free peptide was cleaved from the resin, its purity confirmed by
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reverse-phase HPLC as described in section 2.2.5.6 and its composition confirmed by
fast-atom bombardment mass spectrometry (FAB MS) as described in section 2.2.5.7.
After purification, (E)S3c and S4b were coupled to BSA using glutaraldehyde
as the coupling reagent and (CGE)S3 and S4b were coupled to KLH using MBS as
the coupling reagent.
Three mice were immunised with 10 pg each of peptide conjugate and given a
booster immunisation of the same dose after three weeks. Antisera were harvested and
tested using a solid phase ELISA for reaction with peptide, pertussis toxin, and both
KLH- and BSA-conjugates coated directly onto the microtitre plate (see section
2.2.8.1). Reaction with a peptide from B. pertussis fim 3 was used as a negative
control. The amino acid sequence of the fim 3 peptide is given in appendix 1.
If mouse antipeptide antisera cross-reacted most strongly with pertussis toxin,
peptide and peptide conjugate captured onto ELISA plates,the peptide-conjugate used
to immunise those mice were also used to immunise rabbits, to generate larger
volumes of sera, needed for further studies. The rabbit antipeptide antisera were tested
for reaction with pertussis toxin, peptide (sequence as in the immunogen) and peptide-
conjugate as well as with a peptide derived from fim 3 of Bordetellapertussis in a
solid phase ELISA assay. The rabbit antipeptide antisera were also tested for reaction
with pertussis toxin captured onto ELISA plates by monoclonal antibody as described
in section 2.2.8.1 and for reaction with pertussis toxin subunits separated by SDS
PAGE. Other methods are described in each relevant section of the text.
3.2.3 Monoclonal antibodies
Monoclonal antibodies were prepared as described by Gorringe et al. (1985).
Monoclonal antibody was purified from ascites fluid as described in section 2.2.4.
The anti-pertussis toxin titre of each antibody in ascites fluid was measured using a
solid phase ELISA as before and results are shown in table 3.1. Briefly, 1-2 ml was
dialysed against column equilibration buffer and applied to a DEAE sepharose CL6B
column after centrifugation to remove debris, or the ascites fluid was diluted to 10 ml
using equilibration buffer and applied to a Mono Q HR 5/5 column through a
superloop. Each column was eluted as described in section 2.2.4 and fractions
containing protein determined by absorbance at 280 nm were tested for anti-pertussis
toxin activity using a solid phase ELISA. Those fractions containing most anti-
pertussis toxin antibody judged by the ELISA test were pooled (see table 3.1 for anti-
pertussis toxin titres of the purified antibodies) and reacted with the pin decapeptides at
decreasing dilution, the highest dilution being 1:200, decreasing to 1:100, 1:10 and 1:2
(the least dilution).
Purification of the antibodies gave similar chromatographic profiles,
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Fig. 3.2 Typical anion exchange profile
Ascites fluid containing monoclonal antibody was diluted to 10 ml using
5 mM Tris-Cl, pH 8.0 and applied to a Mono-Q column through a superloop. The
column was then eluted with 5 mM Tris-Cl, 200 mM NaCl, pH 8.0 and fractions
containing assayed for anti-(pertussis toxin) activity using a solid phase ELISA using








Production and anti-pertussis toxin titres of mouse monoclonal
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independent of the two methods mentioned above and a typical anion exchange profile
is shown in figure 3.2. The first peak, which can be seen at 19 minutes was found to
contain the highest anti-pertussis toxin activity, shown in table 3.1 Judged from a
solid phase ELISA using pertussis toxin as coating antigen.
The monoclonal antibody L10 was the only antibody that was not purified
efficiently using anion exchange, so 1 ml of L10 was purified from ascites fluid using
protein A sepharose CL4B as described in section 2.2.4.3. Fractions containing
protein (judged from A280 were tested for anti-pertussis toxin activity in a solid phase
ELISA and those containing highest anti-toxin activity were pooled.
3.2.4 Efficiency of pin peptide synthesis
To assess the efficiency of the peptide synthesis indirectly, the reaction of a
reference MAB provided by the suppliers of the epitope mapping kit, with two control
tetrapeptides was assessed using the ELISA method described in section 2.2.3.1. One
set of two tetrapeptides was synthesised simultaneously with the decapeptides and the
other set was provided by the suppliers of the kit. One of the tetrapeptides, PLAQ,
reacts strongly with the reference serum, but the other tetrapeptide, GLAQ, does not
react. Comparison of the reaction of the reference MAB with the suppliers' control
peptides and with the control peptides synthesised at the same time as the test
decapeptides gives an indication of the success of the peptide synthesis.
A more direct way of assessing the efficiency of the synthesis was also used.
Antisera raised against synthetic peptides (anti-Sla, -Sic, S3a, and S4b)whose
sequences were derived from pertussis toxin subunits, were reacted at 1:300 dilution
with the completed pin peptides, to determine whether the antisera recognised
decapeptides located in the sequence of the immunising peptide.
3.3 Results
3.3.1 Western blotting of antibodies used in reaction with pin
peptides
Figure 3.3 shows the subunit specificity of the antibodies reacted with the pin
peptides, assessed by Western blotting of pertussis toxin subunits separated by SDS
PAGE. Antibodies were reacted at 1:1000 dilution unless stated otherwise and all
monoclonal antibodies were tested as ascites fluid.
As was expected, each antipeptide antibody reacted with the subunit from
which the peptide sequence was raised at 1:1000 dilution.
Antibodies Sla and Sic (lanes one and two) reacted with subunit SI and
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weakly with subunits S2 and S3.
Antibodies anti-S3a, -S3b and -(E)S3c reacted with subunit S3 and weakly
with SI (lanes three to five). Cross-reaction of anti-(E)S3c was reduced but not
eliminated by inclusion of 250 mM NaCl in the blot incubation buffer.
Reaction of subunit S4 with anti-S4b diluted 1:4000 in blocking buffer
containing 250 mM NaCl is shown in lane six. At 1:1000 dilution anti-S4b reacted
with the subunit from which the peptide was derived, and cross-reacted with subunit
S3 (not shown). Several dilutions of anti-S4b were made in blot blocking buffer that
contained increasing concentrations of NaCl. These dilutions were then incubated
with the separated pertussis toxin subunits to assess nonspecific binding of the
antiserum to immunoblots.
Monoclonal antibodies L3, L9 and L10 all reacted with subunit SI and weakly
with S3 (lanes 7, 12 and 13) and L12 only reacted with SI (lane 15). Monoclonal L4
(lane 8) reacted very weakly with subunit S3 and L6 and LI 1 (lanes 10 and 14) did not
show a detectable reaction with any of the subunits. Monoclonals L5, L7 and L13
(lanes 9, 11 and 16) reacted with subunit S3 and weakly with SI. When the toxin
sample was prepared in a buffer containing 2-ME and blotted with L5, L7 and LI3, L5
and LI3 recognised subunit S3, but L7 did not.
Mouse polyclonal anti-toxin antiserum 4/292 bound all the separated subunits
(lane 17). Anti-toxoid antibody 289/9 also bound the subunits, but more weakly (lane
18).
Rabbit polyclonal antiserum 12A20A bound to all the separated subunits (lane
19). 985/989 and 978/983 also bound the toxin subunits (lanes 20 and 21), but more
weakly than 12A20A. The extent of binding of these antisera to the toxin subunits
were not identical, possibly because the antisera contained antibodies of different
clonal origin: Variations in the apparent position of the subunits in these lanes would
be explained by this and possibly by slight variations in protein loading, resulting in
wide bands on staining of the blots. Finally, lanes 22 and 23 show negative control
immunoblots treated with anti-mouse IgG conjugated to horse radish peroxidase and
anti-rabbit IgG conjugated to alkaline phosphatase, respectively.
3.3.2 Antipeptide antibody binding to pin decapeptides
3.3.2.1 Efficiency of pin peptide synthesis
Both the supplier's and the author's positive control tetrapeptides (PLAQ)
gave an ELISA absorbance at 405 nm over 1.2 and the negative control tetrapeptides
(GLAQ) had an absorbance less than 0.2, indicating successful synthesis of the




Western blotting of pertussis toxin subunits
Lane Antibody Subunit(s) bound
1 anti-Sla SI (also S2,S3)
2 anti-Slc SI (S2, S3)
3 anti-S3a S3 (SI)
4 anti-S3b S3 (SI)
5 anti(E)S3c S3 (SI)
6 anti-S4b S4
7 L3 SI (S3)
8 L4 S3
9 L5 S3 (SI)
10 L6 None
11 L7 S3 (SI)
12 L9 SI (S3)
13 L10 SI (S3)
14 Lll None
15 L12 SI
16 L13 S3 (SI)
17 4/292 all (S1-S5)
18 289/9 all (S1-S5)
19 12A20A ail (S1-S5)
20 985/989 all (S1-S5)
21 978/983 all (S1-S5)
22 anti-mouse IgG conjugate (a) None
23 anti-rabbit IgG conjugate (b) None
(a), (b). anti-mouse and anti-rabbit IgG conjugated to alkaline phosphatase
(c). All antipeptide antisera reacted with blots in PBS pH 7.2 (final concentration of
NaCl 250 mM)
Subunits in parentheses indicate weak cross-reaction with antibody
tflNM
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Synthesis of the subunit decapeptides was confirmed indirectly using rabbit antipeptide
antibodies. The amino acid sequences of the peptides used to raise these
sera and anti-pertussis toxin titres of the sera in a solid phase EL1SA (see section
2.2.3.1 for the ELISA method) are given in table 3.2. The antipeptide sera were
reacted with the pin decapeptides from subunits SI, S3 and S4 and these were used as
controls. For example, anti-Sla was reacted with S3 and S4 decapeptides, which
contained decapeptides not in the immunising peptide.
Two rabbit-antipeptide antisera, anti-Sla and anti-Slc (kindly provided by Dr.
R.N. Seabrook, PHLS, Porton, U.K.) were used to confirm the synthesis of the SI
subunit decapeptides. These antisera were raised against two synthetic peptides from
the SI amino acid sequence, each conjugated to a carrier. Their production is
described elsewhere (Seabrook et al., 1990).
Figure 3.4 shows the reaction of anti-Sla with SI decapeptides with a five
amino acid overlap. As was expected, the antibody recognised decapeptides that were
in the sequence of the immunising peptide, confirming the peptide synthesis, but the
strength of reaction differed between reacting peptides. Decapeptide 1 had the
strongest reaction, followed by decapeptide 3, then 2, so residues within decapeptides
1 and 3 seem important for recognition by anti-Sla.
Figure 3.6 shows the reaction of anti-Sla with SI decapeptides with an eight
amino acid overlap. Anti-Sla bound decapeptides containing residues from the N- and
C-terminal regions of the immunising peptide, confirming the peptide synthesis.
Again the strongest reaction was with decapeptides that were in the sequence of
the immunising peptide and again the strength of reaction differed between reacting
peptides. Decapeptide 1 from the N-terminal sequence of SI, (the same sequence as
decapeptide 1 above) again had the expected strong reaction with anti-Sla, but peptide
2 did not react at all. This suggests that residues 1 and/or 2 of SI are important in the
binding of anti-Sla because only these residues differ between peptides 1 and 2.
However, internal peptide residues may also be involved in the interaction.
Three more decapeptides, 5, 6 and 7, also found in the sequence of the
immunogen, reacted strongly with anti-Sl a, but peptide 4, which has only two amino
acids different from peptide 5, did not bind anti-Sla. This implicates residues 17
and/or 18 in decapeptide 5, in the epitope bound by anti-Sla. Strength of reaction
with anti-Sla decreased between decapeptides 6 and 7, implying that residues 19 and
20 (decapeptide 6) may also be involved in binding of this antibody. Weaker reaction
was seen with decapeptide 7, so residues in this peptide could be involved in anti-Sla
binding, as the binding to decapeptide 7 is lost in decapeptide 8.
Figure 3.5 shows anti-Slc binding to SI decapeptides with a five amino acid
overlap. Anti-Slc only recognised decapeptide 42 that contained residues in the
sequence of the immunising peptide and so confirmed the synthesis. A strong reaction
was seen with this peptide, suggesting that most, if not all residues necessary for
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Fig. 3.4 Reaction of anti-Sla with SI decapeptides with
a five amino acid overlap
Decapeptides were incubated with blocking buffer (10%(v/v) newborn calf serum,
0.4%(v/v)Tween 20) for 90 minutes and then with rabbit anti-Sla at a dilution of
1:300, overnight. Reaction with the decapeptides was detected by ELISA (see section
2.2.3.1 for details).
The bar (t <) shows pin decapeptides contained in the peptide immunogen.
Fig. 3.5 Reaction of anti-Slc with SI decapeptides with
a five amino acid overlap
Anti-Slc was reacted with the decapeptides at a dilution of 1:300, other experimental
conditions being as above.
Absorbance(405nm)
Absorbance(405nm)
Fig. 3.6 Reaction of anti-Sla with SI decapeptides with an
eight amino acid overlap
Decapeptides were incubated with blocking buffer (10%(v/v) newborn calf serum,
0.4%(v/v)Tween 20) for 90 minutes and then with rabbit anti-Sla at a dilution of

















Fig. 3.7 Reaction of anti-Slc with SI decapeptides with a
five amino acid overlap
Decapeptides were incubated with blocking buffer (10%(v/v) newborn calf serum,
0.4%(v/v)Tween 20) for 90 minutes and then with rabbit anti-Slc at a dilution of
1:300, overnight. Reaction with the decapeptides was detected by ELISA (see section
2.23.1 for details).
 
antibody binding were contained in this decapeptide.
Anti-Slc was also tested against SI decapeptides with an eight amino acid
overlap (fig. 3.7) and was found to react strongly with peptides 104, 105 and 106 as
expected because all three peptides have sequence in common with the reactive peptide
(42) of S1 decapeptides with a five amino acid overlap. This suggests that the N-
terminal residues of the immunising peptide (237-247) interacted with anti-Slc.
One rabbit-antipeptide antibody, anti-S3a, was used to confirm the synthesis of
the S3 subunit decapeptides. It was kindly provided by Dr. R.N. Seabrook (PHLS,
Porton, U.K.). Its production is described elsewhere (Seabrook et al., 1990).
Figure 3.8 shows binding of anti-S3a to S3 decapeptides. Strong reactions
were observed with decapeptides 14, 15 and 16 and all three peptides were contained
within the sequence of the immunising peptide, so confirming the decapeptide
synthesis.
The strongest binding was seen with decapeptide 15, compared with slightly
weaker binding seen with decapeptides 16 and 14. This suggests that N-terminal
residues in the immunising peptide bound anti-S3a more strongly than C-terminal
residues in the immunising peptide, but that both regions contributed to the overall
binding of anti-S3a.
The synthesis of the S4 decapeptides was also confirmed by reaction with an
antipeptide antibody. At the time of synthesis, an anti-S4 antipeptide antibody that
bound the pin peptides was not available, so a decapeptide that reacted strongly with a
polyclonal antibody (12A20A) was synthesised and rabbit antisera raised against a
KLH-conjugate of that peptide (section 3.3.6.5.1). The sequence of the peptide and
the anti-pertussis toxin titre of the antibody are given in table 3.2. Anti-S4b was found
to react with two S4 decapeptides (17 and 18, figure 3.9) that contained residues in the
sequence of the immunising peptide and so confirmed the S4 peptide synthesis. The
strongest reaction was with decapeptide 18, which consisted of the whole amino acid
sequence of the immunising peptide. A slightly weaker reaction was seen with peptide
17, which only contained five from the ten amino acids used as immunogen. This
indicates that amino acids in the N- and C-terminal of the immunogen were involved in
binding of this antibody.
In summary, reactions of rabbit antisera raised against synthetic peptides with
the decapeptides confirmed as far as possible that the syntheses consisted of the
expected amino acid sequences. Each antibody reacted with pertussis toxin used as
coating antigen in a solid phase ELISA, shown in table 3.2 and with pertussis toxin
subunits separated by SDS PAGE and immunoblotted (fig. 3.3).
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Fig. 3.8 Reaction of anti-S3a with S3 decapeptides with
a five amino acid overlap
Decapeptides were incubated with blocking buffer (10%(v/v) newborn calf serum,
0.4%(v/v)Tween 20) for 90 minutes and then with rabbit anti-S3a at a dilution of
1:300, overnight. Reaction with the decapeptides was detected by ELISA (see section
2.2.3.1 for details). As previously, the bar below the graph shows decapeptides
contained in the amino acid sequence of the peptide immunogen
Fig. 3.9 Reaction of anti-S4b with S4 decapeptides with
a five amino acid overlap



















3.3.2.2 Reactions of antipeptide antisera with all the pin
peptides
Cross-reaction of antibodies with peptides that contain similar partial sequences
have been reported (Jacob et al., 1983; Kazemi and Finkelstein, 1991; Trifilieff et al.,
1991).
It was decided to investigate cross-reaction of a panel of rabbit antipeptide
antibodies raised against pertussis toxin subunit sequences, at 1:300 dilution, with the
pin peptides from the sequences of the other subunits that were synthesised in this
study. Antipeptide antibodies to the S2 and S5 subunits were not tested as they were
not available at the time of study.
Some of the antipeptide antisera in the study bound on Western blots to
subunits other than the ones from which their peptide sequences were derived
(figure 3.3), it was interesting to see if these antisera cross-reacted with pin peptides
derived from the same subunit(s) as the ones they cross-reacted with on Western blots.
The panel of antibodies tested included anti-Sla, -Sic, -S3a, and -S3b
antipeptide antibodies, which were raised in rabbits as mentioned above
(Seabrook et al., 1990). Their anti-pertussis toxin titres and sequences of the peptide
immunogens are given in table 3.2 . Two other rabbit-antipeptide antibodies that were
raised during this study were also tested, anti-S4b and -(E)S3c (see section 2.2.5 for
details of their production and table 3.2 for the peptide sequences that they were raised
against).
Anti-Sla did not cross-react with S3 or S4 decapeptides. Anti-Slc cross-
reacted weakly (about 30% above the background absorbance at 405 nm of 0.32) with
two S3 decapeptides (6 and 23), both of which have only two amino acids
homologous with the peptide used to raise anti-Slc. This binding could be due to the
partial sequence identity between the decapeptides and the peptide immunogen. Two
amino acids identity in an S4 decapeptide (21) with the peptide immunogen used to
raise anti-Slc could be responsible for the weak cross-reaction (25% above
background absorbance at 405 nm of 0.27) of S4 decapeptides with anti-Slc.
Anti-S3a reacted strongly with one peptide (52) of SI decapeptides with an
eight amino acid overlap (figure 3.10). This decapeptide was part of a region of
reactive decapeptides (52-57) and had three non-adjacent amino acids identity with the
anti-S3a peptide immunogen. Anti-S3a also reacted with SI decapeptide 47, which
had only one amino acid in common with the peptide used to raise anti-S3a.
Anti-S3a did not cross-react with SI decapeptides with a five amino acid
overlap. Decapeptide 56 (8 residue overlap) had the same amino acid sequence as
decapeptide 23 (5 residue overlap), but the latter decapeptide (23) did not react with
anti-S3a, possibly because those pin peptides had been screened a considerable
number of times when this reaction was performed.
75
Fig. 3.10 Reaction of anti-S3a with SI decapeptides with
an eight, amino acid overlap
Decapeptides were incubated with blocking buffer (10%(v/v) newborn calf serum,
0.4%(v/v)Tween 20) for 90 minutes and then with rabbit anti-S3a at a dilution of











The lack of reaction of anti-S3a with SI decapeptides with a five amino acid
overlap and the strong reaction with SI decapeptides with an 8 residue overlap
highlights the problem that whatever arbitrary pin peptide overlap of amino acids (five,
for instance) is decided upon, there is no guarantee that an antibody binding site of
greater that five residues will be within one peptide.
Anti-S3a also cross-reacted with S1 when pertussis toxin subunits were
separated by SDS PAGE. Binding of this antibody was not reduced to background by
inclusion of 250 mM NaCl to either the pin or immunoblot antibody incubation
buffers, (higher concentrations of NaCl were tried but binding to SI was not totally
inhibited).
Anti-S3a weakly cross-reacted with S4 decapeptide 17, which has only two
amino acids identical with the peptide immunogen and could account for the weak
reaction.
Anti-S3b did not cross-react with any SI decapeptides with a five amino acid
overlap or eight residue overlap or with S3 or S4 decapeptides. This antibody had a
low anti-pertussis toxin titre (pertussis toxin coating antigen) as seen in table 3.2. A
possibility for the lack of reaction with the pin peptides is that the peptide is that not all
residues required for anti-S3b binding were contained in any S3 pin decapeptide.
Anti-(E)S3c reacted with weakly with S3 decapeptides 11 and 14, that were
contained in the immunising peptide and with decapeptides 16, 25 and 27, all of which
contained partial sequences in the immunising peptide sequence. None of the peaks
were over 25% above background binding (absorbance average 0.32).
Anti-(E)S3c cross-reacted weakly with S1 decapeptides with an eight amino
acid overlap: peptides 10-13 cross-reacted with anti-(E)S3c as did peptide 18. These
peptides did not possess more than two amino acids identity with the immunising
peptide and the cross-reaction was reduced to background levels by incubation of the
antibody with the pins in a buffer containing 250 mM salt. The cross-reaction was
also seen with Western blots using anti-(E)S3c against pertussis toxin subunits
separated by SDS PAGE and was reduced by incubating the antibody with the
immunoblots in a buffer containing 250 mM NaCl (see chapter 4). Anti-(E)S3c was
also be expected to react with the S2 subunit, since peptide (E)S3c has sequence
homology with the same region of S2, but cross-reaction with the S2 subunit was not
detected on immunoblots.
Anti-S4b, raised against a pin decapeptide that was found to bind a polyclonal
antibody, (the sequence of the peptide immunogen is given in table 3.2) cross-reacted
with decapeptides 17 and 18 that were contained in the immunising peptide, the
strongest reaction being with the decapeptide containing the whole sequence of the
immunising peptide (fig. 3.9). Anti-S4b did not cross-react with the other pin
decapeptides.
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Table 3.3 Reaction of rabbit antipeptide antisera with pin decapeptides
(Subunit-specificity of rabbit antipeptide antisera)
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In short, some antipeptide antisera cross-reacted weakly with pin decapeptides
with as few as two amino acids identity with the immunising peptide. The only
antipeptide antibody that strongly cross-reacted with pin peptides was anti-S3a, which
reacted with SI decapeptides with an eight amino acid overlap (Table 3.3).
This means that reaction of antipeptide antibodies, especially weak reaction with the
pin decapeptides, must be viewed with scepticism in the first instance, and even strong
reactions with antipeptide antisera (e.g. anti-S3a with SI decapeptides) could be due to
reasons other than sequence identity, for example peptide flexibility, as mentioned
earlier. Antiprotein antibodies are less subject to cross-reaction with the pin
decapeptides than antipeptide antisera, as is shown in sections 3.3.3, 3.3.4.
3.3.3 Reaction of pin decapeptides with mouse polyclonal
antibodies
Reactions of a mouse anti-(pertussis toxin) antibody (4/292), mouse anti-
pertussis toxoid(289/9) antibody and convalescent mouse serum with the pin peptides
were assessed and compared with the reactions of rabbit and human antisera. The
convalescent mouse serum sample was kindly provided by Dr. K. Redhead (NIBSC,
Potters Bar, U.K.) and the mouse anti-(pertussis toxin) antisera were generously
supplied by Dr. A. Robinson, PHLS CAMR.
Table 3.1 shows the anti-pertussis toxin titre of antibodies 4/292 and 289/9 in a
solid phase ELISA using pertussis toxin as the coating antigen. Just enough
convalescent mouse serum was available to react with the pin decapeptides at 1:250
dilution in pin blocking buffer (2.2.3.1), so an anti-pertussis toxin titre was not
obtained for this sample.
4/292 and 289/9 were reacted with the pins at both 1:300 and 1:200 dilution in
pin blocking buffer. None of the three sera reacted against the pin decapeptides.
3.3.4 Reaction of monoclonal antibodies with pin peptides
The pin peptides were screened for reaction with a panel of mouse monoclonal
antibodies (MABs), to identify linear antigenic determinants, i.e. peptides that bound
antibody. Mouse monoclonal antibodies were used as ascites fluid or were purified by
DEAE-sepharose or by Mono-Q anion exchange chromatography and then reacted
with the pin peptides. As stated earlier, a large proportion of B cell epitopes are
thought to be conformational, and the aim of these experiments was to identify
peptides that either form subsites of discontinuous epitopes or at least mimic part of the
antigenic epitope with which the antibody paratope interacts.
Monoclonal antibody (MAB) that was raised against another protein (fim 2
from pertussis toxin fimbriae) was used as a negative reaction control. This
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monoclonal antibody did not react with the pin decapeptides, as ascites fluid or
purified antibody and gave an average background of 0.2. Anti-pertussis toxin MABs
that did not react with the pin peptides were also used as negative controls.
The panel of antibodies, their IgG isotype and anti-pertussis toxin titre is given
in table 3.1. Each set of pin decapeptides from subunits SI (both five and eight amino
acid overlap), S3 and S4 (both five amino acid overlap) were reacted with each MAB
as ascites fluid at 1:100 dilution and as purified antibody diluted as little as possible
(maximum dilution 1:4), which was prepared at the same time as the pin peptides were
screened with the ascites fluid.
There were three exceptions to this scheme, being L3, L5 and LI 1, which
were reacted as ascites fluid only with the pin decapeptides. As they did not react at all
with the decapeptides as ascites (generating a background level of absorbance of 0.15
or less), they were not purified as there was little chance of the purified antibody
reacting with the pin peptides.
Most of the MABs did not cross-react with the pin decapeptides, either as
ascites fluid or as purified antibody. An exception was L10, which reacted weakly
with the SI pin decapeptides (5 overlapping residues) 11, 23 and 24 (44, 37 and 46%
above the average background of 0.4 at 405 nm as ascites fluid). It was hoped that
purification of L10 using protein A-sepharose would reduce the background binding
and reveal specific binding peaks. This cannot have been the case, because no reaction
with the SI decapeptides was seen, even when the purified L10 was reacted with the
pins at 1:4 dilution (background level of absorbance was 0.25 at 405 nm).
L10 reacted weakly with S3 decapeptides as ascites fluid. One S3 peptide
(peptide 1, A405 0.38) bound L10 to produce an absorbance almost double the
background level (A405 0.145). However, after purification L10 did not bind any of
the S3 decapeptides above background level.
Monoclonal antibodies L7 and L9 both reacted weakly as ascites fluid with S3
decapeptides. Neither reacted with single peptides but they did react with regions of
peptides. L7 as ascites fluid reacted weakly with decapeptides 6-8, 10, 21-23, 32 and
34 (background A405 0.6, maximum peak absorbance 1.175). When reacted with
purified L7, S3 decapeptides 22 and 39 generated an absorbance distinctly above the
background level.
L9 as ascites fluid reacted weakly with S3 decapeptides 11 and 22 and the level
of background binding was high at 0.45. Purified L9 bound to one decapeptide (22)
to give an absorbance at 405 nm double that of the background (fig. 3.11).
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Fig. 3.11 Reaction of purified monoclonal antibody L9 with
S3 decapeptides with a five amino acid overlap
Decapeptides were incubated with blocking buffer (10%(v/v) newborn calf serum,
0.4%(v/v)Tween 20) for 90 minutes and then with L9 overnight. Reaction with the
decapeptides was detected by ELISA (see section 2.2.3.1 for details).
Absorbance(405nm)
3.3.5 Binding of rabbit antisera by pin decapeptides
3.3.5.1 Results of binding of rabbit antisera
Three rabbit polyclonal antisera (12A20A, 985/989 and 978/983) raised against
pertussis toxin were kindly provided by Dr. L. Irons (PHLS, Porton, U.K.).
Sample 985/989 was raised with a primary dose of 50 pig pertussis toxin in incomplete
Freund's adjuvant with no booster and harvested 16 weeks after the first dose.
Sample 12A20A was raised with a primary dose of 10 pig pertussis toxin in
incomplete Freund's adjuvant, boosted at three weeks with 50 pig pertussis toxin in
the same adjuvant and the serum harvested 20 weeks after the initial dose.
Sample 978/983 was raised with a primary dose of 50 pig pertussis toxin in
alhydrogel adjuvant. No booster was administered and the serum was harvested after
16 weeks.
Anti-(pertussis toxin) titres in a solid phase ELISA using pertussis toxin as
coating antigen are given in table 3.1.
Sample 978/983 did not cross-react with any pin decapeptides. This antibody
was reacted with the pin decapeptides at dilutions ranging between 1:400 and 1:50 and
generated no binding peaks in the pin ELISA test.
The rabbit anti-(pertussis toxin) antibody 12A20A bound pertussis toxin
adsorbed onto ELISA plates, as did 985/989 (table 3.1). Despite the fact that 12A20A
had a lower anti-pertussis toxin titre than 985/989, 12A 20A had the strongest reaction
of all three rabbit antibodies with the pin decapeptides. 12A20A was reacted with the
pin decapeptides at 1:500 to 1:100, but 1:100 dilution gave a high background level of
binding to the decapeptides, so 1:400 was chosen for inclusion in figure 3.12a,
because the background binding level was low.
Sample 12A20A (fig. 3.12a) bound strongly to peptides 3 and 41 of SI
(5 residue overlap), when diluted 1:400 and also cross-reacted with SI decapeptides
(8 residue overlap) as antibody 985/989 did when diluted 1:100. SI decapeptides
(8 residue overlap) 5 and 7, 102-104 were strongly bound and decapeptides 15,16 and
65 were bound more weakly (fig 3.13). Decapeptide 6 reacted weakly with 12A20A,
possibly because this decapeptide was more difficult to synthesise than decapeptides 5
or 7.
The SI decapeptides (8 overlap) bound were similar for 985/989 and 12A 20A but the
level of reactivity with the peptides did differ. 12A 20A reacted most strongly with
decapeptides 5 and 103 as can be seen in figure 3.13, whereas 985/989 reacted most
strongly with decapeptide 6 and more weakly with decapeptide 102.
Sample 12A20A did not cross-react with S3 decapeptides at dilutions between
1:400 and 1:100. Lower dilutions were not tested because decreasing the antibody
dilution only succeeded in raising the level of background binding.
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Fig. 3.12a Reaction of polyclonal antiserum 12A20A with
SI decapeptides with a five amino acid overlap
Decapeptides were incubated with blocking buffer (10%(v/v) newborn calf serum,
0.4%(v/v)Tween 20) for 90 minutes and then with 12A20A at a dilution of 1:400
overnight. Reaction with the decapeptides was detected by ELISA (see section
2.2.3.1 for details).
Fig. 3.12b Reaction of polyclonal antiserum 12A20A
pre-incubated with 20 //g/ml pertussis toxin, with SI
decapeptides with a five amino acid overlap




Fig. 3.13 Reaction of rabbit polyclonal antiserum 12A20A
with SI decapeptides with an eight amino acid overlap
Decapeptides were incubated with blocking buffer (10%(v/v) newborn calf serum,
0.4%(v/v)Tween 20) for 90 minutes and then with 12A20A at 1:400 dilution















Serum sample 12A20A (1:400) cross-reacted with the same S4 decapeptide
(18, fig. 3.14a) as 985/989. Even though 12A20A was four times more dilute than
985/989 when reacted with the pin decapeptides, 12A20A reacted more strongly than
985/989 with both SI and S4 decapeptides.
Sample 985/989 diluted 1:100 in pin blocking buffer reacted weakly with the
same regions of SI decapeptides (8 residue overlap) as sample 12A20A, but did not
react at all with SI decapeptides (5 residue overlap), possibly because the 5-residue
overlapping decapeptides were synthesised less successfully than the 8-overlapping
ones. Sample 985/989 did not react at all with S3 decapeptides, but did react with the
same S4 decapeptide as sample 12A20A. Sample 985/989 did not cross-react with
any S3 decapeptides, but did react with S4 decapeptide 18 (A405 nm 0.65), a strong
reaction when compared to the average background binding (A405 nm 0.3).
In summary, samples 12A20A and 985/989 both reacted with the same regions
of SI decapeptides (8 residue overlap) and the same S4 pin decapeptide. None of the
sera reacted with the S3 decapeptides.
3.3.5.2 Inhibition of rabbit polyclonal antibody binding to SI and
S4 pin decapeptides by pertussis toxin
Sample 12A20A bound strongly to SI and S4 decapeptides, so the antibody
(1:400) was preincubated with pertussis toxin to determine whether this inhibited
antibody binding to the pin decapeptides. A 1:400 dilution was used because this was
the highest dilution to react strongly with the pin decapeptides and produce a low
background level of binding.
Several concentrations of pertussis toxin were tried for the preincubation (0.2,
2, and 20 //g/ml), diluted in the pin blocking buffer. 0.2 and 2 /<g/ml did not inhibit
12A20A binding to SI (5 residue overlap) or S4 decapeptides, but 20 /<g/ml did
In fig. 3.12a , which shows 12A20A binding to SI decapeptides (5 residue
overlap), two peaks can be seen at decapeptides 3 (A405 0.6) and 41 (A405 0.35).
After preincubation of 12A 20A with 20 //g/ml pertussis toxin, the two peaks at
peptides 3 and 41 were reduced to background level (fig. 3.12b).
Figure 3.14a shows 12A20A binding to S4 decapeptide 18 (A405 1.04). After
preincubation with 20 /<g/ml pertussis toxin (fig. 3.14b), the peak at decapeptide 18
had been reduced to background level.
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Fig. 3.14a Reaction of 12A20A with S4 decapeptides with
a Ave amino acid overlap
Experimental conditions were as described for figure 3.12a and 3.12b.
.3.14b Reaction of 12A20A pre-incubated with 20 //g/ml pertussis
toxin, with S4 decapeptides with a five amino acid overlap
Experimental conditions were as described for figure 3.12a and 3.12b.
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3.3.6 Studies on peptide S4b
3.3.6.1 Synthesis of free peptide S4b
As both 12A20A and 985/989 bound to one S4 decapeptide, decapeptide 18
(amino acids 86-95, sequence QLTFEGKPAL) was synthesised as a C-terminal amide
with a C-terminal glycine spacer followed by a cysteine residue and was named
peptide S4b (table 3.2).
The glycine and cysteine residues were incorporated to enable coupling of S4b
to KLH, using the thiol-reactive cross-linking reagent, MBS, in preparation for
immunisation of rabbits.
The peptide was purified by reverse phase HPLC as described in section
2.2.5.6 S4b eluted as a single peak at 19.27 minutes (fig. 3.15).
3.3.6.2 Mass spectrometry of peptide S4b
The purification of S4b by HPLC only showed that the peptide was
homogeneous. It did not indicate whether the peptide residues had been properly
deprotected, had been derivatised in the deprotection process, or was of the expected
mass, so an additional check on the peptide was made. Peptide S4b was subjected to
fast atom bombardment mass spectrometry (FAB MS) as described in section 2.2.5.7.
This technique was used to determine whether S4b had a molecular mass that would
be expected for the residues which it contained, that is to determine if S4b had been
derivatised during deprotection, or if a truncated form of S4b had been generated.
Peptide S4b produced the expected measured mass of molecular ion ([M + H]+) of
1262.8 Da, and the fragmentation pattern for the peptide fittedthe sequence of peptide
S4b, shown in figure 3.16. This indicated that the peptide had not been truncated in
synthesis and had not been derivatised during deprotection. For instance, if the
preparation contained a full-length and a truncated peptide, two molecular ions would
be generated, one having the calculated mass of the full-length peptide and one with a
lower mass that would indicate an incomplete synthesis. Subtraction of the lower
from the higher mass of molecular ion would enable calculation of the mass of the
missing residues.
3.3.6.3 Inhibition of 12A20A binding to S4 pin peptides by
peptide S4b
Antibody 12A20A (1:400) was preincubated with three concentrations of
peptide S4b (1,10 and 100 //g/ml) in pin blocking buffer and incubated with the S4
pin decapeptides. Peptide S4b was found to inhibit 12A20A binding to the same
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Fig. 3.15 Reverse phase HPLC-purification of peptide S4b







































Fig. 3.16 FAB mass spectrum of peptide S4b
See section 2.2.5.7 for details.
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extent as pertussis toxin, that is, to background levels (as in fig. 3.14b).
Binding of 12A20A to S4 pin decapeptides was inhibited by peptide S4b and
pertussis toxin, suggesting that the 12A20A anti-pin peptide reaction was specific, i.e.
directed against similar sites on the pin and free peptide and on pertussis toxin.
3.3.6.4 Mouse anti-S4b
Peptide S4b was conjugated to bovine serum albumin (BSA) using
glutaraldehyde or conjugated to keyhole limpet haemocyanin (KLH) using m-
maleimidobenzoyl-N-hydroxysuccinimide ester (MBS).
Anti-S4b sera were raised in mice against BSA-S4b and KLH-S4b using the
method described in section 2.2.7.1. Nonspecific binding was controlled for using a
peptide (3f) derived from B. pertussis fim 3 , whose sequence is given in appendix 1.
Antibodies to BSA-S4b and KLH-S4b recognised the homologous peptide,
peptide conjugate and pertussis toxin, in a solid phase ELISA in which the antigen was
coated directly onto the microtitre plate (table 3.4).
Anti-KLHS4b recognised homologous peptide and peptide conjugate with
higher titres than anti-BSA-S4b. Anti-KLH-S4b also recognised BSA-S4b coated
directly onto the microtitre plate, more strongly than anti-BSA-S4b recognised KLH-
S4b coated onto the microtitre plate (table 3.4). Despite anti-KLH-S4b having a lower
anti-pertussis toxin titre than anti-BSA-S4b, the larger amounts of antipeptide serum
needed for further work was raised against KLH-S4b in rabbits. (NB. anti-carrier
reactions were controlled for by measuring binding to carrier-coated plates).
3.3.6.5 Rabbit anti-S4b
3.3.6.5.1 Binding of rabbit anti-S4b to peptide S4b and
pertussis toxin
The method of generation of rabbit antipeptide antibodies is described in
section 2.2.7.2.
Rabbit anti-S4b was assayed for antipeptide and antiprotein reactivity by solid
phase ELISA, in which the antigen was coated directly onto the plate, as with the
mouse antipeptide sera above. A KLH-peptide conjugate (KLH-3f) whose synthetic
peptide sequence was derived from B. pertussis fim 3 was used as a negative control.
The sequence of the latter control peptide is given in appendix 1.
Anti-KLH-S4b bound to pertussis toxin adsorbed onto the microtitre plate, and
more strongly to peptide S4b, KLH-S4b and BSA-S4b adsorbed directly onto the
microtitre plate (table 3.4).
As 'native' antigen coated onto a microtitre plate could contain some denatured
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Table 3.4 Solid phase ELISA titres for rabbit- and mouse-antipeptide
antisera
Antipeptide
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protein and coating the antigen directly onto the microtitre plate could also denature the
antigen (Jemmerson and Blankenfeld, 1989), recognition of pertussis toxin captured
by a monoclonal antibody ( MAB L10) was assessed.
Anti-S4b recognised 'native' pertussis toxin captured by MAB L10 with a titre of 186,
compared with 270 against pertussis toxin coated directly onto the ELISA plate, so
although recognition of pertussis toxin was weak, a small part of the response
appeared to be due to recognition of denatured antigen by the antipeptide antibody.
The subunit specificity of anti-S4b was assessed by Western blotting of
pertussis toxin subunits separated by SDS PAGE (see fig. 3.3).
3.3.6.5.2 Anti-S4b binding to S4 pin decapeptides
Anti-S4b reacted with S4 pin decapeptides 17 and 18, both of which were
contained in the sequence of the peptide immunogen (fig. 3.9).
This indicated that the pin peptide synthesis of S4 decapeptides was successful.
3.3.6.5.3 Inhibition of 12A20A binding to pertussis toxin
Anti-S4b and 12A20A cross-reacted with S4 decapeptide 18, so inhibition of
12A20A binding to pertussis toxin by peptide S4b was assessed, using a solid phase
ELISA .
Serum 12A20A was diluted to give A450 1.2-1.5 and preincubated with
decreasing concentrations of peptide S4b. After 90 minutes this was incubated with
microtitre plate wells coated with pertussis toxin for another 90 minutes. Binding of
12A20A was detected using anti-rabbit (IgG) conjugated to horse radish peroxidase.
The reaction was expected to show an increase in A450 to 1.2-1.5 as peptide S4b was
diluted, if 12A20A bound homologous sites on both S4b and whole pertussis toxin.
However, no inhibition of 12A20A binding to pertussis toxin by peptide S4b was
seen, possibly due to a small proportion of 12A20A antibodies that bind peptide S4b.
3.3.6.5.4 Inhibition of antibody binding to peptide S4b and pertussis
toxin
Anti-S4b and 12A20A bound S4 decapeptide 18, as mentioned earlier, and the
experiment described in the previous section did not show inhibition, so inhibition of
anti-S4b and 12A20A binding to peptide S4b and whole pertussis toxin was attempted
to show that the two antibodies recognised the peptide and toxin.
Mouse anti-S4b was diluted in a fixed concentration of 12A20A
(A450 1.2-1.5) and incubated for 90 minutes, then incubated with peptide S4b-coated
plates or pertussis toxin-coated plates. Binding to the peptide or toxin was detected
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with species-specific anti-rabbit IgG conjugated to horse radish peroxidase. The
experiment was repeated with 12A20A diluted in anti-S4b and peptide binding detected
with species-specific anti-mouse IgG conjugated to horse radish peroxidase. If anti-
S4b and 12A20A bind the same site, then the absorbance at 450 nm was expected to
increase to 1.2-1.5-fold in these two experiments. Anti-S4b and 12A20A diluted in
ELISA blocking buffer were reacted with the peptide-coated wells as controls for
peptide-binding.
This assay did not show that anti-S4b binding could be inhibited by 12A20A,
nor vice versa. The above assay was repeated with pertussis toxin as the coating
antigen, with the same results.
3.3.7 Reaction of Human antisera with pin decapeptides
To assess whether human sera reacted with continuous sequences of amino
acids ('continuous epitopes'), the pin decapeptides of SI, S3 and S4 were reacted with
a small panel of human sera, from subjects convalescent from pertussis. The sera
were kindly provided by Dr. K. Redhead (NIBSC, Potters Bar, U.K.) and their
characteristics and anti-pertussis toxin titres, determined by coating the antigen directly
onto the microtitre plate in a solid phase ELISA are shown in table 3.5. It should be
noted that due to limited sample availability, these sera were only reacted with the pin
decapeptides once.
The panel included sera from subjects of varied age. Eight had the full course
of three DTP vaccinations, one had one vaccination and four had none. One subject
had mild disease, three had no disease and the rest had severe disease and all subjects
but one were culture-positive.
One sample tested was the freeze-dried Bordetella pertussis reference serum
(89/530), pooled by Dr. L.A.E. Ashworth, PHLS CAMR and supplied by the
National Institute for Biological Standards and Control, Potter's Bar, U.K. The
reference serum 89/530 was a pool that included convalescent sera from two adult
pertussis patients and two adult sera from disease-free immunused individuals. No
child sera could be obtained at the time that were of a high enough titre to be included
in the pool. 89/530 was provided as a freeze-dried preparation which was
reconstituted in 0.5 ml PBS pH 7.2 and diluted as the other convalescent sera were.
As a limited supply of each convalescent serum sample was available, the sera
were reacted with the pin decapeptides at the highest concentration practicable and
inhibition of their binding to the pin peptides by pertussis toxin in solution was not
assessed
The human sera were reacted with the pin decapeptides at the lowest dilution
possible for the sample size. The dilution used was 1:200 for all the samples except
169(1)2, which was reacted with the decapeptides at 1:300 dilution. Background
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Table 3.5 Solid phase ELISA titres, age, DTP vaccination status and
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binding to the pin decapeptides was judged to be equal to the level of binding seen
with any human serum sample that did not react with the pin decapeptides.
Sera 135, 145 and 412 had anti-pertussis toxin titres over 10 000 but below
22 000, about a quarter of the anti-pertussis toxin titre of the reference serum
(table 3.5). All three samples came from individuals who had three DTP vaccinations
and were disease free, so they were used to give an idea of the immune response (IgG)
in vaccinated, disease-free individuals.
Sample 135 reacted strongly with decapeptide 114 (A405 0.84, average
background A405 0.39) of SI decapeptides (8 residue overlap). No other peaks were
above background level and sample 135 did not react with either S3 or S4
decapeptides.
Sample 145 reacted weakly with SI decapeptides (8 residue overlap) 23, 35,
47 and 59 and sample 412 did not react with any of the pin decapeptides.
Sample 27(1 )4 was from the oldest individual in the panel and the most likely
to have acquired immunity to pertussis through repeated exposure during the
individual's lifetime. The individual had undergone a full course of three DTP
vaccinations and the sample had an anti-pertussis toxin titre of 14 915 (table 3.5),
when the antigen was coated directly onto the microtitre plate in a solid phase ELISA.
27(1 )4 did not react with SI decapeptides with a 5 residue overlap (average
background A405 0.17), but did react with SI decapeptides with an 8 residue overlap.
However, only one SI decapeptide (8 residue overlap) reacted to give an absorbance at
405 nm that was equal to 0.5 (peptide 114), the rest giving absorbances below this
value. The sequences of these weakly reactive decapeptides did not match those of SI
(5 residue overlap), which would explain the lack of reaction with SI decapeptides
(5 residue overlap). 27(1)4 reacted weakly with S3 decapeptides, but again the
absorbances at 405 nm did not exceed 0.5. No peaks above the average background
were observed when 27(1 )4 was reacted with S4 decapeptides.
169(1)2 was taken from another individual who had three DTP vaccinations
and was convalescent from pertussis. This sample had the highest anti-pertussis toxin
titre in an ELISA in which the antigen was coated directly onto the ELISA plate
(table 3.5), with the exception of the reference serum. Weak cross-reaction was seen
with SI decapeptides with a five residue overlap, but no reaction produced an
absorbance greater than 0.5. When 169(1)2 was reacted with SI decapeptides (8
overlap), no reaction giving an absorbance at 405 nm greater than 0.5 was seen with
the peptides that had the same sequence as the weakly reactive SI (5 residue overlap)
decapeptides.
24(1)2 was taken from the second oldest individual and was the only culture-
negative sample in the panel. The individual had been vaccinated three times with the
DTP vaccine and the sample's anti-pertussis toxin titre is shown in table 3.5.
No peaks distinctly above background were observed when 24(1)2 was
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Fig. 3.17 Reaction of human polyclonal convalescent serum 18(1)1
with S3 decapeptides with a five amino acid overlap
Decapeptides were incubated with blocking buffer (10%(v/v) newborn calf serum,
0.4%(v/v)Tween 20) for 90 minutes and then with 18(1)1 at a dilution of 1:200,
overnight. Reaction with the decapeptides was detected by ELISA (see section
2.2.3.1 for details).
Absorbance(405nm)
reacted against SI, or S4 decapeptides. The sample reacted weakly with S3
decapeptide regions 1-12 and 21-24, but again no reaction produced an absorbance at
405 nm greater than 0.5.
18(1)1 was taken from an unvaccinated convalescent individual and had a low
anti-pertussis toxin titre compared to the reference serum as shown in table 3.5. The
sample produced the strongest reaction of the human sera and bound to one S3
decapeptide. This was decapeptide 6 (A405 1.25) (fig. 3.17) and the background
binding absorbance was 0.25. No peaks distinctly above background were observed
with SI or S4 decapeptides.
Sample 36(1)1 was also taken from an individual who had no DTP
vaccinations and the sample gave a low anti-pertussis toxin titre compared to the
reference serum (table 3.5). This serum did not react with the pin decapeptides with
the exception of SI decapeptide (8 residue overlap) 56. However, the sample did not
react with SI decapeptide (5 residue overlap) 23, which had the same amino acid
sequence as decapeptide 56 mentioned above, so the reaction of 36(1)1 with
decapeptide 56 of SI decapeptides (8 residue overlap) was discounted as being
nonspecific.
Sample 166(1)2 was also from an unvaccinated individual. This serum gave a
higher an ti-pertussis toxin titre than either 36(1)1 or 18(1)1, which were also taken
from unvaccinated individuals. 166(1)2 was from a subject one year older than the
other two and so may have been exposed more to pertussis antigens,which could
explain the higher anti-pertussis toxin titre. Also, samples 36(1)1 and 18(1)1 were
taken 26 days after onset of cough. 166( 1)2 was taken 39 days after onset of cough,
so increasing time for the immune system to generate IgG detectable by the pin peptide
ELISA.
Although 166(1)2 had a higher anti-pertussis toxin titre than 36(1)1 or 18(1)1,
it did not react distinctly with any of the pin decapeptides.
Finally, samples 140(1)1 and 149(1)2 did not react with the pin peptides.
That the human sera had quite high anti-pertussis toxin titres, and did not react
well with the pin decapeptides, probably because of low amounts of correctly
synthesised peptides on the pins.
3.3.8 Glycoconjugate binding to pin and free synthetic peptides
3.3.8.1 Introduction
The B-oligomer of pertussis toxin is involved in receptor recognition (see *
section 1.3.5) and is responsible for the toxin's ability to agglutinate erythrocytes
(Nencioni et al., 1991).
The B-oligomer is also an adhesin, enabling attachment of B. pertussis to cilia
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of the respiratory tract (Saukkonen et al., 1992).
Molecules acting as receptors for pertussis toxin have not yet been identified
but studies have suggested that membrane proteins of different sizes are involved, size
depending on the cell type. Serum glycoproteins such as haptoglobin and fetuin have
also been used as model receptors (chapter 1).
Nogimori et al., (1986) chemically modified the lysine residues of S3-S4 and
this abolished the mitogenic, adjuvant and lymphocytosis activities of the whole toxin,
which implicates S3 in receptor recognition.
Both S2 and S3 subunits have been shown to be involved in recognition of
eukaryotic glycoproteins (Capiau et al., 1986; Schmidt et al., 1989; Schmidt et al.,
1991) via their carbohydrate recognition domains (Saukkonen et al., 1992). Both
subunits S2 and S3 are apparently involved in binding of pertussis toxin to sialylated
glycoconjugate of macrophages (van't Wout et al., 1992) and human T cells
(Witvliet et al., 1992).
Additional evidence for the involvement of S2 and S3 in binding to sialylated
glycoconjugates (also see chapter 1) was provided by Witvliet et al. (1992), who
found that sialidase treatment of a line of human T cells decreased binding of FITC-
labelled pertussis toxin (FITC = Fluorescein isothiocyanate) to them and that binding
apparently involved both S2-S4 and S3-S4 dimers, suggesting that divalent binding of
pertussis toxin activates T cells.
CHO cell lines deficient in sialic acid moieties on cell surface glycoproteins
were found not to be sensitive to ADP-ribosylation of G proteins by pertussis toxin,
(Witvliet et al., 1989) implying sialic acid on cell surface glycoconjugates is required
for the binding and activity of pertussis toxin and only cells displaying sialylated
glycoconjugates are sensitive to intoxication by pertussis toxin (Brennan et al., 1988).
Sialidase (neuraminidase) treatment of CHO cells decreases pertussis toxin binding to
them (Brennan et al., 1988) and sialic acid blocks S3-mediated binding of pertussis
toxin to human macrophages (van't Wout et al., 1992), implying that sialic acid
moieties are important in toxin subunit-carbohydrate interactions.
Subunits S2 and S3 share about 80% amino acid sequence homology
(Locht and Keith, 1986; Nicosia et al., 1986) so it is possible that the recognition sites
have some similarities. However, differences in binding (Francotte et al., 1989;
Witvliet et al., 1989; Schmidt et al., 1989; 1991; Saukkonen et al., 1992) suggest that
differences in structure and/or amino acid sequence may indicate regions that determine
carbohydrate binding specificity.
Linear peptide analogues have been used to mimic carbohydrate recognition
domains of fibronectin (Pierschbacher and Ruoslahti, 1984; Yamada and Kennedy,
1984), so in this study, interaction of synthetic peptides from the S3 subunit of
pertussis toxin with glycoconjugates, using pin-bound peptides (Geysen et al., 1984;
1987) and free peptides were studied in order to identify glycoconjugate binding
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Fig. 3.18a Reaction of S3 decapeptides with a five amino acid overlap
with 20 /*g/ml fetuin in pin blocking buffer (10%(v/v) newborn calf
serum, 0.4%(v/v) Tween 20 in PBS, pH7.2)
See section 2.2.3.2 for details.
Fig. 3.18b Reaction of S3 decapeptides with a five amino acid overlap
with 20 //g/ml fetuin plus 100//g/ml peptide (E)S3c in pin blocking
buffer






















3.3.8.2 Results of glycoconjugate binding to S3 peptides
3.3.8.2.1 Binding of fetuin to S3 pin decapeptides
S3 pin decapeptides were incubated with 20 /rg/ml fetuin as described in
section, 2.2.3.2 (fig.3.18a).
Fetuin recognised S3 decapeptide 10 (residues 46-55, amino acid sequence
RQITPGWSIY). The absorbance was over double that of the average background
(peptide 10 A405 0.725, average background 0.32).
3.3.8.2.2 Synthesis of free peptide (E)S3c and (CGE)S3c
The glycoprotein fetuin bound to S3 decapeptide 10 (residues 46-55), so two
free peptides, (E)S3c and (CGE)S3c consisting of S3 amino acids 44-58 were
synthesised. Their sequences are shown in table 3.2.
The N-terminal glutamic acid was originally included in the synthesis of
(E)S3c to enable efficient coupling to a protein carrier using carbodiimide as the
coupling agent and raising of antipeptide antisera. However, this coupling was not
done because antipeptide antisera raised against (E)S3c conjugated to BSA using
glutaraldehyde reacted with pertussis toxin and the peptide immunogen. The glycine
and cysteine residues were incorporated into (CGE)S3c to enable coupling to KLH,
using the thiol-reactive cross-linking reagent, MBS, in preparation for immunisation of
mice.
The peptides were purified by reverse phase HPLC and (E)S3c eluted as a
single major peak at 23.29 minutes (fig. 3.19a). (CGE)S3c eluted as one major peak
at 24.16 minutes (fig. 3.19b).
3.3.8.2.3 Mass spectrometry of peptides (E)S3c and (CGE)S3c
The purification of (E)S3c and (CGE)S3c by HPLC indicated that the peptide
preparations contained no major contaminants, because they both eluted as one major
peak on the chromatograms. It did not indicate whether peptide residues had been
properly deprotected, or had been derivatised in the deprotection process, so an
additional check on the peptide was made. Peptides (E)S3c and (CGE)S3c were
subjected to fast atom bombardment mass spectrometry (FAB MS) as described in
section 2.2.5.7. This technique was used to determine whether the peptides had a
molecular mass that would be expected for the residues which it contained, that is to
determine if amino acids had been derivatised during deprotection, or if a truncated
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Fig. 3.19a Purification of peptide (E)S3c by reverse phase HPLC
See section 2.2.5.7 for details.
Absorbance220am
Time/miii
Fig. 3.19b Purification of peptide (CGE)S3c by reverse phase HPLC
See section 2.2.5.7 for details.
Absorbance220m
Time/min
Fig. 3.20a FAB mass spectrum of peptide (E)S3c
































Fig. 3.20b FAB mass spectrum of peptide (CGE)S3c
See section 2.2.5.6 for details.
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form the peptide had been generated.
Peptide (E)S3c produced the expected measured average mass of molecular ion
(IM + H]+) of 1958.3 Da, and the fragmentation pattern for the peptide is shown in
figure 3.20a. Peptide (CGE)S3c produced the expected measured average |M + H+]
of 2118.4 Da and the fragmentation pattern for the peptide is shown in figure 3.20b.
That one molecular ion of the expected mass was found, indicated that the peptides
had not been truncated in synthesis and had not been derivatised during deprotection
(subtraction of the masses of individual deprotected amino acids from the molecular
ion indicated that no fragments had been derivatised).
3.3.8.2.4 Inhibition of fetuin binding to S3 pin decapeptides
To determine whether preincubation of peptide (E)S3c inhibited fetuin binding
to the pin decapeptides, 20 pg/ml fetuin was incubated with peptide 20 //g/ml (E)S3c
for 90 minutes at room temperature, at the same time as the S3 pin decapeptides were
incubated with pin blocking buffer, to reduce nonspecific binding. The preincubated
solution containing (E)S3c and fetuin was then incubated with the S3 pin decapeptides
for 7 hours (section 2.2.3.2). Detection of fetuin binding to the S3 decapeptides was
detected as described in section 2.2.3.1. 20 pgl ml peptide did not inhibit fetuin
binding to the S3 decapeptides, so the peptide concentration was increased to 100
pglm\. The result of the latter experiment can be seen in figure 3.18b, which shows
that preincubation with 100 pg/ml peptide totally inhibited fetuin binding to the
decapeptides.
Incubation of the decapeptides with fetuin alone (fig. 3.18a) was used as a
positive control (i.e. no inhibition of fetuin binding).
3.3.8.2.5 Mouse anti-(E)S3c and anti-(CGE)S3c antibodies
Peptide (E)S3c was conjugated to bovine serum albumin (BSA) using
glutaraldehyde and peptide (CGE)S3c was conjugated to keyhole limpet haemocyanin
(KLH) using the cross-linker MBS.
Anti-(E)S3c was raised in mice against peptide conjugated to BSA and anti-
(CGE)S3c serum was raised in mice against peptide conjugated to KLH, using the
method described in section 2.2.7.1.
Antibodies raised against (E)S3c recognised peptide, peptide conjugate and
pertussis toxin, in a solid phase ELISA in which the antigen was coated directly onto
the microtitre plate (table 3.4). Nonspecific binding to the peptide was controlled for
using a peptide (3f) derived from B. pertussis fim 3 as coating antigen and the
sequence of that peptide is given in appendix 1. Nonspecific binding to pertussis toxin
was controlled for using B. pertussis fim 2 as coating antigen.
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Anti-(CGE)S3c recognised pertussis toxin, peptide and homologous peptide
conjugate with much lower titres than anti-(E)S3c in an ELISA assay in which the
antigen was coated directly onto the microtitre plate.
Anti-(E)S3c also recognised KLH-(CGE)S3c peptide conjugate coated directly
onto the microtitre plate, albeit rather weakly (table 3.4).
For these reasons, the larger amounts of antipeptide serum needed for further
studies was raised in rabbits against (E)S3c (peptide conjugated to BSA).
3.3.8.2.6 Rabbit anti-(E)S3c
3.3.8.2.6.1 Binding of rabbit anti-(E)S3c to peptide S3c and
pertussis toxin
The method of generation of rabbit antipeptide antibodies is described in
section 2.2.7.2.
Rabbit anti-(E)S3c was assayed for antipeptide and antiprotein reactivity by
solid phase ELISA, in which the antigen was coated directly onto the plate, as with the
mouse antipeptide sera above. A peptide (3f) whose synthetic peptide sequence was
derived from B. pertussis fim 3 was used as a negative control.
Anti-(E)S3c recognised pertussis toxin, (E)S3c, (E)S3c conjugated to BSA
and (CGE)S3c conjugated to KLH in an ELISA assay in which the antigen was
adsorbed onto the microtitre plate (tables 3.2 and 3.4).
As 'native' antigen coated onto a microtitre plate could contain some denatured
protein and coating the antigen directly onto the microtitre plate could also denature the
antigen, (Jemmerson and Blankenfeld, 1989) recognition of pertussis toxin captured
by a monoclonal antibody (MAB L10) was assessed by solid phase ELISA.
Anti-(E)S3c recognised pertussis toxin captured by MAB L10 as ascites fluid with a
titre of 300, so only part of the anti-pertussis toxin response appeared to be due to
recognition of denatured antigen by the antipeptide antibody.
The subunit specificity of rabbit anti-(E)S3c was assessed by Western blotting
of pertussis toxin subunits separated by SDS PAGE. That is described in section
3.3.1. Results of binding of anti-(E)S3c to S3 pin decapeptides are described in
section 3.3.2.2.
3.3.8.2.6.2 Binding of (E)S3c and pertussis toxin to glycoconjugates
The binding of (E)S3c and pertussis toxin to glycoconjugates other than fetuin
was studied in a solid phase binding ELISA assay. Fetuin, asialofetuin, alpha-l-acid
glycoprotein and mixed bovine brain gangliosides were coated onto the microtitre
plate, incubated with serial dilutions of (E)S3c or pertussis toxin, then incubated with
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Fig. 3.21a Binding of peptide (E)S3c and pertussis toxin to fetuin
coated onto microtitre plates
See section 2.2.8.3 for details.
Fig. 3.21b Binding of peptide (E)S3c and pertussis toxin to
alpha-1-acidglycoprotein coated onto microtitre plates
See section 2.2.8.3 for details.
Absorbance(450nm)
Absorbance(450nm)
Fig. 3.21c Binding of peptide (E)S3c and pertussis toxin to mixed
bovine brain gangliosides coated onto microtitre plates
See section 2.2.8.3 for details.
Fig. 3.21d Binding of peptide (E)S3c and pertussis toxin to
asialofetuin coated onto microtitre plates
See section 2.2.83 for details.
Absorbance(450nm)
Absorbance(450nm)
rabbit anti-(E)S3c or mouse MAB L10 and then incubated with the species-specific
anti-IgG antibody conjugated to horse radish peroxidase.
Background binding was anti-(E)S3c binding to the relevant glycoconjugate
(the background was very similar to that seen with MAB L10).
The results of these experiments are shown in figures 3.21a to 3.21 d.
Apparent binding was taken to be a function of the absorbance (at 450 nm) generated
in the ELISA assay. The higher the absorbance, the greater the apparent binding of the
ligand to the glycoconjugate.
Pertussis toxin and (E)S3c apparently reacted most strongly with fetuin
(fig.3.21a). Maximum binding with fetuin was seen at about 16 pg/ml pertussis toxin
and about the same level with (E)S3c (log ligand concentration 1.2 in figure 3.21a).
Weaker binding was seen with alpha-l-acid glycoprotein (fig. 3.21b).
Maximum binding of pertussis toxin and (E)S3c was not reached at 100 /ig/ml of
either the peptide or pertussis toxin (log ligand concentration 2 in figure 3.21b).
Weaker binding of (E)S3c and pertussis toxin to mixed bovine brain
gangliosides was observed (fig. 3.21c), when results were compared with both fetuin
and alpha-l-acid glycoprotein. Maximum binding was seen with 100pg/ml peptide or
50 /<g/ml pertussis toxin.
The weakest apparent binding activity was seen with asialofetuin (fig. 3.21 d).
Maximum absorbance (and binding activity) was lower than with fetuin, alpha-l-acid
glycoprotein and mixed bovine brain gangliosides. Nonspecific binding,which is
shown by the background in the figure, was higher than with the other
glycoconjugates, so the interaction with asialofetuin was the weakest of the
glycoconjugates tested.
3.3.8.2.6.3 Recognition of pertussis toxin by rabbit anti-(E)S3c
2 /ig/ml pertussis toxin or (E)S3c were coated onto microtitre plate wells and
reacted with rabbit anti-(E)S3c in a solid phase ELISA. Background binding was anti-
(E)S3c binding to uncoated wells. The results of the experiment are shown in figure
3.22a and the absorbance at 450 nm was used as an estimate of antibody binding
activity as in the previous section.
It can be seen from the figure that a high dilution of anti-(E)S3c was needed to
titrate out the binding activity of the antibody to (E)S3c to background level. The
absorbance (at 450 nm) did not fall below 2.5 until the antibody was diluted almost
1500-fold and background binding absorbance was seen with antibody diluted about
105-fold.
Binding of anti-(E)S3c to pertussis toxin was weaker. The absorbance was
below 2.5 even at 1:54 dilution of antibody and background binding was reached at
about lCfMbld dilution of antibody, a lower dilution than seen with (E)S3c, above.
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3.3.8.2.6.4 Recognition of pertussis toxin captured onto microtitre
plates by glycoconjugates
Fetuin or mixed bovine brain gangliosides were captured onto microtitre plates,
incubated with pertussis toxin and the pertussis toxin detected with anti-(E)S3c as
described in section 2.2.8.2. If pertussis toxin bound each of the glycoconjugates to
its S3 subunit, it might be expected that anti-(E)S3c would be sterically excluded from
binding pertussis toxin. That is, the antibody (E)S3c was raised against an apparent
fetuin-binding peptide. One could reasonably expect that occupation of the apparent
binding site on S3 by fetuin would stop anti-(E)S3c from binding and because (E)S3c
bound to mixed bovine brain gangliosides (see previous section), binding of the
gangliosides to captured pertussis toxin should also exclude anti-(E)S3c from binding
pertussis toxin.
Figure 3.22b shows the results of the experiment and that both pertussis toxin
captured by fetuin and by mixed bovine brain gangliosides were recognised by anti-
(E)S3c.
3.3.8.2.6.5 Inhibition of anti-(E)S3c binding to peptide (E)S3c
Fetuin and anti-(E)S3c bind to peptide (E)S3c, as described above, so the
ability of fetuin to inhibit binding of anti-(E)S3c to peptide (E)S3c was assessed using
a solid phase ELISA with the peptide as coating antigen (see section 2.2.8 ).
Anti-(E)S3c was diluted in a constant concentration of fetuin (concentration
gives an absorbance at 450 nm of 1.2-1.5 in the absence of peptide) and incubated for
90 minutes, then incubated with the peptide. Binding of fetuin to the peptide was
detected using an anti-fetuin antibody conjugated to horse radish peroxidase.
The assay was repeated with fetuin diluted in a fixed concentration of
anti-(E)S3c. Anti-(E)S3c and fetuin diluted in ELISA blocking buffer were used as
controls.
Both the controls were expected to give a decreasing absorbance at 450 nm as
the ligand was diluted and that was the observed result.
As anti-(E)S3c was diluted in fetuin, the absorbance at 450 nm would be
expected to increase to 1.2-1.5 because the amount of anti(E)S3c would decrease
leaving more peptide free to bind to fetuin and be detected by the anti-fetuin antibody
conjugated to horse radish peroxidase. A similar result was expected with fetuin
diluted in a constant concentration of anti-(E)S3c. However, neither fetuin nor anti-
(E)S3c inhibited the other's binding to peptide (E)S3c.
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Fig. 3.22a Recognition of peptide (E)S3c and pertussis toxin coated
onto microtitre plates, by rabbit anti-(E)S3c
See section 2.2.8 for experimental details.
Fig. 3.22b Recognition of pertussis toxin captured by mixed bovine
brain gangliosides or fetuin, by rabbit anti-(E)S3c
See section 2.2.8.2 for details.
a.
3.23a Pertussis toxin-mediated clumping of CHO cells
(Clumping score 2. See section 3.3.8.2.6.6 for details)
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3.23b Pertussis toxin-mediated clumping of CHO cells
(Clumping score 0. See section 3.3.8.2.6.6 for details)
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3.23c Pertussis toxin-mediated clumping of CHO cells
(Clumping score 1. See section 3.3.8.2.6.6 for details)
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3.3.8.2.6.6 Chinese hamster-ovary cell clumping
The ability of (E)S3c to bind fetuin led to assessment of the ability of anti-
(E)S3c to inhibit pertussis toxin-mediated Chinese hamster ovary cell (CHO)
clumping. The method of assay is described in section 2.2.12 and the effect of
incubating anti-(E)S3c and pertussis toxin with CHO cells was compared to the effect
of incubating CHO cells with and without pertussis toxin.
CHO cells in the presence of 2 ng/ml pertussis toxin (the lowest concentration
found to clump the cells) were found to be be totally clumped and test microtitre plate
wells containing totally clumped cells were given a score of 2 (fig. 3.23a). This
concentration was the minimum found to clump all cells in a well. CHO cells not in
the presence of pertussis toxin did not clump and test wells containing non-clumped
cells were given a score of 0 (fig. 3.23b). Any state of clumping which was not total
was given a score of 1 in the test plate wells (fig. 3.23c).
Neither (E)S3c or anti-(E)S3C inhibited pertussis toxin clumping of CHO cells
at all (wells containing either were given a score of 2).
3.4 Discussion
In this chapter, studies on the antigenicity and glycoconjugate binding of
synthetic peptides derived from the amino acid sequence of pertussis toxin are
described.
The results obtained were to be used in an attempt to identify S3 subunit amino
acids that were involved in B-oligomer binding to carbohydrate, and SI, S3 and S4
amino acids that may constitute 'linear' B cell epitopes, which in turn could be part of
discontinuous B cell epitopes.
As stated in chapter 1, most protein epitopes are thought to be conformational.
However, if overlapping pin decapeptides bind anti-protein antibodies, those
decapeptides can be used as a template for the synthesis of free peptides. Those free
peptides which raise antibodies that cross-react with native protein can be used to
study the structure and function of a protein indirectly.
That few strong positive reactions were seen using the pin peptide technique
suggests that low amounts of peptide were synthesised successfully, a possibility
supported by the reaction of some of the antibodies and antisera with SDS-denatured
toxin subunits on Western blots. Some of the test samples had quite high anti-
pertussis toxin titres, so it was expected that they should react with both the pin
decapeptides and the denatured subunits on Western blot.
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3.4.1 Antibody binding to pertussis toxin subunit pin
decapeptides
A panel of antibodies were tested for reaction with the pin decapeptides, with
pertussis toxin coated onto microtitre plates in a solid phase ELISA and with pertussis
toxin subunits separated by SDS PAGE and immunoblotted onto nitrocellulose.
All but three antibodies tested were reactive with the toxin subunits on
immunoblots, suggesting that antibody binding domains may contain continuous
('linear') regions of amino acids and may bind to the pin decapeptides. MAB L4
weakly recognised subunit S3 and L6 and Lll did not recognise any pertussis toxin
subunits on immunoblots. All the antibodies tested reacted with pertussis toxin in a
solid phase ELISA, the lowest titre being with MAB LI 1.
3.4.1.1 Antipeptide antibodies
Antipeptide antisera raised against synthetic peptides derived from the amino acid
sequence of pertussis toxin subunits were reacted with the pin decapeptides. Some
were found to react weakly with decapeptides that had some amino acid identity with
the peptide immunogen. The amount of identity for an antipeptide antibody against
one pertussis toxin subunit to weakly bind a pin decapeptide derived from another
subunit appeared to be two residues.
Only one antipeptide antibody (anti-S3a) bound strongly to decapeptides
derived from the sequence of another toxin subunit (SI decapeptides with an eight
residue overlap). This antipeptide antibody did not react with SI decapeptides with a
five residue overlap, probably because all but one of these SI decapeptides had
different amino acid sequences to the decapeptides with an eight residue overlap.
This supported the findings of Trifilieff et al., (1991), whose group found that
antipeptide antibodies cross-reacted with peptides that contained similar partial
sequences. Anti-S3a also bound to S3 and SI subunits on immunoblots of pertussis
toxin subunits separated by SDS PAGE, supporting the result that showed binding of
anti-S3a to S1 decapeptides.
The results of pin decapeptide binding of antipeptide antibodies meant that
cross-reaction of an antibody with the pin peptides was only viewed as suggestive of
peptide antigenicity and not as concrete evidence.
3.4.1.2 Mouse antibodies
The three polyclonal antisera and most of the mouse-monoclonal antibodies did not
react with the pin decapeptides. Two possible reasons for this could be that the ELISA
assay used to detect binding to the pin peptides was biased to detection of relatively
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high affinity binding, or that the antibody paratopes recognise conformational epitopes
on the toxin subunits.
MAB L10 has been shown to neutralise the action of the toxin in vitro and to
protect mice from intracerebral challenge with B. pertussis (Bartoloni et al., 1988) and
it has been suggested that L10 binds a discontinuous epitope contained in the N- and
C-terminal regions of the SI subunit of pertussis toxin. L10 did not bind to any of the
SI pin decapeptides above background levels, suggesting that L10 binds a
conformational epitope, or that the antibody bound to the pin decapeptides with too
low an affinity to be detected by the pin ELISA assay.
Cieplak et al., (1988) and Burnette et al., (1988a) had identified epitopes
within SI and found that immunisation with a recombinant SI subunit did not induce
protective immunity in mice, indicating that at least part of the B-oligomer is needed
for protection against infection.
Only L7 and L9 reacted with the pin decapeptides when the antibodies were
reacted as purified antibody. Both reacted weakly with S3 decapeptide 22. MAB L7
has been shown to neutralise pertussis toxin-mediated CHO cell clumping
(Anwar et al., 1987) and recognised mostly subunit S3 on immunoblots (fig. 3.3). L7
no longer recognised subunit S3, when 2-ME was included in the sample buffer, in
preparation for electrophoresis and before immunoblotting with L7. This suggested
that antibody L7 bound a conformational epitope on subunit S3. Decapeptide 22 of S3
may represent part of that conformational epitope, which could explain the weak
binding of L7 to the peptide (A405 nm 0.365), but results of other studies have not
suggested that the residues of decapeptide 22 are involved in a B cell epitope of
pertussis toxin (Chong et al., 1992; Lobet et al., 1993), so it is unlikely that S3
decapeptide 22 is part of a B cell epitope.
3.4.1.3 Rabbit antibodies and binding to free peptide S4b
Two rabbit polyclonal antibodies reacted strongly with the same SI and S4 pin
decapeptides. The antibodies reacted mainly with two SI decapeptides with a five
residue overlap, one near from the N-terminal of the subunit sequence and one from
near the C- terminal. Several B cell epitopes have been attributed to the SI subunit of
pertussis toxin and major B cell epitopes found using monoclonal and antipeptide
antibodies are thought to be within residues 1-18 (Bartoloni et al., 1988; De Magistris
et al., 1989; Chong et al., 1991), and residues 201-235 (De Magistris et al., 1989;
Chong et al., 1991).
The rabbit antibody (12A20A) which reacted most strongly was preincubated
with pertussis toxin, before reaction with the pin decapeptides. That preincubation
was found to inhibit antibody binding to both SI and S4 decapeptides, suggesting that
the antibody bound to homologous sites on the pin decapeptide and the whole toxin.
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Preincubation of 12A20A with free peptide S4b (residues 86-94), which had
the same amino acid sequence (plus two amino acids synthesised to couple S4b to an
immunogenic carrier protein) as the decapeptide bound by 12A20A, also reduced
12A20A binding to the S4 pin decapeptides to background levels, suggesting that
12A20A bound homologous sites on both the pin-bound and free peptides, so
antipeptide antisera were raised against peptide S4b conjugated to immunogenic
protein carriers. Antisera to S4b conjugated to KLH weakly recognised whole
pertussis toxin captured directly and indirectly to microtitre plate wells, suggesting that
the sequence of S4b may be exposed on the surface of the whole toxin. Weak
recognition of whole pertussis toxin by anti-S4b may be due to part-exposure of the
sequence in the whole toxin, or a conformation of the whole toxin that was not
favourable to strong binding of the antipeptide antibody.
Peptide S4b did not inhibit 12A20A binding to toxin coated onto microtitre
plates in a solid phase EL1SA, probably because 12A20A only weakly recognised the
peptide. Anti-S4b and 12A20A did not inhibit each other's binding to peptide S4b or
to pertussis toxin again probably because anti-S4b did not recognise pertussis toxin
well and 12A20A did not recognise peptide S4b well.
Only two studies to date have looked at B cell epitopes of the S4 subunit and
one did not identify any on that subunit (Seabrook et al., 1990). The other study
(Ibsen et al., 1993) used free peptides spanning the whole amino acid sequence of the
S4 subunit and screened them for reaction with a panel of murine monoclonal
antibodies and various polyclonal antisera, by EL1SA using the peptide as coating
antigen. Ibsen et al. (1993) identified six antigenic regions (they bound polyclonal
antisera in this case), one of which included residues 91 -106 of S4 (the reactive S4 pin
decapeptide 18, contained residues 86-95. Monoclonal anti-(pertussis toxin)
antibodies did not recognise region 91-106 or any other S4 peptides, suggesting the
existence of mostly conformational epitopes on the S4 subunit. Antipeptide antisera
raised from the S4 peptides conjugated to diphtheria toxoid recognised pertussis toxin
in an ELISA, but did not neutralise pertussis toxin-mediated Chinese Hamster ovary
cell clumping, which could be partly due to the S4 subunit consisting mostly of
discontinuous B cell epitopes. This could explain the low anti-(pertussis toxin)
reaction of antisera S4b found by the author in ELISA and the lack of reaction of the
author's panel of monoclonal antibodies with the S4 pin decapeptides.
T cell epitopes of S4 have recently been studied by Petersen et al. (1992;
1993). Two major and one minor human T cell epitope (residues 1-15, 21-45 and 41-
65 respectively) and one corresponding epitope in mice which was the C-terminal
portion of residues 1-15, as well as mouse T cell epitopes in residues 21-55, 72-88
and 93-106 were discovered. Peptide S4b has residues in common with two of the
mouse T cell epitopes identified in the studies by the Petersen group, but the
significance of that remains to be seen.
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The results showed that peptide S4b is not likely to be a suitable candidate for
inclusion in a vaccine containing antigens that stimulate B cell immunity.
3.4.1.4 Human antibodies
Samples 135 and 27(1)4 reacted mainly with one SI decapeptide (8 residue
overlap), number 114 (residues 225-234) derived from the C-terminal of the SI amino
acid sequence. Both individuals had three DTP vaccinations, but their ages were <1
and 21 respectively. Individual 135 was disease-free when the sample was taken
whereas individual 27(1)4 had mild disease.
Sample 18(1)1 reacted with one decapeptide from the S3 subunit
(decapeptide 6) that contained residues 26-35. This sample was from an individual
1.58 years of age who had no DTP vaccinations.
The panel of human sera was small, so no conclusions can be made apart from
general ones and extensions of the work would require the testing of many more sera.
Reaction of a sample with the pin decapeptides could not be predicted from the
characteristics of the individual that the sample was taken from. For example, samples
135, 145 and 412 were taken from a similar group, but only 135 reacted strongly with
the pin decapeptides.
What was seen was that all three reactive sera were taken from individuals less
than two years of age . It would be interesting to see if this becomes a trend if more
samples were tested with the pin peptides. The two oldest subjects had three DTP
vaccinations but that did not prevent their contracting the disease and neither reacted
strongly with the pin decapeptides. Whether this means that the protection of the DTP
vaccine decreases with age is obviously impossible to say at this early stage
of investigation.
The number of DTP vaccinations and the effects on samples from a group of
very similar age taken at similar times after onset of cough could also be studied in
further work. Sample 140(1)1 was from a subject who had only one DTP vaccination
and the sample had a high anti-pertussis titre (table 3.5).
3.4.1.5 Comparison of reaction of mouse and rabbit anti-pertussis
toxin and human antibodies with the pin decapeptides
The results showed that there were different responses to the pin decapeptides
both between and within species.
The two reactive rabbit antisera bound to decapeptides derived from near the
N- and C-terminals of the SI amino acid sequence and to a decapeptide derived from
near to the C-terminal of the S4 amino acid sequence. One of the reactive human sera
also bound to decapeptides derived from near the N- and C-terminal regions of SI
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decapeptides (8 residue overlap), but the reactive regions were slightly different
compared to the reactive rabbit antisera. The other two reactive human sera bound to
S3 decapeptides, one binding to a peptide near the N-terminal and the other to an S3
decapeptide derived from the sequence near the C-terminal of the S3 subunit.
The reactive mouse antisera bound to one S3 decapeptide that did not correspond to the
S3 decapeptides reactive with the human sera and the mouse sera reacted with the pin
decapeptides with low affinity. That is, even though the most reactive decapeptides
produced an absorbance at 405 nm that was double the background, the actual
absorbance (taken to indicate antibody-pin peptide affinity) of the reactive decapeptides
was below 0.5 at 405 nm.
The differences in response of different species has been reported previously
using this pin peptide mapping method (Beattie et al., 1992). The differences in
specificity of response (B cell) to a protein antigen was to be expected in different
animals, because of the effects of antigen processing and T cell help, for example.
3.4.2 Glycoconjugate binding to peptides derived from the amino
acid sequence of the S3 subunit of pertussis toxin
A pin decapeptide derived from the amino acid sequence of the S3 subunit of
pertussis toxin was found to bind the glycoprotein fetuin using the pin peptide
mapping method of Geysen et al. (1984; 1987). The technique was used in an attempt
to localise region(s) of the S3 subunit amino acid sequence that bound to the
carbohydrate portion of some glycoproteins.
The binding of fetuin to the pin decapeptide identified (residues 46-55,
sequence RQITPGWSIY) with pin peptide mapping was inhibited by a free peptide
(E)S3c that had the same sequence as the pin decapeptide (with a C-terminal glutamic
acid), suggesting that the pin and free peptide had comparable conformations.
An antipeptide antibody raised to peptide (E)S3c recognised pertussis toxin and
free peptide in a direct and in an indirect capture ELISA assay, in which the toxin or
peptide was either coated directly onto the microtitre plate, or was captured by a
monoclonal antibody or glycoconjugate. This result showed that although reaction
was weak, the antipeptide antibody was capable of recognising the intact toxin and that
the (E)S3c peptide sequence is probably exposed at the toxin surface.
The antipeptide antibody anti-(E)S3c was used to detect binding of peptide
(E)S3c to glycoconjugates. Binding of the peptide to fetuin, alpha-1 -acid glycoprotein
and mixed bovine brain gangliosides was detected. The highest activity appeared to be
with fetuin, slightly weaker reaction was seen with alpha-l-acid glycoprotein, weaker
still with mixed bovine brain gangliosides and the weakest apparent activity was seen
with asialofetuin. An anti-pertussis toxin antibody that bound to SI in immunoblots
(L10) was used to detect pertussis toxin binding to the four glycoconjugates mentioned
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above and showed that the toxin bound to all four, again with decreasing affinity.
The results showed that peptide (E)S3c acted like the whole toxin in binding to
glycoconjugates (Armstrong et al., 1988).
Anti-(E)S3c also recognised pertussis toxin bound to fetuin and mixed
bovine brain gangliosides. Anti-(E)S3c may be expected not to bind to the toxin if it
were bound to the glycoconjugate via the S3 subunit. However, the S2 subunit has an
amino acid sequence about 70% similar to S3, so it is possible that the antibody cross-
reacted with similar amino acids of S2. Another possibility is that pertussis toxin was
bound to the glycoconjugate via its S2 subunit and that anti-(E)S3c bound to the S3
subunit. The latter possibility is supported by subunits S2 and S3 having some
receptors (e.g. fetuin) in common (Witvliet et al., 1989; Chong et al., 1992). No
inhibition of anti-(E)S3c binding to peptide (E)S3c by fetuin was seen, which could
also be explained by the possible cross-reaction of anti(E)S3c with similar residues of
S2 or that the toxin was bound to the S2 subunit, leaving the S3 subunit free to bind
anti-(E)S3c. (The glycoconjugate-binding abilities of peptide (E)S3c were published
in Tallett et al., 1993).
The ability of (E)S3c to bind glycoproteins and glycolipids suggested that this
region of S3 in the whole toxin may be involved in binding of the toxin to target cell
receptors. The ability of anti-(E)S3c to inhibit pertussis toxin-mediated Chinese
hamster ovary cell clumping tested this idea and the antibody did not inhibit the
clumping. This means that peptide (E)S3c is not likely to induce protective antibodies
and so is not likely to be included in a potential vaccine against whooping cough.
The region of the S3 subunit found to bind glycoconjugates in this study was
found to be in the same region of the subunit as a domain similar to eukaryotic C-type
carbohydrate recognition domains (Drickamer 1989) contained in residues 37-52 of S3
(Saukkonen et al., 1992). Region 37-52 of S3 was found to bind leukocytic
gangliosides and binding was inhibited by sialic acid (neuraminic acid). The same
region of S2 was found to bind lactosylceramide (cilia) and mutation in that region of
S2 or S3 resulted in interchanged carbohydrate specificity, indicating the region's
possible role in receptor binding. Saukkonen's and the author's work could be
expanded to identify the possible carbohydrate structure specificity and to determine
whether differences in membrane structure or membrane components alter specificity.
Gangliosides were also found to bind peptide (E)S3c (Tallett et al., 1993)
using intrinsic fluorescence, but whether the interaction is with the carbohydrate
portion or the lipid portion of the ganglioside remains to be seen, because (E)S3c was
also found to bind phospholipid (L-a-lysolethicin) and N-acetylneuramin-lactose.
(N-acetylneuramin-lactose is an analogue of the oligosaccharide part of fetuin and
gangliosides).
Brennan et al., (1988) found no binding of pertussis toxin to glycolipids using
a TLC system, in contradiction to Saukkonen et al.( 1992) and Tallett et al., (1993),
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described above.
However, Hausman and Burns (1993) detected binding of whole pertussis
toxin and B-oligomer to lipid vesicles containing ganglioside Gdla. Gdlaas a
functional receptor was not addressed in this study, but the importance of sialic acid
moieties in toxin binding was. They (Hausman and Burns) claimed that the reason
that Brennan et al., (1988) did not detect any glycolipid binding to pertussis toxin was
because the vesicle-binding system that Hausman and Burns used was more sensitive
than the TLC system used by Brennan's group. This reason could also apply to the
detection of glycolipid binding using fluorescence.
Other regions may be involved in receptor recognition by the S3 subunit that
were not detected by the pin peptide mapping procedure. For example residues 28-45
of S3 inhibited bacterial cells' binding to human macrophages (van't Wout et al.,
1992) and Loosemore et al. (1993) found that residues 149-176 of the S3 amino acid
sequence blocked pertussis toxin-mediated clumping of Chinese Hamster Ovary cells,
suggesting that this region is involved in binding of mammalian target cells.
The sequence of (E)S3c has little sequence similarity with other peptides
involved in carbohydrate binding. Many of these other peptides (for example
fibronectin) contain the peptide sequence RGD (Arg-Gly-Asp) at their recognition site
(Ruoslahti and Pierschbacher, 1986). Peptide (E)S3c does contain a tripeptide PGW,
that is found in the sequence of an integrin-binding peptide of type IV collagen
(Chelberg et al., 1990) and type IV collagen and pertussis toxin have been found to
bind to laminin, an extracellular matrix component (Witvliet et al., 1989; Mayo et al.,
1991), so it is possible that this recognition does not use the RGD sequence in cell
adhesion.
In summary, a glycoconjugate-binding peptide (E)S3c was identified using pin
peptide mapping and free peptide studies. The peptide did not inhibit pertussis toxin-




Chemical cross-linking of pertussis toxin
4.1 Introduction to chemical cross-linking
In this chapter, chemical cross-linking is discussed as another approach for
investigation of the spatial arrangement of toxin subunits and to reaffirm the 1:1:1:2:1
stoichiometry. Reversible and non-reversible cross-linking, one- and two-dimensional
SDS-PAGE, Western blotting and FPLC were used.
Chemical cross-linkers are bifunctional reagents which link neighbouring
polypeptides and can be used to determine the tertiary or quaternary structure of a
protein. One protein subunit may be linked to one or more neighbours, forming
dimers, trimers and so on. Separation of cross-linked species and identification of
their components can aid in mapping the location of subunits in an oligomer.
However, formation of cross-linked species containing more than two subunits can
complicate the development of a map.
Cross-linkers are grouped according to several factors including length, amino
acids linked (or bridged), whether the amino acids linked are the same
(homobifunctional) or different (heterobifunctional), whether they contain an internal
cleavable site and whether the cross-linking reaction is triggered chemically or by light.
Chemical cross-linkers generally react with lysine and/or cysteine residues
(Smith et al., 1978; Geisler et al., 1992). Three cross-linkers were used to study
pertussis toxin subunits in this work. Two homobifunctional, cleavable reagents were
used, dithiobis (succinimidyl propionate), DSP, and disuccinimidyl tartarate, DST.
Their structures are shown in figure 4.1. They acylate amines of lysine residues or at
the N-terminal. DSP has an internal disulphide bond cleavable by reducing agents
(Lomant and Fairbanks, 1976) and DST contains a glycol bond, cleavable by treatment
with periodate (Smith et al., 1978). Cleavable cross-linkers were used because their
cleavage should regenerate the monomers involved in creation of the cross-linked
aggregates.
One non-cleavable, heterobifunctional cross-linker was used, succinimidyl 4-
(p-maleimidophenyl) butyrate, SMPB. One functional group acylates primary amino
groups (e.g.. lysine, N-terminal amine) and the other is a maleimide group which has
a double bond that reacts with the thiol group of cysteine, to form a thioether bond.
SMPB is longer than either DSP or DST and a comparison of their characteristics is
given in table 4.1. SMPB, being the longest linker used, should be less subject to
steric hindrance than DSP or DST, and was used to compare patterns of cross-linked
aggregates with those obtained with DSP or DST.
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Table 4.1 Characteristics of crosslinkers used for





















The principles on which this work were based were that cross-linked
aggregates could be separated by size on first dimension SDS-PAGE and cross-link
bridges connecting the subunits within the aggregates could be cleaved and the
regenerated monomers separated by size on a second dimension of SDS-PAGE .
Separation of the cross-linked aggregates using FPLC was also tried. Uncleaved
aggregates were also run on one dimensional SDS-PAGE and cross-linked aggregates
were detected by using subunit-specific antibodies and Western blotting.
4.2 Methods
4.2.1 Time courses of cross-linking
The method of cross-linking pertussis toxin subunits is shown in section
2.2.10.1. In order to determine an appropriate time of cross-linking and cross-linker
concentration to maximise cross-linked species for a known toxin concentration, time
course experiments were carried out. Experiments were performed at pH 8.3, where
primary amines reactive with the linker are less protonated, since this favours the
cross-linking reaction. The pH used for cross-linking experiments using SMPB was
also pH 8.3. DSP, DST and SMPB were dissolved in dimethyl sulphoxide (DMSO)
to a final stock concentration of 100 mM. An aliquot of stock cross-linker was added
to a known concentration of toxin in cross-linking buffer (pH 8.3), to give final cross-
linker concentrations of 0.1, 0.5, 1.0, 5.0 or 10.0 mM and protein concentration of
0.35, 0.7, or 1.4 mg/ml. Cross-linking at lower protein concentrations, protein-
precipitation and re-sol ubilisation was tried before SDS-PAGE, but the re-
solubilisation step was not effective enough to be able to detect any cross-linked
species by silver-staining.
The reaction mixture was agitated and incubated for 5, 10, 15, 20, 25, or 30
minutes at 30°C. The linking reaction was effectively stopped by addition of excess
Tris-Cl pH 7.8 (decreased pH probably stopped the reaction) and samples were
prepared for electrophoresis (section 2,2.9). Cross-linked species were separated
using 17.5%(w/v) acrylamide SDS PAGE. A control was also run on SDS-PAGE,
containing toxin and the appropriate amount of DMSO, but without cross-linker.
4.2.2 Two-dimensional electrophoresis
Cross-linked pertussis toxin was separated in a first dimension of 17.5%(w/v)
acrylamide gel using no reducing agent, as described in section 2.2.9. A strip was cut
from this first dimension and incubated in cleavage buffer for 45 minutes at 60°C. The
strip was then washed and fixed to the stacking gel of a second dimension 17.5%(w/v)
acrylamide gel. Pertussis toxin was used as a standard after either being boiled with
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0.1%(w/v) SDS, 2%(v/v) 2-ME or with 0.1%(w/v)SDS alone, the latter being used to
check the reduction of SI after cross-link cleavage.
Several cross-link cleavage methods were tried for DSP, before a suitable
method was found. Initially, results indicated either partial cleavage, or at worst, no
detectable cross-link cleavage at all. Possible reasons for this are that the
conformation of the cross-linked aggregates formed shielded the cross-link bridge
from the reducing agent, or that the high concentration of the acrylamide in the gel
increased the time taken for the reducing agent to gain access to the aggregates. In the
first method, a strip was cut from the first dimension and soaked in cleavage buffer,
100 mM Tris-Cl, l%(w/v) SDS, 15 mM DTT (pH 8.9) at room temperature for one
hour. The strip was then soaked in 50 mM Tris-Cl, 1 %(w/v) SDS, (pH 6.7) for five
minutes, a step found to remove artifactual bands on the second dimension gel. The
strip was then fixed to the stacking gel of the second dimension gel. No cross-link
cleavage was detected by silver staining of the second dimension after electrophoresis.
Next the concentration of DTT was increased to 30 and then 45 mM, the other
conditions being the same as used previously, but this had no effect on the cross-
linked material.
Reduction of the cross-links using l%(v/v) 2-ME was tried but to no avail, so
the reaction temperature was increased to 40, 50 and then to 60°C. The last
temperature was successful, but the cleaved monomers were created in such small
amounts that the reaction time was reduced and a time of 45 minutes was decided
upon (30 and 40 minutes produced smaller amounts of cleaved cross-linked
subunits). Finally the concentration of 2-ME was increased to 2% and then 3%(v/v) in
an attempt to decrease the reaction time and temperature. Although 3%(v/v) 2-ME was
most successful, reduction of reaction time and temperature(from 60°C) appreciably
decreased the amount of cleaved cross-linked material.
The final conditions used for cross-link cleavage were soaking of a strip of
first dimension gel in cleavage buffer (100 mM Tris-Cl, l%(w/v) SDS, 3%(v/v) 2-ME
pH 8.9) at 60°C for 45 minutes followed by two washes in 50 mM Tris-Cl, l%(w/v)
SDS (pH 6.7). The strip was then attached to the stacking gel of a second dimension
gel (2.2.10.2).
4.2.3 Western blotting
Western blotting of cross-linked aggregates is covered in section 2.2.9.5.
Cross-linked species were separated in 17.5%(w/v) acrylamide gels using SDS PAGE
(section 2.2.9). The gel lane containing separated cross-linked species was Western
blotted onto nitrocellulose (Towbin et al., 1979). Subunit specific antitoxin and
antipeptide antibodies, the latter being polyclonal sera raised against synthetic peptides
of SI, S3 and S4 (Seabrook et al., 1990), were incubated with the immunoblotted
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pertussis toxin subunits at an appropriate dilution. The antibodies and antisera were
diluted in PBS buffer, pH 7.2, containing added NaCl, which reduced non-specific
binding of antibody to the toxin subunits (NaCl concentrations used are quoted in the
figure legend).
Nitrocellulose was then washed and incubated with second antibody
(anti-mouse or anti-rabbit lgG conjugated to alkaline phosphatase). Bands were
visualised using Fast blue RR salt (Sigma Chem. Co.) dissolved in Naphthol
ASMX™ solution (Sigma Chem. Co.). The results of Western blotting are shown in
figure 4.9
4.2.4 Reverse phase FPLC
Reverse phase FPLC was carried out on a Gilson FPLC system. Pertussis
toxin was prepared as in section 2.2.10.1. 0.1%(v/v) TFA in acetonitrile (buffer B)
was added to a final concentration of 15%(v/v) acetonitrile. Debris was removed by
centrifugation and the sample applied to a TMS-250 column equilibrated with
15%(v/v) buffer B. The column was eluted, the fractions containing protein as




Figure 4.2 shows resolution of pertussis toxin into five subunits by SDS
PAGE in 17.5%(w/v) acrylamide.
Figures 4.3, 4.4 and 4.5 show results of three time courses using the linkers
DSP, DST and SMPB respectively. All three cross-linkers produced reproducible
patterns of cross-linked aggregates in quantities detected by silver staining.
Figure 4.3 shows 0.7 mg/ml toxin cross-linked by 1 mM DSP. Several cross-
linked species were generated and bands indicating S2, S3, S4 and S5 can be seen to
decrease in stain intensity during the experiment, although a corresponding
proportional increase in stain intensity of cross-linked species bands was not seen.
Variation of linker and toxin concentrations all produced the same range of cross-
linked aggregates, making first and second dimension gels difficult to interpret.
Figure 4.4 shows 0.7 mg/ml toxin cross-linked by DST. Three cross-linked
species were created that were detected by silver staining, but in small amounts, as
shown by the faint staining.
Figure 4.5 shows 1.4 mg/ml toxin cross-linked by 5 mM SMPB. Three cross-
linked bands were detected by silver stain. In both SMPB and DST experiments,
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Fig. 4.2 Resolution of pertussis toxin into five subunits by SDS PAGE
in 17.5% (w/v) acrylamide
standardspertussi
toxin
4.3 Separation of DSP-cross-linked pertussis toxin subunits by
SDS PAGE in 17.5%(w/v) acrylamide
(Sigma molecular weight markers)
A: 66kDa, B: 45kDa, C: 36kDa, D: 29kDa, E: 24kDa, F: 20.1kDa
Lane 1 Mr standards
2 Mr standards
3 pertussis toxin (PT)
4 FT +DSP, 5 min
5 PT +DSP, 10 min
6 PT +DSP, 15 min
7 PT +DSP, 20 min
8 PT +DSP, 25 min
9 PT +DSP, 30 min
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4.4 Separation of DST-cross-linked pertussis toxin subunits by
SDS PAGE in 17.5%(w/v) acrylamide
(Bio Rad molecular weight markers)
A: 97kDa, B: 66kDa, C: 45kDa, D: 29kDa, E: 20.1kDa, F: 14.4kDa
Lane 1 Mr standards
2 Mr standards
3 pertussis toxin (PT)
4 PT +DST, 5 min
5 PT +DST, 10 min
6 PT +DST, 15 min
7 PT +DST, 20 min
8 PT +DST, 25 min
9 PT +DST, 30 min
 
4.5 Separation of SMPB-cross-linked pertussis toxin subunits by
SDS PAGE in 17.5%(w/v) acrylamide
(Bio Rad molecular weight markers)
A: 97kDa, B: 66kDa, C: 45kDa, D: 29kDa, E: 20.1kDa, F: 14.4kDa
Lane 1 Mr standards
2 pertussis toxin (PT)
3 PT + SMPB, 5 min
4 PT + SMPB, 10 min
5 PT + SMPB, 15 min
6 PT + SPMB, 20 min
7 PT + SMPB, 25 min




increasing protein concentration from 0.35, to 0.7 and to 1.4 mg/ml and/or increasing
the cross-linker concentration from 0.1, to 0.5, to 1.0, to 5.0 and to 10.0 mM had
little effect on the range of cross-links produced.
SI was not reduced (by 2-ME) before SDS PAGE and the subunit migrated
with an apparent molecular weight of 24 KDa. Subunits S2 and S3 have similar
apparent molecular masses in SDS PAGE as do S4 and S5 so a cross-link band
separated on an SDS PAGE gel could be formed from a number of subunit
combinations. As a simple example, a band with a mobility that suggested an apparent
Mr of 46.5 KDa may be a dimer of subunits SI and S2, S1 and S3, or a trimer of
subunits SI S4 and S5, etc. To identify subunits in the cross-linked species, cleavage
of the cross-links in a one-dimensional SDS PAGE gel was followed by a second
dimension gel of regenerated subunits.
4.3.2 Two dimensional SDS PAGE
4.3.2.1 'Diagonal' two dimensional SDS PAGE
The principle of this two dimensional system is that a first dimension SDS
polyacrylamide gel is used to separate cross-linked aggregates from non-cross-linked
monomers by size. A strip of the first dimension gel is then soaked in a buffer that
cleaves the cross-link bridges. The strip containing the cleaved species and monomers
is then fixed to a second dimension gel.
Subunits that were part of a cross-linked aggregate in the first dimension
migrate as monomers in the second dimension. Non-cross-linked subunits retain the
same relative mobility in the first and second dimensions, and fall on a diagonal line.
Protein subunits cleaved from a cross-linked aggregate migrate to a position below that
diagonal because of their increased mobility relative to the aggregate from which they
were derived. Subunits that were members of a cross-linked species can be identified
by comparison with the mobility of monomeric subunits (see fig. 4.6-4.8). Cross-link
cleavage and two dimensional SDS PAGE have been used in a number of systems and
with a number of cross-linkers to identify protein-protein interactions (Wang and
Richards, 1974; Smith et al., 1978; Bragg and Hou, 1980).
From the time-course experiments, toxin and linker concentrations were
chosen to produce maximum cross-linking without losing resolution of the cross-
linked species, so that the likelihood of detection of cleaved monomers in the second
dimension was improved.
DSP generated cross-linked aggregates in large amounts detected by silver
staining of first dimension gels, as compared to DST. As DST generated such a low
yield of cross-linked species, cleavage of cross-links within the first dimension
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resulted in such losses of protein into the cleavage buffer that detection of cleaved
monomer in the second dimension was not possible. As a result it was decided to
concentrate efforts on identification of subunits cross-linked by DSP, and cross-linked
species were identified.
Monomers S3 and S4 were cleaved from a cross-linked species that had a
mobility suggestive of a possible dimer in the first dimension, and monomers from a
cleaved trimer of SI, S3 and S4 were identifiable by silver staining. A cross-linked
dimer which had an apparent mobility of about 46 KDa had been cleaved in the first
dimension gel. Its components ran as monomers SI and S3 in the second dimension
and were detected by silver staining.
One band identified by silver staining of a first dimension gel had a mobility
between that of the S2 and S3 subunits (see fig. 4.3, band x), suggesting that that
band was a cross-linked species. Cleavage of that species in a first dimension gel
produced a spot on the second dimension, which was 'off-diagonal', indicating that
cross-link cleavage had occurred. The spot detected on the second dimension also had
a mobility very like that of the monomers S4 and S5. This suggests that a cross-linked
dimer of S4 and S5 had been separated and then cleaved in the first dimension and the
regenerated monomers had been separated in the second dimension.
Figure 4.6 shows cleaved cross-links of pertussis toxin subunits in a second
dimension gel. 0.7 mg/ml toxin was cross-linked using 1 mM DSP for 10 minutes at
30°C. Reduced toxin was used as a standard. 'Off-diagonal' spots are visible,
indicating successful cleavage of cross-links.
Resolution is not good because of the overloading of the first dimension gel to
reduce protein losses during cross-link cleavage, but it is possible to identify
tentatively subunits involved in a cleaved dimer of S3 and S4, a trimer of SI, S3 and
S4, and two larger cleaved aggregates whose composition is more complicated. The
toxin standard on the left of the gel suggests that the largest cleaved aggregate
contained all the toxin subunits.
An interesting cleaved species is visible in a position suggesting that S4 and S5
could have been linked by DSP to form a dimer (mentioned earlier). A combined
molecular mass of S4 plus S5 is about 21 kDa, and a species of that molecular mass
would be expected to run at a position between S2 and S3 on first dimension SDS
PAGE. A species that could be this aggregate can be seen in such a position, between
S2 and S3, on figure 4.3.
Figure 4.7 also shows cleaved cross-links. 0.7 mg/ml toxin was cross-linked
using 10 mM DSP for 10 minutes at 30°C. This gel shows a range of cleaved cross¬
links, and their composition difficult to ascertain. However, there is a spot at a
position indicating the possible cleavage of S4 and S5. Toxin was used as a standard
but was left unreduced to check on the cleavage method, as some gels showed that not
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Fig. 4.6 Second dimension gel of cleaved cross-linked

















Fig. 4.7 Second dimension gel of cleaved cross-linked















Fig. 4.8 Second dimension gel of cleaved cross-linked







all SI was reduced by the cleavage treatment and the extra spots due to this
complicated the second dimension gel.
Figure 4.8 shows a third two dimensional gel. 0.7 mg/ml toxin was cross-
linked with 10 mM DSP for 30 minutes at 30°C. Two cross-linked species were
cleaved, as indicated on the accompanying diagram. One contains SI and S3. S4 and
S5 did not stain well in this experiment, so this 'dimer' may contain S4. The other
species cleaved appears to contain all the toxin subunits.
4.3.2.2 Electroelution
The two dimensional gel system did not identify subunits in cross-linked
aggregates with total certainty, so electroelution of first dimension cross-links,
cleavage in solution and electrophoresis on a second gel was tried. A strip from the
first dimension DSP-cross-linked gel was silver stained and areas of unstained gel
corresponding to cross-linked species were cut out. The protein in these areas was
electroeluted as described in section 2.2.9.3. Electroeluted material was then treated
with 3%(v/v) 2-ME, l%(w/v) SDS in a boiling water bath for five minutes (for DSP-
cross-linked toxin), or treated with 15, 30 or 60 mM sodium periodate for up to three
hours at room temperature and the pH adjusted to neutral (for DST-cross-linked
toxin). The material was then applied to another gel to resolve the subunits in the
cleaved aggregates. This method was not successful, because periodate-treated
proteins produced poorly resolved bands on the second gel. Periodate treatment can
alter the electrophoretic mobilities of some proteins, which could explain this result
(Peters and Richards, 1977). The same problem was not encountered with 2-ME
treatment, but a large number of cross-links were generated and it was not possible to
electroelute them one at a time (even when the cross-links were separated on a gradient
gel of 10-20, or 5-20%(w/v) acrylamide).
4.3.3 Western blotting
Four antibodies, murine anti-Si and -S3 antibodies and two rabbit antibodies,
one raised against a peptide synthesised from the amino acid sequence of the S3
subunit ((E)S3c) and one against a peptide derived from the sequence of S4 (S4b)
were used. The peptide amino acid sequences against which the rabbit antipeptide sera
were raised are to be found in chapter 3.
Three antibodies were subunit-specific when reacted with immunoblots of non-
cross-linked pertussis toxin subunits separated by SDS PAGE. The rabbit anti-S3
antipeptide antibody was found to cross-react with the SI subunit monomer on
immunoblots of separated cross-linked subunits and very weakly with SI monomer on
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blots of non-cross-linked pertussis toxin subunits. The cross-reaction was reduced by
incubation of antibody with the immunoblots in a buffer containing 250 mM NaCl
(higher concentrations were also tried). Non-specific binding of the other antibodies
was also reduced by inclusion of up to 250 mM NaCl in the buffer in which the first
antibody was diluted in (if NaCl was added, the concentration is quoted in the figure
legend). Subunit-specific antibodies to subunits S2 and S5 were not available to the
author at the time of the study.
Cross-linked bands were identified as containing S3-S4 and S1-S3-S4. These
subunit combinations were compatible with the apparent Mr of the species. Other
bands were visualised, but their subunit composition could not be identified using this
method due to the lack of a range of subunit-specific antibodies to all five subunits of
the toxin.
Only DSP formed cross-linked species detectable by Western blotting. DST
and SMPB generated cross-links detected by silver stain but the first antibody
concentration needed in the blotting method to detect cross-links was so low that non¬
specific binding of the antibodies to all the toxin subunits occurred. The non-specific
binding could not be reduced so identification of component subunits in a DST- or
SMPB-cross-linked species was not possible.
Lane one of figure 4.9 shows murine anti-(pertussis toxin) antibody binding to
non-cross-linked pertussis toxin subunits and in lane two, the same antibody binding
to cross-linked pertussis toxin species. Several cross-linked species were detected.
Lanes three, four, five and six show uncross-linked pertussis toxin blotted
with murine monoclonal antibodies to SI and S3 and rabbit polyclonal antipeptide
antisera to S3 and S4 respectively.
Lanes seven to ten show the antibodies mentioned in the above paragraph
binding to DSP-cross-linked toxin (0.7 mg/ml toxin cross-linked with 5 mM DSP for
10 minutes at 30°C). Lanes seven and eight show recognition of cross-linked toxin
species by the murine monoclonal anti-Si and anti-S3 antibodies respectively. The
anti-Si antibody recognised non-cross-linked SI and one cross-linked species.
The rabbit anti-S3 antipeptide antibody (lane nine) and the murine anti-S3
antibody (lane eight) both recognised the same bands, but some cross-reaction of the
anti-S3 antipeptide antibody with SI can be seen in lane nine. Reduction of this cross-
reaction was attempted by including NaCl in both the buffer used for diluting the first
and second antibody in, and by reducing the temperature of the antibody binding
reactions to 4°C. Neither of these methods succeeded.
The rabbit anti-S4 antipeptide antibody (lane ten) was used at very high
dilution to reduce cross-reaction with subunit S3 seen at lower dilutions, and this
reduced the amount of antibody available to bind S4. This meant that the bands
detected by the anti-S4 antibody were faint.
One cross-linked band recognised by the anti-S3 antibodies was also bound by
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Fig. 4.9 Western blots of cross-linked and non-cross-iinked pertussis
toxin subunits separated by SDS PAGE in 17.5%(w/v) acrylamide





































11,12 species-specific murine- and rabbit-IgG
conjugated to alkaline phosphatase
(a) Toxin cross-linked (+) by 5 mM DSP, or not cross-linked (-).
(b) Murine monoclonal antibody.
(c) Rabbit polyclonal antibody (note: both rabbit antipeptide antibodies were
incubated with immunoblots in PBS, pH 7.2 with added NaCl (final concentration
250 mM).
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the anti-S4 antibody, indicating that the cross-linked species contained S3 and S4.
The generation of a cross-linked dimer of S3 and S4 by DSP had been suggested by
cleavage of the link and two dimensional SDS PAGE. Another band on the
immunoblot indicates a species having the mobility of a cross-linked trimer. The
species contained SI, S3 and S4, also suggested by cleavage of this cross-linked
species followed by separation of its component subunits with the two dimensional gel
system.
Other bands were detected by this method, but their identification was not
possible, as subunit-specific anti-S2 and anti-S5 antibodies were not available, as
mentioned earlier.
4.6.4 Reverse phase chromatography
This system (TMS-250 C\ column) separated non-cross-linked toxin subunits,
but a large portion of the sample did not interact with the column matrix and eluted in
the void volume. This meant that when DSP-cross-linked material was applied to the
column, almost all of the sample eluted in the void volume and cross-linked material
was not detectable by A220 Conditions of chromatography were varied in order to
increase the amount of material interacting with the column matrix and the experiment
attempted with a different (C8) column . However, this method was abandoned
because indication of components in cross-linked species was provided by other
techniques.
This method was not attempted with DST or SMPB which generated less
cross-linked material than DSP.
4.7 Discussion
Chemical cross-linking was used to study the arrangement of pertussis toxin
subunits in space. Reversible and non-reversible cross-linking reagents were used
with one and two dimensional electrophoresis, Western blotting and FPLC were used.
4.7.1 Time courses and two dimensional electrophoresis
Three cross-linking reagents, dithiobis(succinimidyl propionate),DSP,
disuccinimidyl tartarate, DST and succinimidyl 4-(p-maleimidophenyl) butyrate,
SMPB, were used. Reproducible patterns of cross-linking were created and resolved
using SDS PAGE and these patterns gave an idea of the range and amount of cross-
linked species for a given toxin and cross-linker concentration and reaction time.
One dimensional SDS PAGE did not identify which subunits were involved in a cross-
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linked aggregate as S2 and S3, S4 and S5 have similar molecular masses, so a cross-
linked species resolved by a one dimensional gel may contain several combinations of
those subunits.
To clarify which toxin subunits were involved in cross-linked aggregates,
cleavage of DSP and DST-cross-linked aggregates and resolution by two dimensional
electrophoresis was attempted. The cleavage method used, involving soaking of first
dimension gel strips in a cleavage buffer, meant that too much DST-cross-linked
protein was lost from the gel for any cleaved aggregates to be detected using silver
staining.
DSP-cross-linked species proved difficult to reduce, possibly because the
cross-linked subunits protect the disulphide bond of the cross-linker from the reducing
agent and also difficult to separate using second dimension SDS PAGE. A
temperature of 60°C and a concentration of 2-mercaptoethanol (2-ME) of 3%(v/v)
were finally chosen and reduced cross-links, but spots indicating subunits cleaved
from aggregates were not well resolved in all cases, as seen in figure 4.7, for example.
This could be because the first dimension gel was overloaded, leading to streaking in
the second dimension, or simply because too many cross-linked species were
generated in the first dimension to be properly resolved in the second dimension
(again, see fig. 4.7).
The results of diagonal two dimensional cross-linking with DSP add to the
evidence of identification of an S3-S4 dimer (Tamura et al., 1982; Sekura et al., 1983;
1985). Interestingly SI, which contains no lysine residues in its amino acid sequence
(Locht and Keith, 1986; Nicosia et al., 1986), was found to be part of an aggregate
that contained S3 and S4, so SI may have been cross-linked to either S3 or S4 via its
N-terminal amine. Linking of cysteine or arginine residues of SI with S3 or S4 is also
a possibility. An aggregate apparently consisting of SI and S3 was also identified, as
was an aggregate containing S4 and S5. The latter result could be clarified by Western
blotting of cross-linked toxin separated by SDS PAGE with an antibody specific for
S5.
4.7.2 Western blotting
Cross-linking a toxin which has several different subunits of similar molecular
mass, results in an array of cross-linked species that could have been formed from
various combinations of subunits. The two dimensional SDS PAGE system used
during this study did not positively identify as many cross-linked species as hoped, so
Western blotting was used to clarify the results of the diagonal two dimensional
electrophoresis.
This method was unsuccessful for both DST and SMPB. This could be due
to the small amount of cross-linked material generated, and non-specific binding to the
145
blot may have occurred, caused by the requirement for a low dilution of first antibody.
Also, cross-linking may have obscured the antigenic sites for the antibodies.
A number of antibodies, both murine monoclonal and polyclonal and rabbit
polyclonal, were tested to identify which, if any, were specific for one toxin subunit
(section 3.3.1). The majority recognised SI and/or S3, one recognised S4 alone and
none specifically recognised S2 or S5.
Western blotting confirmed the cross-linked S3-S4 dimer and the aggregate
containing SI, S3 and S4. The latter aggregate is unlikely to contain S5, as an
aggregate containing S5 would be expected to have a lower mobility (about 4 mm
higher on the gel) in the first dimension, than was observed.
The S4-S5 dimer suggested by two dimensional electrophoresis was not
detected by the anti-S4 antibody, possibly because the yield of cross-linked material
was too low to be detected. A cross-linked S4-S5 species was expected to have a
mobility between that of S2 and S3 on a first dimensional gel, and a band detected by
silver staining of DSP-cross-linked toxin (fig. 4.3) does in fact show such a band
between S2 and S3. The positive identification of the S4-S5 dimer would require an
increased yield of this species and blotting with both anti-S4 and -S5 antibodies.
Increasing the yield of this aggregate could be a difficult task, if S5 is shielded from by
the other toxin subunits, as proposed by Tamura et al. (1982) and Sekura et al.
(1983). Such shielding may protect the subunit from the action of cross-linkers by
'hiding' surface-exposed primary amines.
Immunoblotting did not indicate the presence of a cross-linked SI-S3 dimer
seen using the two dimensional electrophoresis system in figure 4.8, possibly because
the dimer formation by cross-linking obscured the antigenic sites of the subunit-
specific antibodies. It is also possible that silver staining of the gel seen in figure 4.8
did not detect S4, explaining the apparent SI-S3 dimer observed.
It appears from the results using the 1.2 nm cross-linker DSP, that SI may sit
'on top' of the S3 and S4 subunits with S5 'underneath' and shielded by the other
toxin subunits (Fig. 4.10). No aggregates containing S2 were identified using DSP
and the two dimensional electrophoresis system, but may be identifiable using other
cross-linkers and by immunoblotting.
The currently accepted model of the toxin is supported by this study, but the
results are incomplete and further work with other cross-linkers is required. A linker
with a longer cross-link bridge than DSP but with the same amino acid specificity
could be used and the cross-link map compared to one generated with a cleavable
heterobifunctional linker, with one functional group having specificity for lysine
residues and the other being specific for cysteine residues. This would help to
generate a map of the toxin subunits that would be confirmed by the eventual
determination of the toxin's crystal structure.
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Fig. 4.10 Proposed structural model of pertussis toxin deduced by
crosslinking with DSP (1.2 nm)
Figure shows subunits cross-linked by DSP and cleavage of cross-links which
identified components of subunit aggregates
 
Chapter 5
Binding of NAD+ to pertussis toxin and its SI subunit
5.1 Introduction
The SI subunit of pertussis toxin catalyses ADP-ribosyl transfer from NAD+
to a C-terminal cysteine residue of some G proteins (Ui, 1990). This results in
uncoupling of some effectors (e.g. adenylate cyclase) from their respective cell surface
receptors and generates some of the toxic effects of pertussis toxin, including
histamine sensitisation and lymphocytosis (chapter 1).
When no protein substrate is available, water acts as the ADP-ribose acceptor
and NAD+ is hydrolysed to ADP-ribose and nicotinamide and binding of NAD+ to the
SI subunit is the initial event in both the ADP-ribosyltransferase and NAD+-
glycohydrolase activities of pertussis toxin.
In the work described in this chapter, fluorescence quenching was used to
study the interaction of NAD+ with whole pertussis toxin and isolated S1 subunit
purified from whole pertussis toxin, at various temperatures and interaction of NAD+
with recombinant SI subunit analogues.
Intrinsic tryptophan fluorescence quenching has been used to study the
interaction of NAD+ with diphtheria toxin fragment A (DTA, Kandel et al., 1974),
Pseudomonas aeruginosa exotoxin A (ETA, Chung and Collier, 1977). The
quenching of DTA and ETA fluorescence seen on NAD+-binding may be due to
interaction with a tryptophan residue in each toxin and a tryptophan in ETA (W466) is
thought to be involved in interaction with NAD+ (Brandhuber et al., 1988).
Although ETA and DTA have sequence similarity, they have little similarity
with pertussis toxin, cholera toxin and Pseudomonas aeruginosa exotoxin A and ETA
and DT act on a different target. However, experiments using site-directed
mutagenesis have indicated that tryptophan 26 (W26) of the SI subunit of pertussis
toxin is important in the toxin's enzymic activity, that is, either the toxin's NAD+-
binding or catalytic activity (Cortina and Barbieri, 1989; Locht et al., 1990; Loosemore
et al., 1990). It was shown in this study that the intrinsic tryptophan fluorescence of
pertussis toxin, its isolated SI subunit and SI subunit analogues were all quenched on
the addition of NAD+, which suggests that a tryptophan may be involved in NAD+-
binding.
Other residues may be involved in NAD+-binding. Glutamate 129 (E129) of
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pertussis toxin S1 subunit is involved in expression of enzymic activity and alteration
or replacement of this residue has been found to reduce enzymic activity (Pizza et al.,
1988; Loosemore et al., 1990; Lochtet al., 1990). NAD+ has been shown to interact
with glutamate 129 of the SI subunit using photoaffinity labelling (Cockle, 1989) and
that photolabelling was undetectable when this residue was replaced by either an
aspartate or glycine residue.
Glutamate 148 of DTA and glutamate 553 of ETA have both been shown to
interact with NAD+ (Carroll and Collier, 1987; Douglas and Collier, 1990) and
mapping of the NAD+-binding site of DTA and ETA using X-ray diffraction identified
glutamate 148 and glutamate 553 as being at or near the NAD+ active site, so
glutamate 129 of the SI subunit of pertussis toxin may have an analogous role in
enzymic activity to glutamate 148 and glutamate 553 of DTA and ETA.
It has been established that tryptophan 26 (W26) and glutamate 129 (E129) of
the SI subunit of pertussis toxin are essential for the toxin's enzyme activity (Pizza
et al., 1988; Cortina and Barbieri, 1989; Locht et al., 1989), but to what extent they
are involved NAD+-binding and/or catalytic activity is still being established.
NAD+-binding to the SI subunit of whole pertussis toxin and isolated SI
subunit was studied by the author to determine if binding was affected by SI being
attached to the B-oligomer of the toxin. NAD+-binding to a truncated analogue of S1
(rSld) and rSld with the glutamate residue at position 129 altered by site-directed
mutagenesis to an aspartate (rSldE129D) was also studied to determine the importance
of glutamate 129 in NAD+-binding.
Tryptophan 50 (W50) and glutamate 148 (E148) of DTA, and tryptophan 466
(W466) and glutamate 553 (E553) in ETA are thought to be involved in the catalytic
activity of both these toxins (Brandhuber et al., 1988). Both fluorescence studies on
DTA and ETA gave dissociation constants (Kd) for NAD+ in the micromolar range
and similar Km values were obtained for the proteins' NAD+-gIycohydrolase
activities. Equilibrium dialysis, used by Lobban et al. (1991) also yielded dissociation
constants for whole pertussis toxin that were of the same order as the Km values
obtained from NAD+-glycohydrolase assays.
The similarities between DTA and ETA binding of NAD+ using intrinsic
fluorescence quenching, and the involvement of analogous tryptophan and glutamate
residues in the enzymic activities of DTA, ETA and pertussis toxin suggested that
intrinsic fluorescence quenching could be used to study NAD+-binding to whole
pertussis toxin, isolated SI subunit and SI subunit analogues.
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Fluorescence quenching by NAD+ was studied by the author using a
recombinant SI subunit lacking C-terminal amino acids (rSld, consisting of amino
acids 2-187) and rSld that contained aspartate (D) instead of the wild-type glutamate
(E) residue found at position 129 (rSldE129D). The two recombinant SI subunit
analogues were produced in E. coli and were kind gifts of Dr. C. Locht, Institut
Pasteur, France. Their production is described elsewhere (Locht et al., 1987).
The emission spectrum of pertussis toxin's tyrosine and tryptophan residues
was measured by excitation at 285 nm. The emission spectrum showed two wide
peaks at 300-315 nm and 320-350 nm. The second peak was due to tryptophan
fluorescence, giving similar maximum and peak-width as other tryptophan
fluorophores (Burstein et al., 1973) and the first peak was due to tyrosine
fluorescence.
Quenching of fluorescence on addition of NAD+ was observed at an excitation
wavelength 285 nm and emission spectra recorded at a wavelength of 333 nm.
Experimental conditions are described in chapter 2.
5.2 Results
5.2.1 Corrections and calculation of the apparent dissociation
constant, Kd
Fluorescence quenching data were corrected for dilution of the solution on
addition of NAD+. A correction for the absorbance of the solution at the excitation
and emission wavelengths was applied (Lakowicz, 1983):
Fcorr = Fo • Antilog |(Aex+Aem)/2I
where Fcorr is the corrected fluorescence intensity, Fo is the observed fluorescence
intensity and Aex and Aem are the absorbances of the solution at the excitation and
emission wavelengths respectively.
In the simple reaction below for protein P and ligand, L:
P + L * ► PL
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the dissociation constant Kd is given by:
Kd = [P][L] (1)
[PL]
A binding site may or may not be saturated with L so the fractional saturation, r can be
calculated:
r = [PL] (2)
[PJ + [PL]






Equation 4 was adapted for graphical calculation of the dissociation constant:
r = _J_ - _r_ (5)
[L] Kd Kd
A plot of r against r/[L] gives a slope of -1/Kd and this graphical representation
is shown in figures 5.1 to 5.13.
The number of NAD+-binding sites was assumed to be one (n =1) on the SI
subunit (Lobban et al, 1991).
The maximum fluorescence quench (AfmaxX when the protein is saturated with ligand
was measured. Afmax was then used to calculate r, the fractional saturation of the
protein with ligand:
r - Afo/Afmax (6)
where Af0 is the change in relative fluorescence at a particular concentration of ligand,
L. The concentration of the protein was known, so the concentration of free ligand
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could be calculated using the fractional saturation, r, and the manipulated fluorescence
data are presented as plots of r/Ifree NAD+] (//M) against r (Scatchard, 1949) as stated
above and analysed using least squares best fit calculations. The gradient of each plot
yielded a value for the apparent association constant, Ka and the reciprocal of this
value is the apparent dissociation constant, Kd (piM).
5.2.2 Effect of temperature on the NAD+-dissociation
constant, Kd
Fluorescence titrations were done as described in section 2.2.11.1 at 14, 20,23,30,
and 40°C. Results of the titrations of whole pertussis toxin are shown in figures 5.1
to 5.5
and results of titrations of isolated S1 subunit are shown in figures 5.6 to 5.10. Kd
values were calculated from the reciprocal of the gradients and the Kd values are
shown in table 5.1. The dissociation constants obtained for whole pertussis toxin
were similar to those for isolated SI subunit (table 5.1). The enthalpy of binding at
constant pressure, AH (kJ moT^), was calculated from the relationship below:
d In Ka = AH (7)
d T RT2
Where Ka is the association constant, T is the absolute temperature (i.e. in Kelvin) and
R is the gas constant (8.314 J K"* moH ). Integration of equation 7 gives:
In Ka = - AH + constant
RT
If log Ka is plotted against 1/T, a straight line will be obtained that will have a slope of
-AH/2303R and AH can be calculated.
The enthalpy of binding (AH) for whole pertussis toxin and isolated S1 subunit were
similar (fig. 5.11), suggesting that the presence of the B-oIigomer does not
significantly affect NAD+-binding.
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Fig. 5.1 Fluorescence quenching on binding of NAD+
to whole pertussis toxin at 14°C
Protein was titrated with NAD+ as described in section 2.2.11.1.
Fig. 5.2 Fluorescence quenching on binding of NAD+
to whole pertussis toxin at 20°C
Protein was titrated with NAD+ as described in section 2.2.11.1.
r
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Fig. 5.3 Fluorescence quenching on binding of NAD+
to whole pertussis toxin at 23°C
Protein was titrated with NAD+ as described in section 2.2.11.1.
Fig. 5.4 Fluorescence quenching on binding of NAD+
to whole pertusis toxin at 30°C
Protein was titrated with NAD+ as described in section 2.2.11.1.
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Fig. 5.5 Fluorescence quenching on binding of NAD+
to whole pertussis toxin at 40°C
Protein was titrated with NAD+ as described in section 2.2.11.1.
Fig. 5.6 Fluorescence quenching on binding of NAD+
to isolated SI subnnit at 14°C
Protein was titrated with NAD+ as described in section 2.2.11.1.
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Fig. 5.7 Fluorescence quenching on binding of NAD+
to isolated SI subunit at 20°C
Protein was titrated with NAD+ as described in section 2.2.11.1.
Fig. 5.8 Fluorescence quenching on binding of NAD+
to isolated SI snbnnit at 23°C
Protein was titrated with NAD+ as described in section 2.2.11.1.
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Fig. 5.9 Fluorescence quenching on binding of NAD+
to isolated SI subunit at 30°C
Protein was titrated with NAD+ as described in section 2.2.11.1.
Fig. 5.10 Fluorescence quenching on binding of NAD+
to isolated SI subunit at 40°C
Protein was titrated with NAD+ as described in section 2.2.11.1.
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Fig. 5.11 Enthalpy of binding of NAD4* to whole pertnssis toxin and
isolated SI snbnnit
1/TxlO"3
o PT AH = -60kJ mol-1
□ SI AH = -53 kJ mol"1
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Table 5.1 Dissociation constants for NAD+-binidng to whole pertussis
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5.2.3 NAD+-binding to recombinant SI subunit analogues
Fluorescence titrations were carried out as described in section 2.2.11.2 at
37°C using whole pertussis toxin, rSld, and rSldE129D. Results of the titrations are
shown in figures 5.12, 5.13 and 5.14 respectively and the dissociation constants
calculated from these plots are shown in table 5.1. The apparent dissociation constant
for rSld was 38piM, which was about twice the apparent Kd obtained for whole
pertussis toxin at the same temperature. The Kd obtained for rSldE129D was 54/,<M,
slightly higher than the Kd for rSld. (NB. limited amounts of isolated SI subunit
were available, so measurements of fluorescence quenching at 37°C with NAD+ were
not possible).
5.3 Discussion
5.3.1.1 Effect of interaction of the SI subunit with the B- oligomer
on NAD+-binding
Binding of NAD+ to whole pertussis toxin and isolated S1 subunit showed
that there was little difference in dissociation constants across a range of temperatures
and little difference in enthalpy of binding. The results suggest that the isolated SI
subunit and SI attached to the B-oligomer do not have detectably different
conformations and that the NAD+-binding site is accessible on the surface of S1,
independent of whether the SI subunit is attached to the B-oligomer.
5.3.1.2 Binding of NAD+ to SI subunit analogues
Quenching of intrinsic tryptophan fluorescence showed some difference in Kd
between pertussis toxin (Kd 12 +/- 2 jaM), rSld (Kd 38piM) and rSldE129D
(Kd 54 /<M). The dissociation constant for rSld is about two-fold higher than that for
whole pertussis toxin and the dissociation constant for rS1dE129D was about five-fold
higher than that for whole pertussis toxin. These results suggest that NAD+-binding
to the truncated SI analogue (rSld) and the mutated SI analogue (rSldE129D) is
slightly disturbed, possibly due to slight changes in conformation of the analogues as
compared to the wild-type whole toxin, and that glutamate 129 is not essential for
NAD+-binding, because the Kd values for the SI analogues were not drastically
different to the Kd for NAD+ of the whole toxin.
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Fig. 5.12 Fluorescence quenching on binding of NAD+
to whole pertussis toxin at 37°C
Fig. 5.13 Fluorescence quenching on binding of NAD+
to rSld at 37°C
(Protein was titrated as described in section 2.2.11.1)
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Fig. 5.14 Fluorescence quenching on binding of NAD+
to rSldE129D at 37°C
Protein was titrated with NAD+ as described in section 2.2.11.1.
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That the conformation of rSld has not been dramatically altered when
compared to the conformation of native SI subunit is supported by studies carried out
by Locht et al. (1989). The group identified conformational epitopes on the SI
subunit of whole pertussis toxin that were recognised by anti-(pertussis toxin)
antibodies and those antibodies were also found to react with the Sl-analogue rSld,
indicating that the conformation of rSld was not dramatically different to that of wild
type SI in the whole toxin.
Quenching of rSld and rSldE129D fluorescence studies carried out by the
author and enzymatic analysis of the SI subunit analogues were investigated in
Antoine et al. (in preparation). The NAD+-glycohydrolase assay method is described
in Locht et al. (1987) and the assays were performed at 37°C. Truncation of SI to
produce rS 1 d, or modification of glutamate 129 by site-directed mutagenesis to an
aspartate did not significantly affect the Michaelis constant for the NAD+-
glycohydrolase activity and the dissociation constants for NAD+-binding to rSld or
rSldE129D found by fluorescence quenching were not dramatically different.
However, the catalytic efficiency of the mutated SI analogue rSldE129D was
significantly affected when compared to rSld in an NAD+-glycohydrolase assay. The
Kcat for rSld in the NAD+-glycohydrolase assay was 1.24 min "1 and the KCat for
rSldE129D was more than 100-fold less than that of rSld.
Anti-Si antibodies known to recognise three-dimensional epitopes of SI and
rSld (Locht et al., 1989, mentioned above) also recognised rSldE129D, indicating
that the three-dimensional structure of rSldE129D was not very different to SI subunit
of the whole toxin.
That the dissociation constants and Michaelis constants of rSld and
rSldE129D for NAD+ were not very different and the catalytic turnover of
rSldE129D was more than two orders of magnitude lower than rSld suggested that
glutamate 129 is involved mainly in catalysis, rather than the binding of NAD+ and
that the mutation of glutamate 129 to aspartate did not significantly affect the
conformation of the molecule.
5.3.2 Other residues involved in the enzymic activity of pertussis
toxin
Several other amino acid residues of SI have been identified as important for
the enzymic activity of pertussis toxin and others have been proposed as important and
await further work.
An N-terminal region containing residues 8-15 of SI is necessary for
expression of enzymic activity of pertussis toxin, either in catalysis or NAD+-binding
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and aspartate 11 (D11), and arginine 13 (R13) are necessary for the enzymic activity of
pertussis toxin (Pizza et al., 1988; Burnette et al., 1988; Locht et al., 1989; Cieplak
et al., 1990). Site-directed mutagenesis has identified arginine 9 as being important
for enzyme activity because substitution of this residue for lysine reduced the ADP-
ribosyltransferase activity to below detectable levels (Burnette et al., 1988).
A histidine residue (H21) of diphtheria toxin fragment A has been shown to be
involved in NAD+-binding (Papini et al., 1989), the imidazole of the histidine
possibly interacting with the sugar moiety of the adenosine of NAD+. A possible
analogous histidine of pertussis toxin SI subunit is histidine 35 (H35), which may
contribute to enzymic activity (Domenighini et al., 1991).
Chemical modification of the SI subunit's two cysteines with sulphydryl-
reactive compounds suggested that either one or both is involved in enzymic activity.
The truncated recombinant SI analogue rSld has only one cysteine (C41) and lacks
the other, which is located in the C-terminal region of rSld. Analogue rS Id has
similar NAD+-glycohydrolase and ADP-ribosyltransferase activity to wild type S1
subunit (Locht et al., 1987; 1990), suggesting that cysteine 200 is not required for
enzymic activity. Site-directed mutagenesis has identified cysteine 41 as being
involved in enzymic activity (Locht et al., 1990), and a replacement of cysteine 41
with glycine altered the Km for NAD+, but not the kcap suggesting that cysteine 41 is
involved in NAD+-binding. Site-directed mutagenesis carried out by Cortina and
Barbieri, (1989) also suggested that cysteine 41 could be involved in NAD+-binding.
In summary, quenching of tryptophan fluorescence of S1 of whole pertussis
toxin, isolated SI subunit and SI analogues suggests that a tryptophan (possibly
tryptophan 26) may be involved in NAD+ binding. However, binding of NAD+ to
another residue in the N-terminal region of SI may result in the fluorescence
quenching seen. The pertussis toxin B-oligomer is not essential for efficient binding
of NAD+ because dissociation constants for S1 subunit of whole pertussis toxin and
isolated SI subunit were very similar over a range of temperatures. Glutamate 129 of
the S1 subunit does not seem essential for NAD+-binding, as a mutated S1 analogue
(rSldE129D) bound NAD+ in fluorescence quenching experiments with an affinity
that was not greater than one order of magnitude different to the affinity of NAD+ for
whole pertussis toxin.
The involvement of residues of SI in NAD+-binding and catalysis can be
implied from fluorescence quenching and kinetic studies of mutant proteins, but a full
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picture of the residues involved awaits the resolution of the crystal structure of
pertussis toxin by X-ray diffraction.
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Chapter 6
Summary and Future Work
The subunit arrangement of pertussis toxin and the function of some of the
subunits in terms of NAD+-binding, antigenicity and glycoprotein-binding have been
investigated by the author in this thesis.
The spatial arrangement of the subunits of pertussis toxin were investigated
using chemical cross-linking reagents. Using the cross-linker DSP, it was shown that
subunits S3 and S4 are close together in the whole toxin and SI is close to subunits S3
and S4. SI contains no lysine residues in its amino acid sequence, indicating that SI
was linked via its N-terminal to either S3 or S4. These two results were confirmed by
Western blotting using subunit-specific monoclonal antibodies to subunits SI and S3
and polyclonal antisera to subunits S4 , adding to the evidence of an S3-S4
association (Tamura et al., 1982; Sekura et al., 1983) in the whole toxin. One
cleaved cross-linked species, that only contained subunits S4 and S5 was identified
using two-dimensional SDS PAGE, but the yield of cross-linked material was too low
to confirm that S4 was present and an anti-S5 antibody was not available to the author
at the time of study. A cleaved cross-link species consisting of subunits SI and S3
was also identified using two-dimensional SDS PAGE, but this result was not
confirmed by Western blotting. No cross-linked species containing S2 were identified
in the study, either because there were no accessible residues in the amino acid
sequence of S2, or the yield of cross-links contaniing S2 was too low. No dimers
were detected that contained SI and S5 or SI and S4, indicating that the subunits were
not accessible to the cross-linker and suggesting that SI may sit 'on top' of the S4 and
S5 subunits, in agreement with Tamura et al. (1982).
The results obtained so far are in agreement with the proposed structure of the
toxin to date and are supported by recent structural studies using X-ray crystallography
(R. Reid, personal communication).
Further work to investigate the arrangement of the toxin subunits using cross-
linkers would include obtaining of S5-specific antibodies to confirm the composition
of the cross-linked species thought to contain S4 and S5 and S2-specific antibodies to
detemine the compostion of other cross-linked species by Western blotting. Yields of
cross-linked material may be increased from those obtained in the study by the use of
water-soluble cross-linking reagents. The cross-linking reaction would then occur
throughout the cross-linking solution, rather than at the aqueous-organic solvent
interface. When using the linkers DSP, DST and SMPB, the linker was dissolved in
DMSO and an aliquot added to the cross-linking buffer containing protein, so the
cross-linking reaction only occurs at the interface of the two solvents.
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Heterobifunctional cross-linkers would generate different cross-linked species to those
generated using homobifunctional linkers and would help to clarify the subunit
structure of the toxin further.
Antigenicity of pertussis toxin subunits was studied using decapeptides
covalently bound to polypropylene pins. The amino acid sequences of the peptides
were derived from the entire amino acid sequences of subunits SI, S3 and S4.
Although peptides that bound antibody were identified, using mouse
monoclonal antibodies, rabbit polyclonal and human polyclonal antisera, pin peptide-
binding patterns differed within and between species and no major continuous
antigenic epitopes were identified. As synthesis of each pin decapeptide was carried
out under the same conditions, the success of the syntheses probably varied and
generated different amounts of each pin peptide. This may have been the case, for
example the reaction of anti-Sla with SI decapeptides with an eight amino acid
overlap, where decapeptides 5 and 7 reacted with anti-Sla but decapeptide 6 did not
(decapeptide 6 could have been a relatively unsuccessful synthesis). That quite low
amounts of decapeptide were synthesised on the pins could account for the few
reactive peptides seen with antibodies and antisera having quite high anti-(pertussis
toxin) titres. The pin synthesis technique was useful for primary screening in this
study and it should be emphasised that conclusions made from this work alone should
at least be backed up by studies of free peptides, containing the reactive pin peptide
sequence.
One pin decapeptide (sequence QLTFEGKPAL) bound a rabbit polyclonal
anti-(pertussis toxin) antisera and that binding was inhibited by whole toxin, or a free
peptide containing the same amino acids (peptide S4b, sequence QLTFEGKPALGC).
However, rabbit anti-S4b antisera did not react strongly with whole pertussis toxin,
suggesting that the sequence of the peptide in subunit S4 of the whole toxin may exist
in a different conformation, or that only part of the peptide is exposed on the surface of
the S4 subunit in the whole toxin, or that peptide S4b was not particularly
immunogenic. These results suggested that peptide S4b was unlikely to induce
protective antibodies and is unlikely to be a candidate for a new acellular pertussis
vaccine.
Glycoprotein- and glycolipid-binding to the S3-derived pin decapeptides was
investigated in an attempt to identify peptides which may be involved in cell-
recognition. One pin decapeptide derived from the amino acid sequence of the S3
subunit (residues 46-55, sequence RQITPGWSIY) was found to bind the glycoprotein
fetuin. Fetuin-binding of the pin decapeptide was inhibited by a free peptide
containing the same amino acids (peptide (E)S3c, sequence EYLRQITPGWSIYGLY)
and an antipeptide antibody raised against peptide (E)S3c weakly recognised whole
pertussis toxin in an antigen-capture ELISA, indicating that all or part of the sequence
of peptide (E)S3c is likely to be at the surface of subunit S3 in the whole toxin.
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Pin peptide (residues 46-55) weakly bound only one other antisera, so the
peptide does not constitute a major continuous antigenic epitope.
The author found that peptide (E)S3c also bound alpha-1-acid glycoprotein,
mixed bovine brain gangliosides and asialofetuin each with decreasing affinity.
Armstrong et al. (1988) had previously shown that whole toxin bound differentially to
glycoproteins, so peptide (E)S3c acted like whole toxin in binding to glycoproteins.
A region of S3 thought similar to eukaryotic C-type carbohydrate recognition domains
(Saukkonen et al, 1992) contains residues contained in peptide (E)S3c, more evidence
suggesting that at least some of the residues of peptide (E)S3c could be involved in
cellular recognition.
Antisera raised against peptide (E)S3c did not inhibit pertussis toxin-mediated
clumping of Chinese Hamster Ovary cells, which is thought to involve the S3 subunit,
so peptide (E)S3c is unlikely to induce protective antibodies.
It would be interesting to investigate glycoprotein- and glycolipid- binding to
pin decapeptides derived from the amino acid sequence of the S2 subunit of pertussis
toxin. This would identify differences in glycoprotein-binding between peptides of
subunits S3 and S2 and may provide information on the attachment of pertussis toxin
to eukaryotic cells. Subunits S2 and S3 have 70% sequence similarity, so both
subunits are very structurally similar and both have been implicated in the cell
clumping phenomenon (Lang et al., 1989), so the effects of a combination of
antibodies raised against glycoprotein-binding regions of S2 and S3, on pertussis
toxin-mediated clumping of Chinese Hamster ovary cells could be investigated.
Lastly, the binding of NAD+ to whole pertussis toxin, isolated SI subunit and
recombinant SI analogues was studied using intrinsic tryptophan fluorescence
quenching. Dissociation constants were obtained at a number of temperatures for
whole pertussis toxin and isolated SI subunit and the Kd values were used to calculate
the enthalpy change on binding of NAD+ for both whole toxin and SI subunit. The
Kd values determined for whole toxin and SI subunit using fluorescence quenching
were similar. The Kd values for whole toxin were similar to those obtained by
Lobban et al. (1991) using equilibrium dialysis.
The results suggest that the B-oligomer is not necessary for binding of NAD+
to the SI subunit.
Dissociation constants were determined for NAD+-binding to rSld, a C-
terminally truncated recombinant analogue of the SI subunit with better solubility than
isolated S1 subunit and an S1 mutant analogue which contained one altered amino acid
at position 129, called rSldE129D. The Kd value for rSldE129D (Kd 54 ^M) was
less than one order of magnitude greater than the Kd value for rSld (38 /iM) and
whole pertussis toxin (12 ^M). The results suggest that glutamate 129 is not at the
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binding site for NAD+ and that removal of the C-terminal region of the SI subunit did
not affect binding of NAD+. Antibodies raised against whole pertussis toxin that are
specific for conformational epitopes of SI also recognise rSld and rSldE129D (Locht
et al., in preparation), so rSld and rSldE129D probably have three-dimensional
structures comparable to the SI subunit of whole pertussis toxin.
Future work would include investigation of the effects of other mutations
within the amino acid sequence of the SI subunit on binding of NAD+. These would
include mutations at position histidine 35 (H35), as this residue has been implicated in
enzymic activity of the toxin (Kaslow et al., 1989), cysteine 41 (C41; Locht et al.,
1989), arginine 9 (R9) and other mutations within region 8-15 of the SI subunit, that
are known to affect enzymic activity (Cieplak et al., 1989). Effects of of alteration of
the length of amino acid side chain, size and charge of the residues would be
investigated along with binding of NAD+-analogues to rSld and mutated forms of
rSld.
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Appendix 1
Amino Acid Sequences of Pin Decapeptides and peptide 3f
SI subunit (5 amino acid overlap)
peptide n°- sequence peptide n°- sequence
1 DDPPATVYRY 27 LAHRRIPPEN
2 TVYRYDSRPP 28 IPPENIRRVT
3 DSRPPEDVFQ 29 IRRVTRVYHN
4 EDVFQNGFTA 30 RVYHNGITGE
5 NGFTAWGNND 31 GITGETTTTE
6 WGNNDNVLDH 32 TTTTEYSNAR
7 NVLDHLTGRS 33 YSNARYVSQQ
8 LTGRSCQVGS 34 YVSQQTRANP
9 CQVGSSNSAF 35 TRANPNPYTS
10 SNSAFVSTSS 36 NPYTSRRSVA
11 VSTSSSRRYT 37 RRSVASIVGT
12 SRRYTEVYLE 38 SIVGTLVRMA
13 EVYLEHRMQE 39 LVRMAPVIGA
14 HRMQEAVEAE 40 PVIGACMARQ
15 AVEAERAGRG 41 CMARQAESSE
16 RAGRGTGHFI 42 AESSEAMAAW
17 TGHFIGYIYE 43 AMAAWSERAG
18 GYIYEVRADN 44 SERAGEAMVL
19 VRADNNFYGA 45 EAMVLVYYES








S3 subunit (5 amino acid overlap)
peptide n°- sequence peptide n°* sequence
1 VAPGIVIPPK 38 LTGISLCNPA




































S4 subunit (5 amino acid overlap)























SI subunit (8 amino acid overlap)
peptide n°* sequence peptide n°* sequence
36 AVEAERAGRG
1 DDPPATVYRY 37 EAERAGRGTG
2 PPATVYRYDS 38 ERAGRGTGHF
3 ATVYRYDSRP 39 AGRGTGHFIG
4 VYRYDSRPPE 40 RGTGHFIGY1
5 RYDSRPPEDV 41 TGHFIGYIYE
6 DSRPPEDVFQ 42 HFIGYIYEVR
7 RPPEDVFQNG 43 IGYIYEVRAD
8 PEDVFQNGFT 44 YIYEVRADNN
9 DVFQNGFTAW 45 YEVRADNNFY
10 FQNGFTAWGN 46 VRADNNFYGA
11 NGFTAWGNND 47 ADNNFYGAAS
12 FTAWGNNDNV 48 NNFYGAASSY
13 AWGNNDNVLD 49 FYGAASSYFE
14 GNNDNVLDHL 50 GAASSYFEYV
15 NDNVLDHLTG 51 ASSYFEYVDT
16 NVLDHLTGRS 52 SYFEYVDTYG
17 LDHLTGRSCQ 53 FEYVDTYGDN
18 HLTGRSCQVG 54 YVDTYGDNAG
19 TGRSCQVGSS 55 DTYGDNAGRI
20 RSCQVGSSNS 56 YGDNAGRILA
21 CQVGSSNSAF 57 DNAGRILAGA
22 VGSSNSAFVS 58 AGRILAGALA
23 SSNSAFVSTS 59 RILAGALATY
24 NSAFVSTSSS 60 LAGALATYQS
25 AFVSTSSSRR 61 GALATYQSEY
26 VSTSSSRRYT 62 LATYQSEYLA
27 TSSSRRYTEV 63 LATYQSEYLA
28 SSRRYTEVEL 64 TYQSEYLAHR
29 RRYTEVELEH 65 QSEYLAHRRI
30 YTEVELEHRM 66 EYLAHRRIPP
31 EVELEHRMQE 67 LAHRRIPPEN
32 ELEHRMQEAV 68 HRRIPPENIR
33 EHRMQEAVEA 69 RIPPENIRRV
34 RMQEAVEAER 70 PPENIRRVTR


























































































Circular dichroism of peptide (E)S3c
Far u.v. circular dichroism spectra of peptide (E)S3c (kindly performed by Dr.
L. Irons, PHLS, Porton Down, U.K.) in water showed a minimum at 194 nm with an
peak height of about -16 000 deg.cm^.dmopl (fig. Al). There were no other peaks in
the spectrum, suggesting that (E)S3c had little secondary structure in water. When
trifluoroethanol was added to (E)S3c in water the molar ellipticity at 194 nm moved to
a positive intensity of about 7 000 deg.cm^.dmoH
Short linear peptides are thought to exist in many rapidly changing
conformations. Trifluoroethanol is thought to stabilise transient structures and is
known to stabilise alpha-helix in peptides (Dyson et al., 1988), so its interaction with
peptide (E)S3c was observed. The alpha helix content of the peptide in water appeared
to be less than 5% estimated from the mean residue ellipticity at 222 nm, although it is
not known what contribution the aromatic amino acids tyrosine and tryptophan make
to the far u.v. C.D. spectra. Circular dichroism spectra of peptide (E)S3c will have to
be supported by NMR studies to determine to what extent secondary structure exists in
peptide (E)S3c.
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Localisation of a receptor-recognition domain on the S3 subunit
of pertussis toxin by peptide mapping
April TALLETT'2, Richard N. SEABROOK', Laurence I. IRONS', Andrew ROBINSON1, Simon VAN HEYNINGEN2
and Tony ATKINSON'
1 Divisions of Biologies and Biotechnology, Centre for Applied Microbiology and Research, Public Health Laboratory Service,
Porton Down, Salisbury, England
2 Department of Biochemistry, The University of Edinburgh, Scotland
(Received November 2, 1992) — EJB 92 1550
Overlapping 10-amino-acid peptides, which consecutively span the amino acid sequence of the
S3 subunit of pertussis toxin, were synthesised on polyethylene pins and screened for their ability
to bind the glycoprotein fetuin. Fetuin binding was localised to a single peptide comprising amino
acids 46—55. A free peptide, (E)S3c, of longer sequence (S3 amino acids 44—58) was also found
to bind a-1-acid glycoprotein, mixed brain gangliosides and fetuin. (E)S3c also recognised asialofe-
tuin but with a lower apparent affinity relative to fetuin. The single tryptophan residue of the peptide
yielded a fluorescence-emission maximum of 355 nm. In the presence of either ganglioside or the
phospholipid L-a-lysolecithin, but not V-acetylneuramin-lactose or lactosylceramide, the emission
intensity of (E)S3c was enhanced and the emission maximum blue-shifted to 340 nm by ganglioside,
or to 345 nm by L-a-lysolecithin. Monosialogangliosides, disialogangliosides, and trisialoganglio-
sides, when fluorescence-titrated, were each found to bind the peptide with a similar dissociation
constant of 4.4 ±2.8 pM. These findings demonstrate that region 44—58 of the pertussis-toxin S3
subunit is likely to be involved in the recognition of both glycosylated and phospholipid constituents
of target-cell membranes.
Pertussis toxin (PT) is an ADP-ribosylating toxin se¬
creted by the causative agent of whooping cough, Bordetella
pertussis (Weiss and Hewlett, 1986), and is currently con¬
sidered an important virulence determinant involved in the
disease process. PT can function as one of the B. pertussis
adhesins, which facilitate the first stage of infection by en¬
abling attachment of the bacteria to the cilia of the respi¬
ratory tract (Relman et al., 1990; Saukkonen et al„ 1992).
In addition, several of the systemic disease effects which
may result from infection, such as lymphocytosis, enhanced
vascular permeability and stimulation of insulin secretion,
can be reproduced by PT in experimental models (Ui,
1988). Consequently in order to induce PT-neutralising anti¬
bodies, acellular vaccines designed to protect children from
whooping cough contain a detoxified form of the protein
(Robinson et al., 1985).
The PT molecule comprises of subunits S1/S2/S3/S4/S5
in the ratio 1:1:1:2:1 (Tamura et al., 1982). The ADP-ri-
bosyltransferase activity and NAD-glycohydrolase activity
are contained within the SI subunit (A-protomer), while the
remaining subunits form a pentameric B-oligomer which is
involved in eukaryotic cell recognition (Ui, 1988). The A-B
Correspondence to R. N. Seabrook, Division of Biotechnology,
CAMR, PHLS, Porton Down, Salisbury, England SP4 OJG
Abbreviations. AcTrpNH,, V-acetyl-L-tryptophanamide; Finoc,
A'-(9-fluorenylmethoxycarbonyl); MBG, mixed brain ganglioside;
PT, pertussis toxin.
Enzyme. NAD glycohydrolase (EC 3.2.2.5).
functional organisation of PT is similar to that of other bac¬
terial protein toxins such as cholera toxin, Escherichia coli
heat-labile toxin and diphtheria toxin. The interaction of the
B-oligomer with eukaryotic membrane glycoproteins and
glycolipids is primarily mediated by subunits S2 and S3 (Ca-
piau et al., 1986; Schmidt et al., 1991), which are both
closely associated in the B-oligomer with subunit S4 (Tamura
et al., 1982). S2 and S3 differ in their range of receptor-
binding specificities, but also possess some receptors in com¬
mon (Witvliet et al., 1989; Saukkonen et al., 1992). Attach¬
ment of the holotoxin to a target cell is considered to be
followed by penetration of the target cell membrane by the
catalytic SI subunit (Ui, 1988). However, there are some
biological activites of PT that occur independently of the S1
subunit, including T-cell mitogenicity and erythrocyte ag¬
glutination, both of which have been directly attributed to B-
oligomer cell attachment (Nencioni et al., 1991).
In addition to membrane glycoreceptors, the B-oligomer
also mediates PT binding to sialylated serum proteins, such
as fetuin and haptoglobin (Irons and Maclennan, 1979), and
to mucosal proteins, such as a-1-acid glycoprotein (Arm¬
strong et al., 1988). Optimal binding of PT to glycoprotein
depends upon the presence of A-acetylneuraminic acid and
lactosamine constituents in the oligosaccharide (Armstrong
et al., 1988; Witliviet et al., 1989). Furthermore, the exis¬
tence of carbohydrate recognising domains in both the S2
and S3 subunits, has recently been confirmed using site-di¬
rected mutants of PT (Saukkonen et al., 1992). Since certain
carbohydrate-recognising domains of other proteins, such as
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fibronectin (Pierschbacher and Ruoslahti, 1984), have been
mimicked by linear-peptide analogues, we have chosen to
assess whether a peptide from the amino acid sequence of
the S3 subunit of PT could also bind either glycoprotein or
glycolipid. To prepare consecutive and overlapping peptides
spanning the S3 amino acid sequence, we employed the pin-
peptide-mapping technique (Geysen et ah, 1987) which has
been successfully used to identify antibody-binding peptides




The following were purchased from Sigma Chemicals:
7V-acetylneuramin-lactose, /V-acetyl-L-tryptophanamide (Ac-
TrpNH2), n-l-acid glycoprotein, antibody-enzyme conju¬
gates, asialofetuin, 2,2'-azino-bis(3-ethylbenzthiazoline-6-
sulphonic acid), bovine serum albumin, Chaps, fetuin, glutar-
aldehyde, lactosylceramide, L-a-lysolecithin, and Tween 20.
Mixed brain ganglioside (MBG) and gangliosides GM1, GDla
and Grib were from Calbiochem. Organic solvents were of
the highest grade available: diisopropylethylamine, ethanedi-
thiol and phenol were obtained from Aldrich Chemicals;
dichloromethane, dimethylformamide, methanol and tri-
fluoroacetic acid were from Romil Chemicals; acetic anhy¬
dride and piperidine were both from BDH Chemicals.
Derivatised polypropylene pins for overlapping peptide syn¬
thesis, A-(9-fluorenylmethoxycarbonyl) (Fmoc) amino acid
pentafluorophenyl esters, 1-hydroxybenzotriazole were each
purchased as a kit from Cambridge Research Biochemicals
(ICI, Northwhich, UK). Reagents for the synthesis of the free
peptide were from Applied Biosystems, and both newborn
calf serum and Nunc Immnno-1 microtitre plates were from
Gibco-BRL. PT was purified from culture supernatants by
the method of Irons and Gorringe (1988).
Peptide synthesis
Pin peptides were simultaneously synthesised on a block
of 96 derivatised pins (Geysen et al., 1987) according to the
suppliers procedures. Essentially this involved consecutive
cycles: (1) Fmoc deprotection of the block of pins using 20%
(by vol.) piperidine in dimethylformamide for 20min; (2)
repeated pin washes with both dimethylformamide and meth¬
anol; (3) immersion of the block of pin tips into the corre¬
sponding wells of a polypropylene microtitre plate, which
contained 100 pl/well of the appropriate 30 mM Fmoc-Xaa
(mixed with 30 mM 1-hydroxybenzotriazole in dimethyl¬
formamide) and incubated for 18 h; (4) washing of the pin
tips with dimethylformamide, methanol (4X) and again di¬
methylformamide; (5) repeat the cycle with step 1 for the
next amino acid in the sequence. After 10 coupling cycles,
the a-amino group of each pin peptide was deprotected (step
1) and acetylated [100 pl/well 10% (by vol.) acetic anhy¬
dride, 2% (by vol.) diisopropylethylamine in dimethylforma¬
mide for 90 min] then washed as described in step 4. The
block of pin peptides was then transferred to a vessel con¬
taining 95% (by vol.) trifluoroacetic acid, 2.5% (mass/vol.)
phenol and 2.5% (by vol.) ethanedithiol for 4 h to deprotect
the amino acid side chains. The block was then washed with
dichloromethane, neutralised with 5% (by vol.) diisopropyl¬
ethylamine in dichloromethane, washed again with dichloro¬
methane and dried before a final wash with both H,0 then
methanol for 18 h. The block of pin peptides was dried over
silica and stored dessicated.
Free peptide (E)S3c was prepared with a C-terminal am¬
ide from a 4-[2',4'-dimethoxyphenyl-/V-(9-fluorenylmethoxy-
carbonyl)-aminomethyl]phenoxy resin, using the Applied Bi¬
osystems FastMoc system and a 431A automatic synthesiser.
Peptide purity was confirmed by reverse-phase HPLC using
a Vydac C8 column and composition was confirmed by mass
spectrometry.
Pin-peptide binding assays
The pin-peptide tips were suspended from the block into
the corresponding wells of a microtitre plate and incubated
for 90 min in 200 pi diluent [10% (by vol.) newborn calf
serum, 0.4% (by vol.) Tween 20, in 50 mM sodium phos¬
phate, 0.9% (mass/vol.) sodium chloride, pH 7.2 (NaCl/P,)]
to reduce non-specific binding. This was followed by incu¬
bation for 7 h with 20 pg/ml fetuin (175 pl/well) in diluent;
three 5-min washes with 0.1% (by vol.) Tween 20 in NaCl/
Pi, overnight incubation with 175 pl/well of a 1:250 dilution
of affinity-purified rabbit anti-fetuin serum (provided by Dr
L. A. E. Ashworth) in diluent, four 2-min washes with 0.1%
(by vol.) Tween 20 in NaCl/Pj, a 90-min incubation with a
1 :500 dilution of goat anti-(rabbit IgG) serum conjugated to
peroxidase (175 pl/well) and washed as previously described.
Colour was developed by incubating the pin peptides with
150 pl/well 0.05% (mass/vol.) 2,2'-azinobis(3-ethylbenzthia-
zolone-6-sulphonic acid), 80 mM citric acid, 100 mM disod-
ium hydrogen orthophosphate, 0.01% (by vol.) H202,
(pH 4.0) for 30 min and was measured at 405 nm on a Titer-
tek Multiscan.
To rejuvenate the pin peptides for subsequent assays, the
block of pins was sonicated for 30 min at 60°C in disruption
buffer [0.1% (by vol.) 2-mercaptoethanol, 1.0% (mass/vol.)
SDS, 100 mM sodium dihydrogen orthophosphate, pFI 7.2],
followed by two H20 washes at 60°C, immersed in boiling
methanol and air dried for storage at 4°C.
Anti-peptide serum
Peptide conjugation to bovine serum albumin using glu-
taraldehyde has been described before (Seabrook et al.,
1990). New Zealand white rabbits were each immunised with
150 pg of the peptide—bovine-serum-albumin conjugate dis¬
persed in Freund's incomplete adjuvant. At 3 weeks and
6 weeks, the dose was repeated and serum was harvested at
8 weeks from primary immunisation.
ELISA procedures
ELISA have been described previously (Seabrook et al.,
1990). PT and peptide (E)S3c recognition of receptor-coated
ELISA plates was detected by a subsequent incubation with
either mAb L10 (1:500 dilution; Irons and Gorringe, 1988)
for PT, or by rabbit anti-(E)S3c serum (1:350 dilution) for
peptide (E)S3c This was followed by an incubation with goat
anti-(rabbit IgG) serum conjugated to peroxidase (1 :625 di¬
lution).
Fluorescence
Spectra and ligand-titration measurements were made at
30°C with a Perkin Elmer LS 5 spectrofluorimeter as pre¬
viously described (Seabrook et al., 1991). The stock ligand
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solutions were 1 mg/ml in NaCl/Pi for Chaps, A'-acctylneur-
amin-lactose, gangliosides and 1-a-lysolecithin. Lactosylcer-
amide was 1 mg/ml in dimethylformamide. Inner filter cor¬
rections for ultraviolet absorbance were made using Fcort =
F ■ antilog [(Aex + Aem)/2], where F is the observed fluo¬
rescence emission intensity and Aex and Aem the absorbances
of the solution at the emission and excitation wavelengths,
respectively. Dissociation constants were computed using
Enzfitter software (Elsevier Biosoft) from plots of the in¬
crease in fluorescence (AF) against ligand concentration.
RESULTS
Localisation of an S3 binding domain for glycoprotein
Consecutive overlapping 10-amino-acid peptides, span¬
ning the complete DNA-derived amino acid sequence (Locht
and Keith, 1986) of the S3 subunit, were synthesised in
duplicate with a five-residue overlap (except for the final
peptide, 39, which overlapped the previous peptide by six
residues). To confirm the fidelity of the synthesis, an anti¬
body previously raised to an S3 peptide sequence (Seabrook
et ah, 1990) was shown to bind its expected antigenic pin
peptide (Fig. 1 a). Subsequently, the pin peptides were as¬
sayed with the glycoprotein receptor fetuin, which was found
to recognise pin-peptide 10 (amino acids 46 — 55; sequence
RQITPGWSIY) with an absorbance almost double that of
the average obtained for the remaining S3 peptides (Fig. 1 b).
To explore the peptide/receptor interaction in greater de¬
tail, a free peptide (E)S3c, of sequence EYLRQITPGWSIY-
GLY-CONH2, was synthesised. This peptide consisted of S3
residues 44—58, preceded by an N-terminal glutamic acid.
(The latter was incorporated to improve carbodiimide coup¬
ling effeciency to the carrier protein. Flowever, we sub¬
sequently observed that immunisation with a glutaraldehyde-
prepared conjugate yielded a higher antibody titre). The puri¬
fied peptide produced the expected [M+H]4 = 1958.3 Da by
mass spectrometry. Peptide (E)S3c, when incubated before¬
hand with fetuin, was found to inhibit the subsequent binding
of fetuin to the pin peptide (Fig. 1 c), confirming the speci¬
ficity of the peptide/glycoprotein interaction.
Several monoclonal and polyclonal antibodies were
screened with the block of pin peptides, but none of the anti¬
bodies were found to recognise pin-peptide 10. This suggests
that the region of the S3 subunit represented by the fetuin-
binding peptide does not form part of an intrinsic contiguous
S3 epitope.
Peptide (E)S3c recognition of glycoprotein and glycolipid
The ability of (E)S3c and PT to bind fetuin, a-l-acid
glycoprotein, asialofetuin and MBG was compared in a solid-
phase binding assay (Fig. 2). Both PT and the peptide dem¬
onstrated their highest apparent binding activity with fetuin
as the receptor (Fig. 2a), slightly weaker binding with a-l-
acid glycoprotein and ganglioside receptors (Fig. 2 b and c)
and their lowest apparent activity with asialofetuin (Fig. 2d).
These results show that peptide (E)S3c was able to mimic
some of the receptor binding characteristics of the holotoxin
(Armstrong et ah, 1988).
Anti-(E)S3c antibodies
Antibodies raised to an (E)S3c —bovine-serum-albumin





Fig. 1. Peptide mapping of (a) rabbit anti-(peptide S3a) serum
(1:300 dilution), (b) fetuin (20//g/ml) and (c) fetuin incubated
with peptide (E)S3c (100 /rg/ml). Fetuin recognition was detected
with rabbit anti-fetuin serum (1:250) and anti-(rabbit IgG) serum
conjugated to peroxidase (1:500) was used for colour production in
each case.
either antigen was coated directly onto the microtitre plate
(Fig. 3 a). This anti-peptide serum recognition of PT confirms
the putative surface exposure of the receptor-recognition do¬
main within the holotoxin (Westhof et al., 1984). The anti-
peptide serum was also able to recognise fetuin-bound or
ganglioside-bound PT (Fig. 3 b). This result is interesting,
since as found for cholera-toxin/GM, interaction (Ghoshe and
Karush, 1988), it might be expected that the receptor occu¬
pied domain would sterically exclude the anti-peptide serum
from binding PT. However, the result may be explained by
two different possibilities. Firstly, there is likely to be anti¬
genic cross-reactivity with similar amino acids in the S2 sub-
unit (Locht and Keith, 1986). Secondly, the S2 subunit of PT
has been shown to have some glycoprotein receptors, such as
fetuin, in common with S3 (Witvliet et al., 1989), therefore it
is likely that some of the PT molecules will be bound to
fetuin via S2, leaving S3 available for antibody binding.
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Fig. 2. ELISA of pertussis toxin (•) and peptide (E)S3c (O)
recognition of (a) fetuin-coated, (b) a-l-acid glycoprotein-coated,
(c) MBG-coated and (d) asialofetuin-coated wells (2 //g/ml). Vari¬
ous concentrations of pertussis toxin or peptide were incubated with
the receptor-coated wells (2 pg/ml), followed by incubation with
either anti-(pertussis toxin) mAb LIO (1:500) or anti-(E)S3c serum
(1:350) and by a subsequent incubation with the corresponding
species specific anti-IgG-serum conjugated to peroxidase (1:625).
Background (X) was anti-(E)S3c serum recognition of receptor-co¬
ated wells (a similar background was obtained for mAb L10).
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Fig. 3. ELISA of rabbit anti-(E)S3c serum recognition of (a) (•)
pertussis toxin-coated and peptide-(E)S3c-coated (O) wells
(2//g/ml) and (b) of pertussis toxin (50 //g/ml) captured onto the
ELISA plates by either (•) fetuin-coated or (O) MBG-coated
wells (2 //g/ml). Background (X) is anti-(E)S3c serum recognition
of fetuin-coated wells.
The anti-peptide serum did not neutralise the Chinese-
hamster-ovary-cell-clumping activity of PT (Gellenius et al.,
1985).
(E)S3c fluorescence
When excited at 280 nm, the peptide produced a fluo¬
rescence spectrum with a tryptophan emission maximum at
355 nm and a typically weak tyrosine emission at 306 nm
(Lakowicz, 1983; Fig. 4 a). On addition of MBG, a fluo¬
rescence-emission enhancement and a blue-shift in the tryp¬
tophan emission maximum was observed (Fig. 4a). At a satu¬
rating concentration of MBG, the tryptophan emission maxi¬
mum had shifted by 15 nm to 340 nm. Both the ganglioside-
induced fluorescence enhancement and the blue-shift in the
emission maximum are consistent with a decrease in the sol¬
vent exposure of the peptide tryptophan (Burstein et al.,
1973). Fluorescence changes were not observed for the
model fluorophore AcTrpNFL or PT when either were mixed
with MBG (data not shown). The enhancement of (E)S3c
fluorescence intensity was titrated with gangliosides GMi
(one Neu residue), GDla (two Neu residues) and GTlb (three
Neu residues). The minimum amount of ganglioside required
to achieve saturation of fluorescence enhancement was found
to vary for the different gangliosides (Fig. 4 b); however, as¬





Fig. 4. Fluorescence characteristics of peptide (E)S3c. (A) Emis¬
sion spectrum of 4 |iM peptide (1), peptide mixed with 242 pM l-
a-Iysolecithin (2) and of peptide mixed with 30 pg/ml MBG (3). The
excitation wavelength was 280 nm. (B) Increase in (E)S3c fluorescence
intensity following the addition of either GM. (A). GDI„ (•) or GT1b (■)•
(C) (E)S3c increase in fluorescence intensity resulting from the addition
of L-a-lysolecithin (□) or Chaps (O). Excitation and emission slit widths
were 2.5 nm and 5.0 nm. respectively. The excitation wavelength was
280 nm and the emission wavelength 355 nm for the titrations shown in
(B) and (C).
ometry of binding is currently under investigation), dis¬
sociation constants of 7.2, 2.1 and 1.6 pM were obtained for
Gm„ GDla and GTlb, respectively. Both A-acetylneuramin-lac-
tose (1 — 80 pM) and the cerebroside lactosylceramide (1 —
30 pM), which lacks the Neu and galactosyl(/?l — 3lA-acetyl¬
galactosamine moieties of the ganglioside, were found not to
perturb (E)S3c fluorescence when mixed with the peptide
(data not shown). The findings with lactosylceramide are
similar to those of Saukkonen et al. (1992), who found by
TLC that this glycolipid was only recognised by the S2 sub-
unit and not the S3 subunit of PT.
The phospholipid L-a-lysolecithin was also found to shift
the (E)S3c emission maximum (Fig. 4 a) and to enhance the
fluorescence intensity, which had not reached saturation after
the addition of 242 pM phospholipid (Fig. 4 c). L-a-Lysoleci-
thin and detergents such as Chaps have been shown to en¬
hance the enzyme activity of PT (Moss et al., 1986). Chaps,
however, did not enhance the (E)S3c emission intensity
(Fig. 4 c), which demonstrates that the fluorescence changes
which were induced by either glycophospholipids or phos¬
pholipids are not the result of dielectric changes to the sol¬
vent.
The addition of 1.75 pM fetuin to a 4 pM solution of
(E)S3c produced an 8.5% decrease in the initial (E)S3c fluo¬
rescence emission intensity (after correction for fetuin ab-
sorbance and fluorescence). Lower concentrations of fetuin
also demonstrated (E)S3c fluorescence quenching (data not
shown), but the results were not sufficiently reproducible for
titration-curve construction.
DISCUSSION
A region of the S3 subunit of PT (amino acids 46—55,
RQITPGWSIY) which binds the glycoprotein fetuin, was
localised by the pin-peptide mapping procedure (Geysen et
al., 1987). Previously, this technique has primarily been ap¬
plied to the identification of peptides which represent sub-
sites of anti-protein serum epitopes (Getzoff et al., 1987).
The localised glycoprotein-binding region of S3 is closely
analogous to the recently defined region II of a carbohydrate-
recognition domain proposed for the S3 subunit (Saukkonen
et al., 1992). The possibility of multiple regions of S3 con¬
tributing to receptor binding cannot be excluded on the basis
of our peptide-mapping results. Indeed, during the course of
our work, it has been shown that a peptide corresponding to
S3 amino acids 28—45 inhibits bacterial cells from binding
to macrophages (van't Wout et al., 1992).
In addition to sialylated glycoproteins, it has recently
been demonstrated that sialylated glycolipids (gangliosides)
can recognise the S3 subunit of PT (Saukkonen et al., 1992).
In this paper, a free peptide, (E)S3c, containing S3 amino
acids 44-58 (YLRQITPGWSIYGLY, preceded by an N-ter-
minal glutamic acid and succeeded by an amide group), was
able to bind MBG in solid-phase ELISA. Gangliosides were
also found to enhance the intrinsic fluorescence emission
intensity of peptide (E)S3c and blue-shifted the emission
maximum. These changes are consistent with a decrease in
the solvent exposure of the tryptophan residue. This decrease
in solvent exposure may be due to the tryptophan interacting
with the oligosaccharide moiety of the ganglioside, as pro¬
posed for GM1-induced fluorescence changes in cholera toxin
(Fishman et al., 1978). However, considering that phospholi¬
pids such as L-a-lysolecithin can induce (E)S3c fluorescence
changes similar to those induced by ganglioside, and that N-
acetylneuramin-lactose (an analogue of the oligosaccharide
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moiety of both fetuin and ganglioside) does not perturb
(E)S3c fluorescence, an alternative proposal is that the tryp¬
tophan is interacting with the lipid component of the ganglio¬
side. This has been shown to be the case for the binding of
glucagon to phospholipid vesicles, which also results in a
blue-shift of the glucagon fluorescence emission maximum
and an enhancement of the emission intensity (Schneider and
Edelhoch, 1972; Kimura et ah, 1992). Indeed, it has recently
been proposed that tryptophan side chains can bury into the
hydrophobic interior of a lipid bilayer, whilst the same amino
acid maintains a hydrogen bond with the lipid polar head
group (Schiffer et al., 1992).
The S3 amino acid sequence represented by the free pep¬
tide does not have any strong sequence similarity with other
carbohydrate-binding peptides (Ruoslahti and Pierschbacher,
1986), except for the Pro-Gly-Trp sequence, which occurs in
an integrin-binding peptide derived from type-IV collagen
(Chelberg et ah, 1990). Interestingly, both PT and type-IV
collagen have been found to recognise a common glyco¬
protein, laminin (Mayo et ah, 1991; Witvliet et ah, 1989).
The conformation in solution for the collagen-derived pep¬
tide, and for peptides containing the fibronectin recognition
sequence Arg-Gly-Asp, appears to consist of consecutive or
nested //-turn structures (Mayo et ah, 1991; Reed et ah,
1988). For peptide (E)S3c, the ability of antibodies raised
against the peptide to also recognise the holotoxin, is consis¬
tent with a putative //-turn conformation (Krchnak et ah,
1989; Westhof et ah, 1984). However, clearly the elucidation
of the peptide's secondary structure requires a detailed study
by NMR which is currently in progress.
The ability of the S3-derived peptide, (E)S3c, to bind
glycoprotein, glycolipid and phospholipid, suggests that the
analogous region of the S3 subunit maybe involved in both
holotoxin binding to target-cell receptors and also the sub¬
sequent penetration, by the toxin, of the cell-membrane phos¬
pholipid bilayer. Consequently, it was anticipated that anti-
(E)S3c serum would inhibit the interaction of PT with target
cells, such as Chinese-hamster-ovary cells. However, there
was no attenuation by these antibodies of PT-induced Chi-
nese-hamster-ovary-cell clumping. This finding is similar to
results previously obtained with cholera toxin, where anti¬
bodies raised to a peptide (CTP-6), which incorporates the B-
subunit tryptophan involved in GMI binding, failed to inhibit
cholera-toxin activity (Jacob et al., 1984). Thus, it is unlikely
that a peptide analogue of the S3-subunit receptor-binding
domain, will be able to induce protective antibodies and re¬
place detoxified PT as a whooping-cough-vaccine compo¬
nent.
A. T. was a Science and Engineering Research Council (U. K.)
postgraduate CASE student. We are grateful to Dr C. Shone for
(E)S3c synthesis and to Dr L. A. E. Ashworth for providing the anti-
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